Loading…
How to read the money
Income and expense are whole-filing amounts associated with this lobbyist, not personal compensation or an allocated share.
No topic inference: each bill number appears in source LDA issue text assigned to this lobbyist.
Telehealth Expansion Act of 2025
Client: CHAMBER OF COMMERCE OF THE U.S.A. · Firm: CHAMBER OF COMMERCE OF THE U.S.A.
H.R. 1650/S. 763, Telehealth Expansion Act of 2025 H.R. 2528/S. 1847, Association Health Plans Act H.R. 6703, Lower Health Care Premiums for All Americans Act, including PBM transparency provisions Various issues relating to the employer-sponsored health care system, implementation of regulatory process, provider network adequacy, health savings account (HSAs), health reimbursement account (HRAs), association health plans (AHPs), cost sharing reduction payments (CSRs), individual health reimbursement arrangements (ICHRAs), employer mandates; implementation of the One Big Beautiful Bill Act, (P.L. 119-21); health reimbursement arrangements and other account-based group health plans; mental health parity; Federal Trade Commissions multilateral pharmaceutical merger taskforce; telehealth, including coverage of telehealth under High-Deductible Health Plans (HDHPs) and expanding telehealth options for employees; impact of Pharmacy Benefit Managers Practices; FTC-2022-0015; petition to HHS to grant march-in rights for the patents on the drug Xtandi; legislative proposals to tax employer-provided health care coverage; artificial price caps on providing insulin; Executive Order 14297, Delivering Most‑Favored‑Nation Prescription Drug Pricing to American Patients; ERISA preemption protections including information on constructive changes/modifications to ERISA; TRUMP AMERICA AI Act and AI proposals impacting health care; efforts to reform the World Health Organizations (WHO) engagement with private sector; continued U.S. membership to the WHO; support for necessary market conditions to incentivize health sector investment, grow markets, sustain business operations, and improve access to health commodities globally; promote greater harmonization of standards and investment in digital health; health-related policy issues in the G20/G7 forums and other multilateral forums; support for continued and reformed U.S. foreign assistance, including in global health
Specific issues are shown only where the LDA source assigned them to this lobbyist. Targets apply to the associated filing.
CHAMBER OF COMMERCE OF THE U.S.A. via CHAMBER OF COMMERCE OF THE U.S.A.
2026 · third_quarter · Q3
H.R. 2528/S. 1847, Association Health Plans Act H.R. 5463, Choice Arrangement Act of 2025 S. 2875, Custom Health Option and Individual Care Expense (CHOICE) Act Notice, List of Bulk Drug Substances for Which There Is a Clinical Need Under Section 503B of the Federal Food, Drug, and Cosmetic Act (91 Fed. Reg. 23,431-23,444, May 1, 2026) Proposed Rule, Electronic Disclosure by Group Health Plans Under ERISA (91 Fed. Reg. 46,602-46,632, July 23, 2026) Various issues relating to the employer-sponsored health care system, implementation of regulatory process, provider network adequacy, health savings account (HSAs), health reimbursement account (HRAs), association health plans (AHPs), cost sharing reduction payments (CSRs), individual health reimbursement arrangements (ICHRAs), employer mandates, and legislative proposals to expand government-run healthcare; implementation of the One Big Beautiful Bill Act, (P.L. 119-21); health reimbursement arrangements and other account-based group health plans; mental health parity; telehealth, including coverage of telehealth under High-Deductible Health Plans (HDHPs) and expanding telehealth options for employees; legislative proposals to tax employer-provided health care coverage; Executive Order 14297, Delivering Most‑Favored‑Nation Prescription Drug Pricing to American Patients; Executive Order 14420, Delivering Gold Standard Childhood Vaccine Recommendations for Americans, including maintaining evidence-based vaccine review through the CDC Advisory Committee on Immunization Practices (ACIP) and the feasibility of separating combination vaccines such as MMR; ERISA preemption protections including information on constructive changes/modifications to ERISA; TRUMP AMERICA AI Act and AI proposals impacting health care, including a consistent national framework, regulatory clarity for clinical AI, responsible governance, interagency and public-private coordination, and health data interoperability; Food and Drug Administration (FDA) and Department of Health and Human Services (HHS) pending rulemaking to rescind the "adequate provision" standard for direct-to-consumer (DTC) prescription drug advertisements; Food and Drug Administration (FDA) proposal not to include semaglutide, tirzepatide, or liraglutide on the 503B Bulks List, and issues related to pharmaceutical innovation incentives, fair competition, and domestic pharmaceutical manufacturing and supply chain resilience; policies related to prior authorization, HIPAA reform, and health information interoperability; efforts to reform the World Health Organizations (WHO) engagement with private sector; continued U.S. membership to the World Health Organization (WHO); support for necessary market conditions to incentivize health sector investment, grow markets, sustain business operations, and improve access to health commodities globally; promote greater regulatory convergence and harmonization; health-related policy issues in the G20/G7 forums and other multilateral forums; support for continued and reformed U.S. foreign assistance, including in global health
Source: Senate LDA
Telehealth Expansion Act of 2025
Client: CHAMBER OF COMMERCE OF THE U.S.A. · Firm: CHAMBER OF COMMERCE OF THE U.S.A.
H.R. 1650/S. 763, Telehealth Expansion Act of 2025 H.R. 2528/S. 1847, Association Health Plans Act H.R. 6703, Lower Health Care Premiums for All Americans Act, including PBM transparency provisions Various issues relating to the employer-sponsored health care system, implementation of regulatory process, provider network adequacy, health savings account (HSAs), health reimbursement account (HRAs), association health plans (AHPs), cost sharing reduction payments (CSRs), individual health reimbursement arrangements (ICHRAs), employer mandates; implementation of the One Big Beautiful Bill Act, (P.L. 119-21); health reimbursement arrangements and other account-based group health plans; mental health parity; Federal Trade Commissions multilateral pharmaceutical merger taskforce; telehealth, including coverage of telehealth under High-Deductible Health Plans (HDHPs) and expanding telehealth options for employees; impact of Pharmacy Benefit Managers Practices; FTC-2022-0015; petition to HHS to grant march-in rights for the patents on the drug Xtandi; legislative proposals to tax employer-provided health care coverage; artificial price caps on providing insulin; Executive Order 14297, Delivering Most‑Favored‑Nation Prescription Drug Pricing to American Patients; ERISA preemption protections including information on constructive changes/modifications to ERISA; TRUMP AMERICA AI Act and AI proposals impacting health care; efforts to reform the World Health Organizations (WHO) engagement with private sector; continued U.S. membership to the WHO; support for necessary market conditions to incentivize health sector investment, grow markets, sustain business operations, and improve access to health commodities globally; promote greater harmonization of standards and investment in digital health; health-related policy issues in the G20/G7 forums and other multilateral forums; support for continued and reformed U.S. foreign assistance, including in global health
Association Health Plans Act
Client: CHAMBER OF COMMERCE OF THE U.S.A. · Firm: CHAMBER OF COMMERCE OF THE U.S.A.
H.R. 2528/S. 1847, Association Health Plans Act H.R. 5463, Choice Arrangement Act of 2025 S. 2875, Custom Health Option and Individual Care Expense (CHOICE) Act Notice, List of Bulk Drug Substances for Which There Is a Clinical Need Under Section 503B of the Federal Food, Drug, and Cosmetic Act (91 Fed. Reg. 23,431-23,444, May 1, 2026) Proposed Rule, Electronic Disclosure by Group Health Plans Under ERISA (91 Fed. Reg. 46,602-46,632, July 23, 2026) Various issues relating to the employer-sponsored health care system, implementation of regulatory process, provider network adequacy, health savings account (HSAs), health reimbursement account (HRAs), association health plans (AHPs), cost sharing reduction payments (CSRs), individual health reimbursement arrangements (ICHRAs), employer mandates, and legislative proposals to expand government-run healthcare; implementation of the One Big Beautiful Bill Act, (P.L. 119-21); health reimbursement arrangements and other account-based group health plans; mental health parity; telehealth, including coverage of telehealth under High-Deductible Health Plans (HDHPs) and expanding telehealth options for employees; legislative proposals to tax employer-provided health care coverage; Executive Order 14297, Delivering Most‑Favored‑Nation Prescription Drug Pricing to American Patients; Executive Order 14420, Delivering Gold Standard Childhood Vaccine Recommendations for Americans, including maintaining evidence-based vaccine review through the CDC Advisory Committee on Immunization Practices (ACIP) and the feasibility of separating combination vaccines such as MMR; ERISA preemption protections including information on constructive changes/modifications to ERISA; TRUMP AMERICA AI Act and AI proposals impacting health care, including a consistent national framework, regulatory clarity for clinical AI, responsible governance, interagency and public-private coordination, and health data interoperability; Food and Drug Administration (FDA) and Department of Health and Human Services (HHS) pending rulemaking to rescind the "adequate provision" standard for direct-to-consumer (DTC) prescription drug advertisements; Food and Drug Administration (FDA) proposal not to include semaglutide, tirzepatide, or liraglutide on the 503B Bulks List, and issues related to pharmaceutical innovation incentives, fair competition, and domestic pharmaceutical manufacturing and supply chain resilience; policies related to prior authorization, HIPAA reform, and health information interoperability; efforts to reform the World Health Organizations (WHO) engagement with private sector; continued U.S. membership to the World Health Organization (WHO); support for necessary market conditions to incentivize health sector investment, grow markets, sustain business operations, and improve access to health commodities globally; promote greater regulatory convergence and harmonization; health-related policy issues in the G20/G7 forums and other multilateral forums; support for continued and reformed U.S. foreign assistance, including in global health
Association Health Plans Act
Client: CHAMBER OF COMMERCE OF THE U.S.A. · Firm: CHAMBER OF COMMERCE OF THE U.S.A.
H.R. 2528/S. 1847, Association Health Plans Act H.R. 5463, Choice Arrangement Act of 2025 H.R. 8324, Great American Healthcare Plan, including provisions related to expansion of Health Savings Accounts (HSAs) S. 2875, Custom Health Option and Individual Care Expense (CHOICE) Act Various issues relating to the employer-sponsored health care system, implementation of regulatory process, provider network adequacy, health savings account (HSAs), health reimbursement account (HRAs), association health plans (AHPs), cost sharing reduction payments (CSRs), individual health reimbursement arrangements (ICHRAs), employer mandates; implementation of the One Big Beautiful Bill Act, (P.L. 119-21); health reimbursement arrangements and other account-based group health plans; mental health parity; telehealth, including coverage of telehealth under High-Deductible Health Plans (HDHPs) and expanding telehealth options for employees; legislative proposals to tax employer-provided health care coverage; artificial price caps on providing insulin; Executive Order 14297, Delivering Most‑Favored‑Nation Prescription Drug Pricing to American Patients; ERISA preemption protections including information on constructive changes/modifications to ERISA; TRUMP AMERICA AI Act and AI proposals impacting health care; Food and Drug Administration (FDA) and Department of Health and Human Services (HHS) pending rulemaking to rescind the "adequate provision" standard for direct-to-consumer (DTC) prescription drug advertisements, RIN number: 0910-AJ14; efforts to reform the World Health Organizations (WHO) engagement with private sector; continued U.S. membership to the World Health Organization (WHO); support for necessary market conditions to incentivize health sector investment, grow markets, sustain business operations, and improve access to health commodities globally; promote greater harmonization of standards and investment in digital health; health-related policy issues in the G20/G7 forums and other multilateral forums; support for continued and reformed U.S. foreign assistance, including in global health
Association Health Plans Act
Client: CHAMBER OF COMMERCE OF THE U.S.A. · Firm: CHAMBER OF COMMERCE OF THE U.S.A.
H.R. 1650/S. 763, Telehealth Expansion Act of 2025 H.R. 2528/S. 1847, Association Health Plans Act H.R. 6703, Lower Health Care Premiums for All Americans Act, including PBM transparency provisions Various issues relating to the employer-sponsored health care system, implementation of regulatory process, provider network adequacy, health savings account (HSAs), health reimbursement account (HRAs), association health plans (AHPs), cost sharing reduction payments (CSRs), individual health reimbursement arrangements (ICHRAs), employer mandates; implementation of the One Big Beautiful Bill Act, (P.L. 119-21); health reimbursement arrangements and other account-based group health plans; mental health parity; Federal Trade Commissions multilateral pharmaceutical merger taskforce; telehealth, including coverage of telehealth under High-Deductible Health Plans (HDHPs) and expanding telehealth options for employees; impact of Pharmacy Benefit Managers Practices; FTC-2022-0015; petition to HHS to grant march-in rights for the patents on the drug Xtandi; legislative proposals to tax employer-provided health care coverage; artificial price caps on providing insulin; Executive Order 14297, Delivering Most‑Favored‑Nation Prescription Drug Pricing to American Patients; ERISA preemption protections including information on constructive changes/modifications to ERISA; TRUMP AMERICA AI Act and AI proposals impacting health care; efforts to reform the World Health Organizations (WHO) engagement with private sector; continued U.S. membership to the WHO; support for necessary market conditions to incentivize health sector investment, grow markets, sustain business operations, and improve access to health commodities globally; promote greater harmonization of standards and investment in digital health; health-related policy issues in the G20/G7 forums and other multilateral forums; support for continued and reformed U.S. foreign assistance, including in global health
Association Health Plans Act
Client: CHAMBER OF COMMERCE OF THE U.S.A. · Firm: CHAMBER OF COMMERCE OF THE U.S.A.
H.R. 1650/S. 763, Telehealth Expansion Act of 2025 H.R. 2528/S. 1847, Association Health Plans Act H.R. 6703, Lower Health Care Premiums for All Americans Act, including PBM transparency provisions Various issues relating to the employer-sponsored health care system, implementation of regulatory process, provider network adequacy, health savings account (HSAs), health reimbursement account (HRAs), association health plans (AHPs), cost sharing reduction payments (CSRs), individual health reimbursement arrangements (ICHRAs), employer mandates; implementation of the One Big Beautiful Bill Act, (P.L. 119-21); health reimbursement arrangements and other account-based group health plans; mental health parity; Federal Trade Commissions multilateral pharmaceutical merger taskforce; telehealth, including coverage of telehealth under High-Deductible Health Plans (HDHPs) and expanding telehealth options for employees; impact of Pharmacy Benefit Managers Practices; FTC-2022-0015; petition to HHS to grant march-in rights for the patents on the drug Xtandi; legislative proposals to tax employer-provided health care coverage; artificial price caps on providing insulin; Executive Order 14297, Delivering Most‑Favored‑Nation Prescription Drug Pricing to American Patients; ERISA preemption protections including information on constructive changes/modifications to ERISA; TRUMP AMERICA AI Act and AI proposals impacting health care; efforts to reform the World Health Organizations (WHO) engagement with private sector; continued U.S. membership to the WHO; support for necessary market conditions to incentivize health sector investment, grow markets, sustain business operations, and improve access to health commodities globally; promote greater harmonization of standards and investment in digital health; health-related policy issues in the G20/G7 forums and other multilateral forums; support for continued and reformed U.S. foreign assistance, including in global health
Choice Arrangement
Client: CHAMBER OF COMMERCE OF THE U.S.A. · Firm: CHAMBER OF COMMERCE OF THE U.S.A.
H.R. 2528/S. 1847, Association Health Plans Act H.R. 5463, Choice Arrangement Act of 2025 S. 2875, Custom Health Option and Individual Care Expense (CHOICE) Act Notice, List of Bulk Drug Substances for Which There Is a Clinical Need Under Section 503B of the Federal Food, Drug, and Cosmetic Act (91 Fed. Reg. 23,431-23,444, May 1, 2026) Proposed Rule, Electronic Disclosure by Group Health Plans Under ERISA (91 Fed. Reg. 46,602-46,632, July 23, 2026) Various issues relating to the employer-sponsored health care system, implementation of regulatory process, provider network adequacy, health savings account (HSAs), health reimbursement account (HRAs), association health plans (AHPs), cost sharing reduction payments (CSRs), individual health reimbursement arrangements (ICHRAs), employer mandates, and legislative proposals to expand government-run healthcare; implementation of the One Big Beautiful Bill Act, (P.L. 119-21); health reimbursement arrangements and other account-based group health plans; mental health parity; telehealth, including coverage of telehealth under High-Deductible Health Plans (HDHPs) and expanding telehealth options for employees; legislative proposals to tax employer-provided health care coverage; Executive Order 14297, Delivering Most‑Favored‑Nation Prescription Drug Pricing to American Patients; Executive Order 14420, Delivering Gold Standard Childhood Vaccine Recommendations for Americans, including maintaining evidence-based vaccine review through the CDC Advisory Committee on Immunization Practices (ACIP) and the feasibility of separating combination vaccines such as MMR; ERISA preemption protections including information on constructive changes/modifications to ERISA; TRUMP AMERICA AI Act and AI proposals impacting health care, including a consistent national framework, regulatory clarity for clinical AI, responsible governance, interagency and public-private coordination, and health data interoperability; Food and Drug Administration (FDA) and Department of Health and Human Services (HHS) pending rulemaking to rescind the "adequate provision" standard for direct-to-consumer (DTC) prescription drug advertisements; Food and Drug Administration (FDA) proposal not to include semaglutide, tirzepatide, or liraglutide on the 503B Bulks List, and issues related to pharmaceutical innovation incentives, fair competition, and domestic pharmaceutical manufacturing and supply chain resilience; policies related to prior authorization, HIPAA reform, and health information interoperability; efforts to reform the World Health Organizations (WHO) engagement with private sector; continued U.S. membership to the World Health Organization (WHO); support for necessary market conditions to incentivize health sector investment, grow markets, sustain business operations, and improve access to health commodities globally; promote greater regulatory convergence and harmonization; health-related policy issues in the G20/G7 forums and other multilateral forums; support for continued and reformed U.S. foreign assistance, including in global health
Choice Arrangement
Client: CHAMBER OF COMMERCE OF THE U.S.A. · Firm: CHAMBER OF COMMERCE OF THE U.S.A.
H.R. 2528/S. 1847, Association Health Plans Act H.R. 5463, Choice Arrangement Act of 2025 H.R. 8324, Great American Healthcare Plan, including provisions related to expansion of Health Savings Accounts (HSAs) S. 2875, Custom Health Option and Individual Care Expense (CHOICE) Act Various issues relating to the employer-sponsored health care system, implementation of regulatory process, provider network adequacy, health savings account (HSAs), health reimbursement account (HRAs), association health plans (AHPs), cost sharing reduction payments (CSRs), individual health reimbursement arrangements (ICHRAs), employer mandates; implementation of the One Big Beautiful Bill Act, (P.L. 119-21); health reimbursement arrangements and other account-based group health plans; mental health parity; telehealth, including coverage of telehealth under High-Deductible Health Plans (HDHPs) and expanding telehealth options for employees; legislative proposals to tax employer-provided health care coverage; artificial price caps on providing insulin; Executive Order 14297, Delivering Most‑Favored‑Nation Prescription Drug Pricing to American Patients; ERISA preemption protections including information on constructive changes/modifications to ERISA; TRUMP AMERICA AI Act and AI proposals impacting health care; Food and Drug Administration (FDA) and Department of Health and Human Services (HHS) pending rulemaking to rescind the "adequate provision" standard for direct-to-consumer (DTC) prescription drug advertisements, RIN number: 0910-AJ14; efforts to reform the World Health Organizations (WHO) engagement with private sector; continued U.S. membership to the World Health Organization (WHO); support for necessary market conditions to incentivize health sector investment, grow markets, sustain business operations, and improve access to health commodities globally; promote greater harmonization of standards and investment in digital health; health-related policy issues in the G20/G7 forums and other multilateral forums; support for continued and reformed U.S. foreign assistance, including in global health
Lower Health Care Premiums for All Americans Act
Client: CHAMBER OF COMMERCE OF THE U.S.A. · Firm: CHAMBER OF COMMERCE OF THE U.S.A.
H.R. 1650/S. 763, Telehealth Expansion Act of 2025 H.R. 2528/S. 1847, Association Health Plans Act H.R. 6703, Lower Health Care Premiums for All Americans Act, including PBM transparency provisions Various issues relating to the employer-sponsored health care system, implementation of regulatory process, provider network adequacy, health savings account (HSAs), health reimbursement account (HRAs), association health plans (AHPs), cost sharing reduction payments (CSRs), individual health reimbursement arrangements (ICHRAs), employer mandates; implementation of the One Big Beautiful Bill Act, (P.L. 119-21); health reimbursement arrangements and other account-based group health plans; mental health parity; Federal Trade Commissions multilateral pharmaceutical merger taskforce; telehealth, including coverage of telehealth under High-Deductible Health Plans (HDHPs) and expanding telehealth options for employees; impact of Pharmacy Benefit Managers Practices; FTC-2022-0015; petition to HHS to grant march-in rights for the patents on the drug Xtandi; legislative proposals to tax employer-provided health care coverage; artificial price caps on providing insulin; Executive Order 14297, Delivering Most‑Favored‑Nation Prescription Drug Pricing to American Patients; ERISA preemption protections including information on constructive changes/modifications to ERISA; TRUMP AMERICA AI Act and AI proposals impacting health care; efforts to reform the World Health Organizations (WHO) engagement with private sector; continued U.S. membership to the WHO; support for necessary market conditions to incentivize health sector investment, grow markets, sustain business operations, and improve access to health commodities globally; promote greater harmonization of standards and investment in digital health; health-related policy issues in the G20/G7 forums and other multilateral forums; support for continued and reformed U.S. foreign assistance, including in global health
Lower Health Care Premiums for All Americans Act
Client: CHAMBER OF COMMERCE OF THE U.S.A. · Firm: CHAMBER OF COMMERCE OF THE U.S.A.
H.R. 1650/S. 763, Telehealth Expansion Act of 2025 H.R. 2528/S. 1847, Association Health Plans Act H.R. 6703, Lower Health Care Premiums for All Americans Act, including PBM transparency provisions Various issues relating to the employer-sponsored health care system, implementation of regulatory process, provider network adequacy, health savings account (HSAs), health reimbursement account (HRAs), association health plans (AHPs), cost sharing reduction payments (CSRs), individual health reimbursement arrangements (ICHRAs), employer mandates; implementation of the One Big Beautiful Bill Act, (P.L. 119-21); health reimbursement arrangements and other account-based group health plans; mental health parity; Federal Trade Commissions multilateral pharmaceutical merger taskforce; telehealth, including coverage of telehealth under High-Deductible Health Plans (HDHPs) and expanding telehealth options for employees; impact of Pharmacy Benefit Managers Practices; FTC-2022-0015; petition to HHS to grant march-in rights for the patents on the drug Xtandi; legislative proposals to tax employer-provided health care coverage; artificial price caps on providing insulin; Executive Order 14297, Delivering Most‑Favored‑Nation Prescription Drug Pricing to American Patients; ERISA preemption protections including information on constructive changes/modifications to ERISA; TRUMP AMERICA AI Act and AI proposals impacting health care; efforts to reform the World Health Organizations (WHO) engagement with private sector; continued U.S. membership to the WHO; support for necessary market conditions to incentivize health sector investment, grow markets, sustain business operations, and improve access to health commodities globally; promote greater harmonization of standards and investment in digital health; health-related policy issues in the G20/G7 forums and other multilateral forums; support for continued and reformed U.S. foreign assistance, including in global health
Great American Healthcare Plan
Client: CHAMBER OF COMMERCE OF THE U.S.A. · Firm: CHAMBER OF COMMERCE OF THE U.S.A.
H.R. 2528/S. 1847, Association Health Plans Act H.R. 5463, Choice Arrangement Act of 2025 H.R. 8324, Great American Healthcare Plan, including provisions related to expansion of Health Savings Accounts (HSAs) S. 2875, Custom Health Option and Individual Care Expense (CHOICE) Act Various issues relating to the employer-sponsored health care system, implementation of regulatory process, provider network adequacy, health savings account (HSAs), health reimbursement account (HRAs), association health plans (AHPs), cost sharing reduction payments (CSRs), individual health reimbursement arrangements (ICHRAs), employer mandates; implementation of the One Big Beautiful Bill Act, (P.L. 119-21); health reimbursement arrangements and other account-based group health plans; mental health parity; telehealth, including coverage of telehealth under High-Deductible Health Plans (HDHPs) and expanding telehealth options for employees; legislative proposals to tax employer-provided health care coverage; artificial price caps on providing insulin; Executive Order 14297, Delivering Most‑Favored‑Nation Prescription Drug Pricing to American Patients; ERISA preemption protections including information on constructive changes/modifications to ERISA; TRUMP AMERICA AI Act and AI proposals impacting health care; Food and Drug Administration (FDA) and Department of Health and Human Services (HHS) pending rulemaking to rescind the "adequate provision" standard for direct-to-consumer (DTC) prescription drug advertisements, RIN number: 0910-AJ14; efforts to reform the World Health Organizations (WHO) engagement with private sector; continued U.S. membership to the World Health Organization (WHO); support for necessary market conditions to incentivize health sector investment, grow markets, sustain business operations, and improve access to health commodities globally; promote greater harmonization of standards and investment in digital health; health-related policy issues in the G20/G7 forums and other multilateral forums; support for continued and reformed U.S. foreign assistance, including in global health
Association Health Plans Act
Client: CHAMBER OF COMMERCE OF THE U.S.A. · Firm: CHAMBER OF COMMERCE OF THE U.S.A.
H.R. 1650/S. 763, Telehealth Expansion Act of 2025 H.R. 2528/S. 1847, Association Health Plans Act H.R. 6703, Lower Health Care Premiums for All Americans Act, including PBM transparency provisions Various issues relating to the employer-sponsored health care system, implementation of regulatory process, provider network adequacy, health savings account (HSAs), health reimbursement account (HRAs), association health plans (AHPs), cost sharing reduction payments (CSRs), individual health reimbursement arrangements (ICHRAs), employer mandates; implementation of the One Big Beautiful Bill Act, (P.L. 119-21); health reimbursement arrangements and other account-based group health plans; mental health parity; Federal Trade Commissions multilateral pharmaceutical merger taskforce; telehealth, including coverage of telehealth under High-Deductible Health Plans (HDHPs) and expanding telehealth options for employees; impact of Pharmacy Benefit Managers Practices; FTC-2022-0015; petition to HHS to grant march-in rights for the patents on the drug Xtandi; legislative proposals to tax employer-provided health care coverage; artificial price caps on providing insulin; Executive Order 14297, Delivering Most‑Favored‑Nation Prescription Drug Pricing to American Patients; ERISA preemption protections including information on constructive changes/modifications to ERISA; TRUMP AMERICA AI Act and AI proposals impacting health care; efforts to reform the World Health Organizations (WHO) engagement with private sector; continued U.S. membership to the WHO; support for necessary market conditions to incentivize health sector investment, grow markets, sustain business operations, and improve access to health commodities globally; promote greater harmonization of standards and investment in digital health; health-related policy issues in the G20/G7 forums and other multilateral forums; support for continued and reformed U.S. foreign assistance, including in global health
Association Health Plans Act
Client: CHAMBER OF COMMERCE OF THE U.S.A. · Firm: CHAMBER OF COMMERCE OF THE U.S.A.
H.R. 1650/S. 763, Telehealth Expansion Act of 2025 H.R. 2528/S. 1847, Association Health Plans Act H.R. 6703, Lower Health Care Premiums for All Americans Act, including PBM transparency provisions Various issues relating to the employer-sponsored health care system, implementation of regulatory process, provider network adequacy, health savings account (HSAs), health reimbursement account (HRAs), association health plans (AHPs), cost sharing reduction payments (CSRs), individual health reimbursement arrangements (ICHRAs), employer mandates; implementation of the One Big Beautiful Bill Act, (P.L. 119-21); health reimbursement arrangements and other account-based group health plans; mental health parity; Federal Trade Commissions multilateral pharmaceutical merger taskforce; telehealth, including coverage of telehealth under High-Deductible Health Plans (HDHPs) and expanding telehealth options for employees; impact of Pharmacy Benefit Managers Practices; FTC-2022-0015; petition to HHS to grant march-in rights for the patents on the drug Xtandi; legislative proposals to tax employer-provided health care coverage; artificial price caps on providing insulin; Executive Order 14297, Delivering Most‑Favored‑Nation Prescription Drug Pricing to American Patients; ERISA preemption protections including information on constructive changes/modifications to ERISA; TRUMP AMERICA AI Act and AI proposals impacting health care; efforts to reform the World Health Organizations (WHO) engagement with private sector; continued U.S. membership to the WHO; support for necessary market conditions to incentivize health sector investment, grow markets, sustain business operations, and improve access to health commodities globally; promote greater harmonization of standards and investment in digital health; health-related policy issues in the G20/G7 forums and other multilateral forums; support for continued and reformed U.S. foreign assistance, including in global health
Association Health Plans Act
Client: CHAMBER OF COMMERCE OF THE U.S.A. · Firm: CHAMBER OF COMMERCE OF THE U.S.A.
H.R. 2528/S. 1847, Association Health Plans Act H.R. 5463, Choice Arrangement Act of 2025 H.R. 8324, Great American Healthcare Plan, including provisions related to expansion of Health Savings Accounts (HSAs) S. 2875, Custom Health Option and Individual Care Expense (CHOICE) Act Various issues relating to the employer-sponsored health care system, implementation of regulatory process, provider network adequacy, health savings account (HSAs), health reimbursement account (HRAs), association health plans (AHPs), cost sharing reduction payments (CSRs), individual health reimbursement arrangements (ICHRAs), employer mandates; implementation of the One Big Beautiful Bill Act, (P.L. 119-21); health reimbursement arrangements and other account-based group health plans; mental health parity; telehealth, including coverage of telehealth under High-Deductible Health Plans (HDHPs) and expanding telehealth options for employees; legislative proposals to tax employer-provided health care coverage; artificial price caps on providing insulin; Executive Order 14297, Delivering Most‑Favored‑Nation Prescription Drug Pricing to American Patients; ERISA preemption protections including information on constructive changes/modifications to ERISA; TRUMP AMERICA AI Act and AI proposals impacting health care; Food and Drug Administration (FDA) and Department of Health and Human Services (HHS) pending rulemaking to rescind the "adequate provision" standard for direct-to-consumer (DTC) prescription drug advertisements, RIN number: 0910-AJ14; efforts to reform the World Health Organizations (WHO) engagement with private sector; continued U.S. membership to the World Health Organization (WHO); support for necessary market conditions to incentivize health sector investment, grow markets, sustain business operations, and improve access to health commodities globally; promote greater harmonization of standards and investment in digital health; health-related policy issues in the G20/G7 forums and other multilateral forums; support for continued and reformed U.S. foreign assistance, including in global health
Association Health Plans Act
Client: CHAMBER OF COMMERCE OF THE U.S.A. · Firm: CHAMBER OF COMMERCE OF THE U.S.A.
H.R. 2528/S. 1847, Association Health Plans Act H.R. 5463, Choice Arrangement Act of 2025 S. 2875, Custom Health Option and Individual Care Expense (CHOICE) Act Notice, List of Bulk Drug Substances for Which There Is a Clinical Need Under Section 503B of the Federal Food, Drug, and Cosmetic Act (91 Fed. Reg. 23,431-23,444, May 1, 2026) Proposed Rule, Electronic Disclosure by Group Health Plans Under ERISA (91 Fed. Reg. 46,602-46,632, July 23, 2026) Various issues relating to the employer-sponsored health care system, implementation of regulatory process, provider network adequacy, health savings account (HSAs), health reimbursement account (HRAs), association health plans (AHPs), cost sharing reduction payments (CSRs), individual health reimbursement arrangements (ICHRAs), employer mandates, and legislative proposals to expand government-run healthcare; implementation of the One Big Beautiful Bill Act, (P.L. 119-21); health reimbursement arrangements and other account-based group health plans; mental health parity; telehealth, including coverage of telehealth under High-Deductible Health Plans (HDHPs) and expanding telehealth options for employees; legislative proposals to tax employer-provided health care coverage; Executive Order 14297, Delivering Most‑Favored‑Nation Prescription Drug Pricing to American Patients; Executive Order 14420, Delivering Gold Standard Childhood Vaccine Recommendations for Americans, including maintaining evidence-based vaccine review through the CDC Advisory Committee on Immunization Practices (ACIP) and the feasibility of separating combination vaccines such as MMR; ERISA preemption protections including information on constructive changes/modifications to ERISA; TRUMP AMERICA AI Act and AI proposals impacting health care, including a consistent national framework, regulatory clarity for clinical AI, responsible governance, interagency and public-private coordination, and health data interoperability; Food and Drug Administration (FDA) and Department of Health and Human Services (HHS) pending rulemaking to rescind the "adequate provision" standard for direct-to-consumer (DTC) prescription drug advertisements; Food and Drug Administration (FDA) proposal not to include semaglutide, tirzepatide, or liraglutide on the 503B Bulks List, and issues related to pharmaceutical innovation incentives, fair competition, and domestic pharmaceutical manufacturing and supply chain resilience; policies related to prior authorization, HIPAA reform, and health information interoperability; efforts to reform the World Health Organizations (WHO) engagement with private sector; continued U.S. membership to the World Health Organization (WHO); support for necessary market conditions to incentivize health sector investment, grow markets, sustain business operations, and improve access to health commodities globally; promote greater regulatory convergence and harmonization; health-related policy issues in the G20/G7 forums and other multilateral forums; support for continued and reformed U.S. foreign assistance, including in global health
CHOICE Act
Client: CHAMBER OF COMMERCE OF THE U.S.A. · Firm: CHAMBER OF COMMERCE OF THE U.S.A.
H.R. 2528/S. 1847, Association Health Plans Act H.R. 5463, Choice Arrangement Act of 2025 S. 2875, Custom Health Option and Individual Care Expense (CHOICE) Act Notice, List of Bulk Drug Substances for Which There Is a Clinical Need Under Section 503B of the Federal Food, Drug, and Cosmetic Act (91 Fed. Reg. 23,431-23,444, May 1, 2026) Proposed Rule, Electronic Disclosure by Group Health Plans Under ERISA (91 Fed. Reg. 46,602-46,632, July 23, 2026) Various issues relating to the employer-sponsored health care system, implementation of regulatory process, provider network adequacy, health savings account (HSAs), health reimbursement account (HRAs), association health plans (AHPs), cost sharing reduction payments (CSRs), individual health reimbursement arrangements (ICHRAs), employer mandates, and legislative proposals to expand government-run healthcare; implementation of the One Big Beautiful Bill Act, (P.L. 119-21); health reimbursement arrangements and other account-based group health plans; mental health parity; telehealth, including coverage of telehealth under High-Deductible Health Plans (HDHPs) and expanding telehealth options for employees; legislative proposals to tax employer-provided health care coverage; Executive Order 14297, Delivering Most‑Favored‑Nation Prescription Drug Pricing to American Patients; Executive Order 14420, Delivering Gold Standard Childhood Vaccine Recommendations for Americans, including maintaining evidence-based vaccine review through the CDC Advisory Committee on Immunization Practices (ACIP) and the feasibility of separating combination vaccines such as MMR; ERISA preemption protections including information on constructive changes/modifications to ERISA; TRUMP AMERICA AI Act and AI proposals impacting health care, including a consistent national framework, regulatory clarity for clinical AI, responsible governance, interagency and public-private coordination, and health data interoperability; Food and Drug Administration (FDA) and Department of Health and Human Services (HHS) pending rulemaking to rescind the "adequate provision" standard for direct-to-consumer (DTC) prescription drug advertisements; Food and Drug Administration (FDA) proposal not to include semaglutide, tirzepatide, or liraglutide on the 503B Bulks List, and issues related to pharmaceutical innovation incentives, fair competition, and domestic pharmaceutical manufacturing and supply chain resilience; policies related to prior authorization, HIPAA reform, and health information interoperability; efforts to reform the World Health Organizations (WHO) engagement with private sector; continued U.S. membership to the World Health Organization (WHO); support for necessary market conditions to incentivize health sector investment, grow markets, sustain business operations, and improve access to health commodities globally; promote greater regulatory convergence and harmonization; health-related policy issues in the G20/G7 forums and other multilateral forums; support for continued and reformed U.S. foreign assistance, including in global health
CHOICE Act
Client: CHAMBER OF COMMERCE OF THE U.S.A. · Firm: CHAMBER OF COMMERCE OF THE U.S.A.
H.R. 2528/S. 1847, Association Health Plans Act H.R. 5463, Choice Arrangement Act of 2025 H.R. 8324, Great American Healthcare Plan, including provisions related to expansion of Health Savings Accounts (HSAs) S. 2875, Custom Health Option and Individual Care Expense (CHOICE) Act Various issues relating to the employer-sponsored health care system, implementation of regulatory process, provider network adequacy, health savings account (HSAs), health reimbursement account (HRAs), association health plans (AHPs), cost sharing reduction payments (CSRs), individual health reimbursement arrangements (ICHRAs), employer mandates; implementation of the One Big Beautiful Bill Act, (P.L. 119-21); health reimbursement arrangements and other account-based group health plans; mental health parity; telehealth, including coverage of telehealth under High-Deductible Health Plans (HDHPs) and expanding telehealth options for employees; legislative proposals to tax employer-provided health care coverage; artificial price caps on providing insulin; Executive Order 14297, Delivering Most‑Favored‑Nation Prescription Drug Pricing to American Patients; ERISA preemption protections including information on constructive changes/modifications to ERISA; TRUMP AMERICA AI Act and AI proposals impacting health care; Food and Drug Administration (FDA) and Department of Health and Human Services (HHS) pending rulemaking to rescind the "adequate provision" standard for direct-to-consumer (DTC) prescription drug advertisements, RIN number: 0910-AJ14; efforts to reform the World Health Organizations (WHO) engagement with private sector; continued U.S. membership to the World Health Organization (WHO); support for necessary market conditions to incentivize health sector investment, grow markets, sustain business operations, and improve access to health commodities globally; promote greater harmonization of standards and investment in digital health; health-related policy issues in the G20/G7 forums and other multilateral forums; support for continued and reformed U.S. foreign assistance, including in global health
Telehealth Expansion Act of 2025
Client: CHAMBER OF COMMERCE OF THE U.S.A. · Firm: CHAMBER OF COMMERCE OF THE U.S.A.
H.R. 1650/S. 763, Telehealth Expansion Act of 2025 H.R. 2528/S. 1847, Association Health Plans Act H.R. 6703, Lower Health Care Premiums for All Americans Act, including PBM transparency provisions Various issues relating to the employer-sponsored health care system, implementation of regulatory process, provider network adequacy, health savings account (HSAs), health reimbursement account (HRAs), association health plans (AHPs), cost sharing reduction payments (CSRs), individual health reimbursement arrangements (ICHRAs), employer mandates; implementation of the One Big Beautiful Bill Act, (P.L. 119-21); health reimbursement arrangements and other account-based group health plans; mental health parity; Federal Trade Commissions multilateral pharmaceutical merger taskforce; telehealth, including coverage of telehealth under High-Deductible Health Plans (HDHPs) and expanding telehealth options for employees; impact of Pharmacy Benefit Managers Practices; FTC-2022-0015; petition to HHS to grant march-in rights for the patents on the drug Xtandi; legislative proposals to tax employer-provided health care coverage; artificial price caps on providing insulin; Executive Order 14297, Delivering Most‑Favored‑Nation Prescription Drug Pricing to American Patients; ERISA preemption protections including information on constructive changes/modifications to ERISA; TRUMP AMERICA AI Act and AI proposals impacting health care; efforts to reform the World Health Organizations (WHO) engagement with private sector; continued U.S. membership to the WHO; support for necessary market conditions to incentivize health sector investment, grow markets, sustain business operations, and improve access to health commodities globally; promote greater harmonization of standards and investment in digital health; health-related policy issues in the G20/G7 forums and other multilateral forums; support for continued and reformed U.S. foreign assistance, including in global health
Telehealth Expansion Act of 2025
Client: CHAMBER OF COMMERCE OF THE U.S.A. · Firm: CHAMBER OF COMMERCE OF THE U.S.A.
H.R. 1650/S. 763, Telehealth Expansion Act of 2025 H.R. 2528/S. 1847, Association Health Plans Act H.R. 6703, Lower Health Care Premiums for All Americans Act, including PBM transparency provisions Various issues relating to the employer-sponsored health care system, implementation of regulatory process, provider network adequacy, health savings account (HSAs), health reimbursement account (HRAs), association health plans (AHPs), cost sharing reduction payments (CSRs), individual health reimbursement arrangements (ICHRAs), employer mandates; implementation of the One Big Beautiful Bill Act, (P.L. 119-21); health reimbursement arrangements and other account-based group health plans; mental health parity; Federal Trade Commissions multilateral pharmaceutical merger taskforce; telehealth, including coverage of telehealth under High-Deductible Health Plans (HDHPs) and expanding telehealth options for employees; impact of Pharmacy Benefit Managers Practices; FTC-2022-0015; petition to HHS to grant march-in rights for the patents on the drug Xtandi; legislative proposals to tax employer-provided health care coverage; artificial price caps on providing insulin; Executive Order 14297, Delivering Most‑Favored‑Nation Prescription Drug Pricing to American Patients; ERISA preemption protections including information on constructive changes/modifications to ERISA; TRUMP AMERICA AI Act and AI proposals impacting health care; efforts to reform the World Health Organizations (WHO) engagement with private sector; continued U.S. membership to the WHO; support for necessary market conditions to incentivize health sector investment, grow markets, sustain business operations, and improve access to health commodities globally; promote greater harmonization of standards and investment in digital health; health-related policy issues in the G20/G7 forums and other multilateral forums; support for continued and reformed U.S. foreign assistance, including in global health
An act to provide for reconciliation pursuant to title II of H. Con. Res. 14.
Client: CHAMBER OF COMMERCE OF THE U.S.A. · Firm: CHAMBER OF COMMERCE OF THE U.S.A.
H.R. 1, One Big Beautiful Bill Act H.R. 661, MIRACLE Medical Technology Act of 2025 H.R. 919, Chronic Disease Flexible Coverage Act H.R. 1650/S. 763, Telehealth Expansion Act of 2025 H.R. 2213/S. 998, Medical Supply Chain Resiliency Act H.R. 2270, Empowering Employer Child and Elder Care Solutions Act H.R. 2528, Association Health Plans Act H.R. 2571, Self-Insurance Protection Act S. 1096, Preserve Access to Affordable Generics and Biosimilars Act S. 763, Telehealth Expansion Act of 2025 Potential legislation similar to H.R. 9029, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2025 Final Rule, Mental Health Parity and Addiction Equity Act (89 Fed. Reg. 77,586-77,751, September 23, 2024) Advance Notice of Methodological Changes for Calendar Year (CY) 2025 for Medicare Advantage (MA) Capitation Rates and Part C and Part D Payment Policies, U.S. Centers for Medicare & Medicaid Services, U.S. Department of Health and Human Services (2025 Advance Notice, January 31, 2024); Various issues relating to the employer-sponsored health care system, implementation of regulatory process, provider network adequacy, health savings account (HSAs), health reimbursement account (HRAs), employer mandate; implementation of the American Rescue Plan Act (P.L. 117-2); implementation of the Inflation Reduction Act (P.L. 117-169); balance or surprise billing and related issues; single-payer health care options; health reimbursement arrangements and other account-based group health plans; Health and Human Services international pricing index (IPI) model; mental health parity; drug pricing; COBRA subsidies; Federal Trade Commissions multilateral pharmaceutical merger taskforce; telehealth, including coverage of telehealth under High-Deductible Health Plans (HDHPs) and expanding telehealth options for employees; impact of Pharmacy Benefit Managers Practices; FTC-2022-0015; petition to HHS to grant march-in rights for the patents on the drug Xtandi; legislative proposals to tax employer-provided health care coverage; artificial price caps on providing insulin; Reasonable Price Clause in reauthorization draft of the Pandemic and All Hazards Preparedness Act (PAHPA, P.L. 109-417); ERISA preemption protections including information on constructive changes/modifications to ERISA; expansion of the list of preventive care benefits that may be provided by a high-deductible health plan (HDHP); efforts to reform the World Health Organizations (WHO) engagement with private sector; continued U.S. membership to the World Health Organization (WHO); support for necessary market conditions to incentivize health sector investment from private sector; support for private sector involvement in health systems strengthening; promote greater harmonization of standards and investment in digital health; health-related policy issues in the G20/G7 forums and other multilateral forums; support for improving access to health products and technologies globally, including via regulatory alignment, addressing trade barriers, strengthening the global supply chain, and raising awareness on potential pitfalls of local manufacturing; combatting anti-microbial resistance; support for continued and reformed U.S. foreign assistance, including in global health
An act to provide for reconciliation pursuant to title II of H. Con. Res. 14.
Client: CHAMBER OF COMMERCE OF THE U.S.A. · Firm: CHAMBER OF COMMERCE OF THE U.S.A.
H.R. 1, One Big Beautiful Bill Act H.R. 661, MIRACLE Medical Technology Act of 2025 H.R. 919, Chronic Disease Flexible Coverage Act H.R. 1650/S. 763, Telehealth Expansion Act of 2025 H.R. 2028/S. 1847, the Association Health Plans Act H.R. 2213/S. 998, Medical Supply Chain Resiliency Act H.R. 2270, Empowering Employer Child and Elder Care Solutions Act H.R. 2528/S. 1847, Association Health Plans Act H.R. 2571, Self-Insurance Protection Act S. 763, Telehealth Expansion Act of 2025 S. 1096, Preserve Access to Affordable Generics and Biosimilars Act Final Rule, Mental Health Parity and Addiction Equity Act (89 Fed. Reg. 77,586-77,751, September 23, 2024) Request for Information, Ultra Processed Foods (90 Fed. Reg. 35,305-35,309, July 25, 2025) Request for Information, NIH Artificial Intelligence Strategy (Response to NIH RFI NOT-OD-25-117), July 15, 2025 Request for Information, Ensuring Lawful Regulation and Unleashing Innovation to Make America Healthy Again (90 Fed. Reg. 20,478-20,481, July 14, 2025) Various issues relating to the employer-sponsored health care system, implementation of regulatory process, provider network adequacy, health savings account (HSAs), health reimbursement account (HRAs), employer mandate; implementation of the Inflation Reduction Act (P.L. 117-169); implementation of the One Big Beautiful Bill Act, (P.L. 119-21); balance or surprise billing and related issues; single-payer health care options; Affordable Care Act tax credit expiration; health reimbursement arrangements and other account-based group health plans; Health and Human Services international pricing index (IPI) model; mental health parity; COBRA subsidies; Federal Trade Commissions multilateral pharmaceutical merger taskforce; telehealth, including coverage of telehealth under High-Deductible Health Plans (HDHPs) and expanding telehealth options for employees; impact of Pharmacy Benefit Managers Practices; FTC-2022-0015; petition to HHS to grant march-in rights for the patents on the drug Xtandi; legislative proposals to tax employer-provided health care coverage; artificial price caps on providing insulin; Reasonable Price Clause in reauthorization draft of the Pandemic and All Hazards Preparedness Act (PAHPA, P.L. 109-417); ERISA preemption protections including information on constructive changes/modifications to ERISA; expansion of the list of preventive care benefits that may be provided by a high-deductible health plan (HDHP); efforts to reform the World Health Organizations (WHO) engagement with private sector; continued U.S. membership to the World Health Organization (WHO); support for necessary market conditions to incentivize health sector investment from private sector; support for private sector involvement in health systems strengthening; promote greater harmonization of standards and investment in digital health; health-related policy issues in the G20/G7 forums and other multilateral forums; support for improving access to health products and technologies globally, including via regulatory alignment, addressing trade barriers, strengthening the global supply chain, and raising awareness on potential pitfalls of local manufacturing; combatting anti-microbial resistance infectious diseases, and non-communicable diseases; support for continued and reformed U.S. foreign assistance, including in global health
Telehealth Expansion Act of 2025
Client: CHAMBER OF COMMERCE OF THE U.S.A. · Firm: CHAMBER OF COMMERCE OF THE U.S.A.
H.R. 1, One Big Beautiful Bill Act H.R. 661, MIRACLE Medical Technology Act of 2025 H.R. 919, Chronic Disease Flexible Coverage Act H.R. 1650/S. 763, Telehealth Expansion Act of 2025 H.R. 2213/S. 998, Medical Supply Chain Resiliency Act H.R. 2270, Empowering Employer Child and Elder Care Solutions Act H.R. 2528, Association Health Plans Act H.R. 2571, Self-Insurance Protection Act S. 1096, Preserve Access to Affordable Generics and Biosimilars Act S. 763, Telehealth Expansion Act of 2025 Potential legislation similar to H.R. 9029, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2025 Final Rule, Mental Health Parity and Addiction Equity Act (89 Fed. Reg. 77,586-77,751, September 23, 2024) Advance Notice of Methodological Changes for Calendar Year (CY) 2025 for Medicare Advantage (MA) Capitation Rates and Part C and Part D Payment Policies, U.S. Centers for Medicare & Medicaid Services, U.S. Department of Health and Human Services (2025 Advance Notice, January 31, 2024); Various issues relating to the employer-sponsored health care system, implementation of regulatory process, provider network adequacy, health savings account (HSAs), health reimbursement account (HRAs), employer mandate; implementation of the American Rescue Plan Act (P.L. 117-2); implementation of the Inflation Reduction Act (P.L. 117-169); balance or surprise billing and related issues; single-payer health care options; health reimbursement arrangements and other account-based group health plans; Health and Human Services international pricing index (IPI) model; mental health parity; drug pricing; COBRA subsidies; Federal Trade Commissions multilateral pharmaceutical merger taskforce; telehealth, including coverage of telehealth under High-Deductible Health Plans (HDHPs) and expanding telehealth options for employees; impact of Pharmacy Benefit Managers Practices; FTC-2022-0015; petition to HHS to grant march-in rights for the patents on the drug Xtandi; legislative proposals to tax employer-provided health care coverage; artificial price caps on providing insulin; Reasonable Price Clause in reauthorization draft of the Pandemic and All Hazards Preparedness Act (PAHPA, P.L. 109-417); ERISA preemption protections including information on constructive changes/modifications to ERISA; expansion of the list of preventive care benefits that may be provided by a high-deductible health plan (HDHP); efforts to reform the World Health Organizations (WHO) engagement with private sector; continued U.S. membership to the World Health Organization (WHO); support for necessary market conditions to incentivize health sector investment from private sector; support for private sector involvement in health systems strengthening; promote greater harmonization of standards and investment in digital health; health-related policy issues in the G20/G7 forums and other multilateral forums; support for improving access to health products and technologies globally, including via regulatory alignment, addressing trade barriers, strengthening the global supply chain, and raising awareness on potential pitfalls of local manufacturing; combatting anti-microbial resistance; support for continued and reformed U.S. foreign assistance, including in global health
Telehealth Expansion Act of 2025
Client: CHAMBER OF COMMERCE OF THE U.S.A. · Firm: CHAMBER OF COMMERCE OF THE U.S.A.
H.R. 1, One Big Beautiful Bill Act H.R. 661, MIRACLE Medical Technology Act of 2025 H.R. 919, Chronic Disease Flexible Coverage Act H.R. 1650/S. 763, Telehealth Expansion Act of 2025 H.R. 2028/S. 1847, the Association Health Plans Act H.R. 2213/S. 998, Medical Supply Chain Resiliency Act H.R. 2270, Empowering Employer Child and Elder Care Solutions Act H.R. 2528/S. 1847, Association Health Plans Act H.R. 2571, Self-Insurance Protection Act S. 763, Telehealth Expansion Act of 2025 S. 1096, Preserve Access to Affordable Generics and Biosimilars Act Final Rule, Mental Health Parity and Addiction Equity Act (89 Fed. Reg. 77,586-77,751, September 23, 2024) Request for Information, Ultra Processed Foods (90 Fed. Reg. 35,305-35,309, July 25, 2025) Request for Information, NIH Artificial Intelligence Strategy (Response to NIH RFI NOT-OD-25-117), July 15, 2025 Request for Information, Ensuring Lawful Regulation and Unleashing Innovation to Make America Healthy Again (90 Fed. Reg. 20,478-20,481, July 14, 2025) Various issues relating to the employer-sponsored health care system, implementation of regulatory process, provider network adequacy, health savings account (HSAs), health reimbursement account (HRAs), employer mandate; implementation of the Inflation Reduction Act (P.L. 117-169); implementation of the One Big Beautiful Bill Act, (P.L. 119-21); balance or surprise billing and related issues; single-payer health care options; Affordable Care Act tax credit expiration; health reimbursement arrangements and other account-based group health plans; Health and Human Services international pricing index (IPI) model; mental health parity; COBRA subsidies; Federal Trade Commissions multilateral pharmaceutical merger taskforce; telehealth, including coverage of telehealth under High-Deductible Health Plans (HDHPs) and expanding telehealth options for employees; impact of Pharmacy Benefit Managers Practices; FTC-2022-0015; petition to HHS to grant march-in rights for the patents on the drug Xtandi; legislative proposals to tax employer-provided health care coverage; artificial price caps on providing insulin; Reasonable Price Clause in reauthorization draft of the Pandemic and All Hazards Preparedness Act (PAHPA, P.L. 109-417); ERISA preemption protections including information on constructive changes/modifications to ERISA; expansion of the list of preventive care benefits that may be provided by a high-deductible health plan (HDHP); efforts to reform the World Health Organizations (WHO) engagement with private sector; continued U.S. membership to the World Health Organization (WHO); support for necessary market conditions to incentivize health sector investment from private sector; support for private sector involvement in health systems strengthening; promote greater harmonization of standards and investment in digital health; health-related policy issues in the G20/G7 forums and other multilateral forums; support for improving access to health products and technologies globally, including via regulatory alignment, addressing trade barriers, strengthening the global supply chain, and raising awareness on potential pitfalls of local manufacturing; combatting anti-microbial resistance infectious diseases, and non-communicable diseases; support for continued and reformed U.S. foreign assistance, including in global health
Telehealth Expansion Act of 2025
Client: CHAMBER OF COMMERCE OF THE U.S.A. · Firm: CHAMBER OF COMMERCE OF THE U.S.A.
H.R. 661, MIRACLE Medical Technology Act of 2025 H.R. 1650/S. 763, Telehealth Expansion Act of 2025 H.R. 2213/S. 998, Medical Supply Chain Resiliency Act H.R. 2270, Empowering Employer Child and Elder Care Solutions Act H.R. 2528/S. 1847, Association Health Plans Act H.R. 6703, Lower Health Care Premiums for All Americans Act, including provisions excluding PBM transparency reform S. 2828, Child Care Modernization Act of 2025 Various issues relating to the employer-sponsored health care system, implementation of regulatory process, provider network adequacy, health savings account (HSAs), health reimbursement account (HRAs), association health plans (AHPs), cost sharing reduction payments (CSRs), individual health reimbursement arrangements (ICHRAs), employer mandates; implementation of the Inflation Reduction Act (P.L. 117-169); implementation of the One Big Beautiful Bill Act, (P.L. 119-21); balance or surprise billing and related issues; single-payer health care options; Affordable Care Act tax credits; health reimbursement arrangements and other account-based group health plans; Health and Human Services international pricing index (IPI) model; mental health parity; COBRA subsidies; Federal Trade Commissions multilateral pharmaceutical merger taskforce; telehealth, including coverage of telehealth under High-Deductible Health Plans (HDHPs) and expanding telehealth options for employees; impact of Pharmacy Benefit Managers Practices; FTC-2022-0015; petition to HHS to grant march-in rights for the patents on the drug Xtandi; legislative proposals to tax employer-provided health care coverage; artificial price caps on providing insulin; Reasonable Price Clause in reauthorization draft of the Pandemic and All Hazards Preparedness Act (PAHPA, P.L. 109-417); ERISA preemption protections including information on constructive changes/modifications to ERISA; expansion of the list of preventive care benefits that may be provided by a high-deductible health plan (HDHP); efforts to reform the World Health Organizations (WHO) engagement with private sector; continued U.S. membership to the World Health Organization (WHO); support for necessary market conditions to incentivize health sector investment from private sector; support for private sector involvement in health systems strengthening; promote greater harmonization of standards and investment in digital health; health-related policy issues in the G20/G7 forums and other multilateral forums; support for improving access to health products and technologies globally, including via regulatory alignment, addressing trade barriers, strengthening the global supply chain, pooled procurement mechanisms, and raising awareness on potential pitfalls of local manufacturing; combatting anti-microbial resistance infectious diseases, and non-communicable diseases; support for continued and reformed U.S. foreign assistance, including in global health
Telehealth Expansion Act of 2025
Client: CHAMBER OF COMMERCE OF THE U.S.A. · Firm: CHAMBER OF COMMERCE OF THE U.S.A.
H.R. 661, MIRACLE Medical Technology Act of 2025 H.R. 1650/S. 763, Telehealth Expansion Act of 2025 Potential legislation similar to H.R. 1843/S. 1001, Telehealth Expansion Act of 2023 Potential legislation similar to H.R. 2868, Association Health Plans Act Potential legislation similar to H.R. 3800, Chronic Disease Flexible Coverage Act Potential legislation similar to H.R. 4307/S. 2115, Medical Supply Chain Resiliency Act Potential legislation similar to H.R. 6363, Further Continuing Appropriations and Other Extensions Act of 2024, and issues pertaining to H.R. 1843/S. 1001, The Telehealth Expansion Act of 2023 Potential legislation similar to H.R. 6860, Restore Protections for Dialysis Patients Act Potential legislation similar to H.R. 9029, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2025 Potential legislation similar to S. 142, Preserve Access to Affordable Generics and Biosimilars Act Potential legislation similar to S. 150, Affordable Prescriptions for Patients Act of 2023 Potential legislation similar to S. 1067, Ensuring Timely Access to Generics Act of 2023 Potential legislation similar to S. 1114, Expanding Access to Low-Cost Generics Act of 2023 Potential legislation similar to S. 2624, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2024 Potential legislation similar to S. 2780, The Medication Affordability and Patent Integrity Act Final Rule, Mental Health Parity and Addiction Equity Act (89 Fed. Reg. 77,586-77,751, September 23, 2024) Various issues relating to the employer-sponsored health care system, implementation of regulatory process, provider network adequacy, health savings account (HSAs), health reimbursement account (HRAs), employer mandate; implementation of the American Rescue Plan Act (P.L. 117-2); implementation of the Inflation Reduction Act (P.L. 117-169); balance or surprise billing and related issues; single-payer health care options; health reimbursement arrangements and other account-based group health plans; Health and Human Services international pricing index (IPI) model; mental health parity; drug pricing; COBRA subsidies; Federal Trade Commissions multilateral pharmaceutical merger taskforce; telehealth, including coverage of telehealth under High Deductible Health Plans (HDHPs) and expanding telehealth options for employees; impact of Pharmacy Benefit Managers Practices; FTC-2022-0015; petition to HHS to grant march-in rights for the patents on the drug Xtandi; legislative proposals to tax employer-provided health care coverage; artificial price caps on providing insulin; Reasonable Price Clause in reauthorization draft of the Pandemic and All Hazards Preparedness Act (PAHPA, P.L. 109-417); ERISA preemption protections including information on constructive changes/modifications to ERISA; efforts to reform the World Health Organizations (WHO) engagement with private sector; continued U.S. membership to the World Health Organization (WHO); support for necessary market conditions to incentivize health sector investment from private sector; support for private sector involvement in health systems strengthening; promote greater harmonization of standards and investment in digital health; health-related policy issues in the G20/G7 forums and other multilateral forums; support for improving access to health products and technologies globally, including via regulatory alignment, addressing trade barriers, strengthening the global supply chain, and raising awareness on potential pitfalls of local manufacturing; combatting anti-microbial resistance; support for continued and reformed U.S. foreign assistance, including in global health; Advance Notice of Methodological Changes for Calendar Year (CY) 2025 for Medicare Advantage (MA) Capitation Rates and Part C and Part D Payment Policies, U.S. Centers for Medicare & Medicaid Services, U.S. Department of Health and Human Services (2025 Advance Notice, January 31, 2024)
REDI Act
Client: CHAMBER OF COMMERCE OF THE U.S.A. · Firm: CHAMBER OF COMMERCE OF THE U.S.A.
H.R. 1, One Big Beautiful Bill Act H.R. 661, MIRACLE Medical Technology Act of 2025 H.R. 919, Chronic Disease Flexible Coverage Act H.R. 1650/S. 763, Telehealth Expansion Act of 2025 H.R. 2028/S. 1847, the Association Health Plans Act H.R. 2213/S. 998, Medical Supply Chain Resiliency Act H.R. 2270, Empowering Employer Child and Elder Care Solutions Act H.R. 2528/S. 1847, Association Health Plans Act H.R. 2571, Self-Insurance Protection Act S. 763, Telehealth Expansion Act of 2025 S. 1096, Preserve Access to Affordable Generics and Biosimilars Act Final Rule, Mental Health Parity and Addiction Equity Act (89 Fed. Reg. 77,586-77,751, September 23, 2024) Request for Information, Ultra Processed Foods (90 Fed. Reg. 35,305-35,309, July 25, 2025) Request for Information, NIH Artificial Intelligence Strategy (Response to NIH RFI NOT-OD-25-117), July 15, 2025 Request for Information, Ensuring Lawful Regulation and Unleashing Innovation to Make America Healthy Again (90 Fed. Reg. 20,478-20,481, July 14, 2025) Various issues relating to the employer-sponsored health care system, implementation of regulatory process, provider network adequacy, health savings account (HSAs), health reimbursement account (HRAs), employer mandate; implementation of the Inflation Reduction Act (P.L. 117-169); implementation of the One Big Beautiful Bill Act, (P.L. 119-21); balance or surprise billing and related issues; single-payer health care options; Affordable Care Act tax credit expiration; health reimbursement arrangements and other account-based group health plans; Health and Human Services international pricing index (IPI) model; mental health parity; COBRA subsidies; Federal Trade Commissions multilateral pharmaceutical merger taskforce; telehealth, including coverage of telehealth under High-Deductible Health Plans (HDHPs) and expanding telehealth options for employees; impact of Pharmacy Benefit Managers Practices; FTC-2022-0015; petition to HHS to grant march-in rights for the patents on the drug Xtandi; legislative proposals to tax employer-provided health care coverage; artificial price caps on providing insulin; Reasonable Price Clause in reauthorization draft of the Pandemic and All Hazards Preparedness Act (PAHPA, P.L. 109-417); ERISA preemption protections including information on constructive changes/modifications to ERISA; expansion of the list of preventive care benefits that may be provided by a high-deductible health plan (HDHP); efforts to reform the World Health Organizations (WHO) engagement with private sector; continued U.S. membership to the World Health Organization (WHO); support for necessary market conditions to incentivize health sector investment from private sector; support for private sector involvement in health systems strengthening; promote greater harmonization of standards and investment in digital health; health-related policy issues in the G20/G7 forums and other multilateral forums; support for improving access to health products and technologies globally, including via regulatory alignment, addressing trade barriers, strengthening the global supply chain, and raising awareness on potential pitfalls of local manufacturing; combatting anti-microbial resistance infectious diseases, and non-communicable diseases; support for continued and reformed U.S. foreign assistance, including in global health
Medical Supply Chain Resiliency Act
Client: CHAMBER OF COMMERCE OF THE U.S.A. · Firm: CHAMBER OF COMMERCE OF THE U.S.A.
H.R. 1, One Big Beautiful Bill Act H.R. 661, MIRACLE Medical Technology Act of 2025 H.R. 919, Chronic Disease Flexible Coverage Act H.R. 1650/S. 763, Telehealth Expansion Act of 2025 H.R. 2028/S. 1847, the Association Health Plans Act H.R. 2213/S. 998, Medical Supply Chain Resiliency Act H.R. 2270, Empowering Employer Child and Elder Care Solutions Act H.R. 2528/S. 1847, Association Health Plans Act H.R. 2571, Self-Insurance Protection Act S. 763, Telehealth Expansion Act of 2025 S. 1096, Preserve Access to Affordable Generics and Biosimilars Act Final Rule, Mental Health Parity and Addiction Equity Act (89 Fed. Reg. 77,586-77,751, September 23, 2024) Request for Information, Ultra Processed Foods (90 Fed. Reg. 35,305-35,309, July 25, 2025) Request for Information, NIH Artificial Intelligence Strategy (Response to NIH RFI NOT-OD-25-117), July 15, 2025 Request for Information, Ensuring Lawful Regulation and Unleashing Innovation to Make America Healthy Again (90 Fed. Reg. 20,478-20,481, July 14, 2025) Various issues relating to the employer-sponsored health care system, implementation of regulatory process, provider network adequacy, health savings account (HSAs), health reimbursement account (HRAs), employer mandate; implementation of the Inflation Reduction Act (P.L. 117-169); implementation of the One Big Beautiful Bill Act, (P.L. 119-21); balance or surprise billing and related issues; single-payer health care options; Affordable Care Act tax credit expiration; health reimbursement arrangements and other account-based group health plans; Health and Human Services international pricing index (IPI) model; mental health parity; COBRA subsidies; Federal Trade Commissions multilateral pharmaceutical merger taskforce; telehealth, including coverage of telehealth under High-Deductible Health Plans (HDHPs) and expanding telehealth options for employees; impact of Pharmacy Benefit Managers Practices; FTC-2022-0015; petition to HHS to grant march-in rights for the patents on the drug Xtandi; legislative proposals to tax employer-provided health care coverage; artificial price caps on providing insulin; Reasonable Price Clause in reauthorization draft of the Pandemic and All Hazards Preparedness Act (PAHPA, P.L. 109-417); ERISA preemption protections including information on constructive changes/modifications to ERISA; expansion of the list of preventive care benefits that may be provided by a high-deductible health plan (HDHP); efforts to reform the World Health Organizations (WHO) engagement with private sector; continued U.S. membership to the World Health Organization (WHO); support for necessary market conditions to incentivize health sector investment from private sector; support for private sector involvement in health systems strengthening; promote greater harmonization of standards and investment in digital health; health-related policy issues in the G20/G7 forums and other multilateral forums; support for improving access to health products and technologies globally, including via regulatory alignment, addressing trade barriers, strengthening the global supply chain, and raising awareness on potential pitfalls of local manufacturing; combatting anti-microbial resistance infectious diseases, and non-communicable diseases; support for continued and reformed U.S. foreign assistance, including in global health
Medical Supply Chain Resiliency Act
Client: CHAMBER OF COMMERCE OF THE U.S.A. · Firm: CHAMBER OF COMMERCE OF THE U.S.A.
H.R. 1, One Big Beautiful Bill Act H.R. 661, MIRACLE Medical Technology Act of 2025 H.R. 919, Chronic Disease Flexible Coverage Act H.R. 1650/S. 763, Telehealth Expansion Act of 2025 H.R. 2213/S. 998, Medical Supply Chain Resiliency Act H.R. 2270, Empowering Employer Child and Elder Care Solutions Act H.R. 2528, Association Health Plans Act H.R. 2571, Self-Insurance Protection Act S. 1096, Preserve Access to Affordable Generics and Biosimilars Act S. 763, Telehealth Expansion Act of 2025 Potential legislation similar to H.R. 9029, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2025 Final Rule, Mental Health Parity and Addiction Equity Act (89 Fed. Reg. 77,586-77,751, September 23, 2024) Advance Notice of Methodological Changes for Calendar Year (CY) 2025 for Medicare Advantage (MA) Capitation Rates and Part C and Part D Payment Policies, U.S. Centers for Medicare & Medicaid Services, U.S. Department of Health and Human Services (2025 Advance Notice, January 31, 2024); Various issues relating to the employer-sponsored health care system, implementation of regulatory process, provider network adequacy, health savings account (HSAs), health reimbursement account (HRAs), employer mandate; implementation of the American Rescue Plan Act (P.L. 117-2); implementation of the Inflation Reduction Act (P.L. 117-169); balance or surprise billing and related issues; single-payer health care options; health reimbursement arrangements and other account-based group health plans; Health and Human Services international pricing index (IPI) model; mental health parity; drug pricing; COBRA subsidies; Federal Trade Commissions multilateral pharmaceutical merger taskforce; telehealth, including coverage of telehealth under High-Deductible Health Plans (HDHPs) and expanding telehealth options for employees; impact of Pharmacy Benefit Managers Practices; FTC-2022-0015; petition to HHS to grant march-in rights for the patents on the drug Xtandi; legislative proposals to tax employer-provided health care coverage; artificial price caps on providing insulin; Reasonable Price Clause in reauthorization draft of the Pandemic and All Hazards Preparedness Act (PAHPA, P.L. 109-417); ERISA preemption protections including information on constructive changes/modifications to ERISA; expansion of the list of preventive care benefits that may be provided by a high-deductible health plan (HDHP); efforts to reform the World Health Organizations (WHO) engagement with private sector; continued U.S. membership to the World Health Organization (WHO); support for necessary market conditions to incentivize health sector investment from private sector; support for private sector involvement in health systems strengthening; promote greater harmonization of standards and investment in digital health; health-related policy issues in the G20/G7 forums and other multilateral forums; support for improving access to health products and technologies globally, including via regulatory alignment, addressing trade barriers, strengthening the global supply chain, and raising awareness on potential pitfalls of local manufacturing; combatting anti-microbial resistance; support for continued and reformed U.S. foreign assistance, including in global health
Medical Supply Chain Resiliency Act
Client: CHAMBER OF COMMERCE OF THE U.S.A. · Firm: CHAMBER OF COMMERCE OF THE U.S.A.
H.R. 661, MIRACLE Medical Technology Act of 2025 H.R. 1650/S. 763, Telehealth Expansion Act of 2025 H.R. 2213/S. 998, Medical Supply Chain Resiliency Act H.R. 2270, Empowering Employer Child and Elder Care Solutions Act H.R. 2528/S. 1847, Association Health Plans Act H.R. 6703, Lower Health Care Premiums for All Americans Act, including provisions excluding PBM transparency reform S. 2828, Child Care Modernization Act of 2025 Various issues relating to the employer-sponsored health care system, implementation of regulatory process, provider network adequacy, health savings account (HSAs), health reimbursement account (HRAs), association health plans (AHPs), cost sharing reduction payments (CSRs), individual health reimbursement arrangements (ICHRAs), employer mandates; implementation of the Inflation Reduction Act (P.L. 117-169); implementation of the One Big Beautiful Bill Act, (P.L. 119-21); balance or surprise billing and related issues; single-payer health care options; Affordable Care Act tax credits; health reimbursement arrangements and other account-based group health plans; Health and Human Services international pricing index (IPI) model; mental health parity; COBRA subsidies; Federal Trade Commissions multilateral pharmaceutical merger taskforce; telehealth, including coverage of telehealth under High-Deductible Health Plans (HDHPs) and expanding telehealth options for employees; impact of Pharmacy Benefit Managers Practices; FTC-2022-0015; petition to HHS to grant march-in rights for the patents on the drug Xtandi; legislative proposals to tax employer-provided health care coverage; artificial price caps on providing insulin; Reasonable Price Clause in reauthorization draft of the Pandemic and All Hazards Preparedness Act (PAHPA, P.L. 109-417); ERISA preemption protections including information on constructive changes/modifications to ERISA; expansion of the list of preventive care benefits that may be provided by a high-deductible health plan (HDHP); efforts to reform the World Health Organizations (WHO) engagement with private sector; continued U.S. membership to the World Health Organization (WHO); support for necessary market conditions to incentivize health sector investment from private sector; support for private sector involvement in health systems strengthening; promote greater harmonization of standards and investment in digital health; health-related policy issues in the G20/G7 forums and other multilateral forums; support for improving access to health products and technologies globally, including via regulatory alignment, addressing trade barriers, strengthening the global supply chain, pooled procurement mechanisms, and raising awareness on potential pitfalls of local manufacturing; combatting anti-microbial resistance infectious diseases, and non-communicable diseases; support for continued and reformed U.S. foreign assistance, including in global health
Empowering Employer Child and Elder Care Solutions Act
Client: CHAMBER OF COMMERCE OF THE U.S.A. · Firm: CHAMBER OF COMMERCE OF THE U.S.A.
H.R. 1, One Big Beautiful Bill Act H.R. 661, MIRACLE Medical Technology Act of 2025 H.R. 919, Chronic Disease Flexible Coverage Act H.R. 1650/S. 763, Telehealth Expansion Act of 2025 H.R. 2028/S. 1847, the Association Health Plans Act H.R. 2213/S. 998, Medical Supply Chain Resiliency Act H.R. 2270, Empowering Employer Child and Elder Care Solutions Act H.R. 2528/S. 1847, Association Health Plans Act H.R. 2571, Self-Insurance Protection Act S. 763, Telehealth Expansion Act of 2025 S. 1096, Preserve Access to Affordable Generics and Biosimilars Act Final Rule, Mental Health Parity and Addiction Equity Act (89 Fed. Reg. 77,586-77,751, September 23, 2024) Request for Information, Ultra Processed Foods (90 Fed. Reg. 35,305-35,309, July 25, 2025) Request for Information, NIH Artificial Intelligence Strategy (Response to NIH RFI NOT-OD-25-117), July 15, 2025 Request for Information, Ensuring Lawful Regulation and Unleashing Innovation to Make America Healthy Again (90 Fed. Reg. 20,478-20,481, July 14, 2025) Various issues relating to the employer-sponsored health care system, implementation of regulatory process, provider network adequacy, health savings account (HSAs), health reimbursement account (HRAs), employer mandate; implementation of the Inflation Reduction Act (P.L. 117-169); implementation of the One Big Beautiful Bill Act, (P.L. 119-21); balance or surprise billing and related issues; single-payer health care options; Affordable Care Act tax credit expiration; health reimbursement arrangements and other account-based group health plans; Health and Human Services international pricing index (IPI) model; mental health parity; COBRA subsidies; Federal Trade Commissions multilateral pharmaceutical merger taskforce; telehealth, including coverage of telehealth under High-Deductible Health Plans (HDHPs) and expanding telehealth options for employees; impact of Pharmacy Benefit Managers Practices; FTC-2022-0015; petition to HHS to grant march-in rights for the patents on the drug Xtandi; legislative proposals to tax employer-provided health care coverage; artificial price caps on providing insulin; Reasonable Price Clause in reauthorization draft of the Pandemic and All Hazards Preparedness Act (PAHPA, P.L. 109-417); ERISA preemption protections including information on constructive changes/modifications to ERISA; expansion of the list of preventive care benefits that may be provided by a high-deductible health plan (HDHP); efforts to reform the World Health Organizations (WHO) engagement with private sector; continued U.S. membership to the World Health Organization (WHO); support for necessary market conditions to incentivize health sector investment from private sector; support for private sector involvement in health systems strengthening; promote greater harmonization of standards and investment in digital health; health-related policy issues in the G20/G7 forums and other multilateral forums; support for improving access to health products and technologies globally, including via regulatory alignment, addressing trade barriers, strengthening the global supply chain, and raising awareness on potential pitfalls of local manufacturing; combatting anti-microbial resistance infectious diseases, and non-communicable diseases; support for continued and reformed U.S. foreign assistance, including in global health
Empowering Employer Child and Elder Care Solutions Act
Client: CHAMBER OF COMMERCE OF THE U.S.A. · Firm: CHAMBER OF COMMERCE OF THE U.S.A.
H.R. 1, One Big Beautiful Bill Act H.R. 661, MIRACLE Medical Technology Act of 2025 H.R. 919, Chronic Disease Flexible Coverage Act H.R. 1650/S. 763, Telehealth Expansion Act of 2025 H.R. 2213/S. 998, Medical Supply Chain Resiliency Act H.R. 2270, Empowering Employer Child and Elder Care Solutions Act H.R. 2528, Association Health Plans Act H.R. 2571, Self-Insurance Protection Act S. 1096, Preserve Access to Affordable Generics and Biosimilars Act S. 763, Telehealth Expansion Act of 2025 Potential legislation similar to H.R. 9029, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2025 Final Rule, Mental Health Parity and Addiction Equity Act (89 Fed. Reg. 77,586-77,751, September 23, 2024) Advance Notice of Methodological Changes for Calendar Year (CY) 2025 for Medicare Advantage (MA) Capitation Rates and Part C and Part D Payment Policies, U.S. Centers for Medicare & Medicaid Services, U.S. Department of Health and Human Services (2025 Advance Notice, January 31, 2024); Various issues relating to the employer-sponsored health care system, implementation of regulatory process, provider network adequacy, health savings account (HSAs), health reimbursement account (HRAs), employer mandate; implementation of the American Rescue Plan Act (P.L. 117-2); implementation of the Inflation Reduction Act (P.L. 117-169); balance or surprise billing and related issues; single-payer health care options; health reimbursement arrangements and other account-based group health plans; Health and Human Services international pricing index (IPI) model; mental health parity; drug pricing; COBRA subsidies; Federal Trade Commissions multilateral pharmaceutical merger taskforce; telehealth, including coverage of telehealth under High-Deductible Health Plans (HDHPs) and expanding telehealth options for employees; impact of Pharmacy Benefit Managers Practices; FTC-2022-0015; petition to HHS to grant march-in rights for the patents on the drug Xtandi; legislative proposals to tax employer-provided health care coverage; artificial price caps on providing insulin; Reasonable Price Clause in reauthorization draft of the Pandemic and All Hazards Preparedness Act (PAHPA, P.L. 109-417); ERISA preemption protections including information on constructive changes/modifications to ERISA; expansion of the list of preventive care benefits that may be provided by a high-deductible health plan (HDHP); efforts to reform the World Health Organizations (WHO) engagement with private sector; continued U.S. membership to the World Health Organization (WHO); support for necessary market conditions to incentivize health sector investment from private sector; support for private sector involvement in health systems strengthening; promote greater harmonization of standards and investment in digital health; health-related policy issues in the G20/G7 forums and other multilateral forums; support for improving access to health products and technologies globally, including via regulatory alignment, addressing trade barriers, strengthening the global supply chain, and raising awareness on potential pitfalls of local manufacturing; combatting anti-microbial resistance; support for continued and reformed U.S. foreign assistance, including in global health
Empowering Employer Child and Elder Care Solutions Act
Client: CHAMBER OF COMMERCE OF THE U.S.A. · Firm: CHAMBER OF COMMERCE OF THE U.S.A.
H.R. 661, MIRACLE Medical Technology Act of 2025 H.R. 1650/S. 763, Telehealth Expansion Act of 2025 H.R. 2213/S. 998, Medical Supply Chain Resiliency Act H.R. 2270, Empowering Employer Child and Elder Care Solutions Act H.R. 2528/S. 1847, Association Health Plans Act H.R. 6703, Lower Health Care Premiums for All Americans Act, including provisions excluding PBM transparency reform S. 2828, Child Care Modernization Act of 2025 Various issues relating to the employer-sponsored health care system, implementation of regulatory process, provider network adequacy, health savings account (HSAs), health reimbursement account (HRAs), association health plans (AHPs), cost sharing reduction payments (CSRs), individual health reimbursement arrangements (ICHRAs), employer mandates; implementation of the Inflation Reduction Act (P.L. 117-169); implementation of the One Big Beautiful Bill Act, (P.L. 119-21); balance or surprise billing and related issues; single-payer health care options; Affordable Care Act tax credits; health reimbursement arrangements and other account-based group health plans; Health and Human Services international pricing index (IPI) model; mental health parity; COBRA subsidies; Federal Trade Commissions multilateral pharmaceutical merger taskforce; telehealth, including coverage of telehealth under High-Deductible Health Plans (HDHPs) and expanding telehealth options for employees; impact of Pharmacy Benefit Managers Practices; FTC-2022-0015; petition to HHS to grant march-in rights for the patents on the drug Xtandi; legislative proposals to tax employer-provided health care coverage; artificial price caps on providing insulin; Reasonable Price Clause in reauthorization draft of the Pandemic and All Hazards Preparedness Act (PAHPA, P.L. 109-417); ERISA preemption protections including information on constructive changes/modifications to ERISA; expansion of the list of preventive care benefits that may be provided by a high-deductible health plan (HDHP); efforts to reform the World Health Organizations (WHO) engagement with private sector; continued U.S. membership to the World Health Organization (WHO); support for necessary market conditions to incentivize health sector investment from private sector; support for private sector involvement in health systems strengthening; promote greater harmonization of standards and investment in digital health; health-related policy issues in the G20/G7 forums and other multilateral forums; support for improving access to health products and technologies globally, including via regulatory alignment, addressing trade barriers, strengthening the global supply chain, pooled procurement mechanisms, and raising awareness on potential pitfalls of local manufacturing; combatting anti-microbial resistance infectious diseases, and non-communicable diseases; support for continued and reformed U.S. foreign assistance, including in global health
Association Health Plans Act
Client: CHAMBER OF COMMERCE OF THE U.S.A. · Firm: CHAMBER OF COMMERCE OF THE U.S.A.
H.R. 661, MIRACLE Medical Technology Act of 2025 H.R. 1650/S. 763, Telehealth Expansion Act of 2025 H.R. 2213/S. 998, Medical Supply Chain Resiliency Act H.R. 2270, Empowering Employer Child and Elder Care Solutions Act H.R. 2528/S. 1847, Association Health Plans Act H.R. 6703, Lower Health Care Premiums for All Americans Act, including provisions excluding PBM transparency reform S. 2828, Child Care Modernization Act of 2025 Various issues relating to the employer-sponsored health care system, implementation of regulatory process, provider network adequacy, health savings account (HSAs), health reimbursement account (HRAs), association health plans (AHPs), cost sharing reduction payments (CSRs), individual health reimbursement arrangements (ICHRAs), employer mandates; implementation of the Inflation Reduction Act (P.L. 117-169); implementation of the One Big Beautiful Bill Act, (P.L. 119-21); balance or surprise billing and related issues; single-payer health care options; Affordable Care Act tax credits; health reimbursement arrangements and other account-based group health plans; Health and Human Services international pricing index (IPI) model; mental health parity; COBRA subsidies; Federal Trade Commissions multilateral pharmaceutical merger taskforce; telehealth, including coverage of telehealth under High-Deductible Health Plans (HDHPs) and expanding telehealth options for employees; impact of Pharmacy Benefit Managers Practices; FTC-2022-0015; petition to HHS to grant march-in rights for the patents on the drug Xtandi; legislative proposals to tax employer-provided health care coverage; artificial price caps on providing insulin; Reasonable Price Clause in reauthorization draft of the Pandemic and All Hazards Preparedness Act (PAHPA, P.L. 109-417); ERISA preemption protections including information on constructive changes/modifications to ERISA; expansion of the list of preventive care benefits that may be provided by a high-deductible health plan (HDHP); efforts to reform the World Health Organizations (WHO) engagement with private sector; continued U.S. membership to the World Health Organization (WHO); support for necessary market conditions to incentivize health sector investment from private sector; support for private sector involvement in health systems strengthening; promote greater harmonization of standards and investment in digital health; health-related policy issues in the G20/G7 forums and other multilateral forums; support for improving access to health products and technologies globally, including via regulatory alignment, addressing trade barriers, strengthening the global supply chain, pooled procurement mechanisms, and raising awareness on potential pitfalls of local manufacturing; combatting anti-microbial resistance infectious diseases, and non-communicable diseases; support for continued and reformed U.S. foreign assistance, including in global health
Association Health Plans Act
Client: CHAMBER OF COMMERCE OF THE U.S.A. · Firm: CHAMBER OF COMMERCE OF THE U.S.A.
H.R. 1, One Big Beautiful Bill Act H.R. 661, MIRACLE Medical Technology Act of 2025 H.R. 919, Chronic Disease Flexible Coverage Act H.R. 1650/S. 763, Telehealth Expansion Act of 2025 H.R. 2213/S. 998, Medical Supply Chain Resiliency Act H.R. 2270, Empowering Employer Child and Elder Care Solutions Act H.R. 2528, Association Health Plans Act H.R. 2571, Self-Insurance Protection Act S. 1096, Preserve Access to Affordable Generics and Biosimilars Act S. 763, Telehealth Expansion Act of 2025 Potential legislation similar to H.R. 9029, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2025 Final Rule, Mental Health Parity and Addiction Equity Act (89 Fed. Reg. 77,586-77,751, September 23, 2024) Advance Notice of Methodological Changes for Calendar Year (CY) 2025 for Medicare Advantage (MA) Capitation Rates and Part C and Part D Payment Policies, U.S. Centers for Medicare & Medicaid Services, U.S. Department of Health and Human Services (2025 Advance Notice, January 31, 2024); Various issues relating to the employer-sponsored health care system, implementation of regulatory process, provider network adequacy, health savings account (HSAs), health reimbursement account (HRAs), employer mandate; implementation of the American Rescue Plan Act (P.L. 117-2); implementation of the Inflation Reduction Act (P.L. 117-169); balance or surprise billing and related issues; single-payer health care options; health reimbursement arrangements and other account-based group health plans; Health and Human Services international pricing index (IPI) model; mental health parity; drug pricing; COBRA subsidies; Federal Trade Commissions multilateral pharmaceutical merger taskforce; telehealth, including coverage of telehealth under High-Deductible Health Plans (HDHPs) and expanding telehealth options for employees; impact of Pharmacy Benefit Managers Practices; FTC-2022-0015; petition to HHS to grant march-in rights for the patents on the drug Xtandi; legislative proposals to tax employer-provided health care coverage; artificial price caps on providing insulin; Reasonable Price Clause in reauthorization draft of the Pandemic and All Hazards Preparedness Act (PAHPA, P.L. 109-417); ERISA preemption protections including information on constructive changes/modifications to ERISA; expansion of the list of preventive care benefits that may be provided by a high-deductible health plan (HDHP); efforts to reform the World Health Organizations (WHO) engagement with private sector; continued U.S. membership to the World Health Organization (WHO); support for necessary market conditions to incentivize health sector investment from private sector; support for private sector involvement in health systems strengthening; promote greater harmonization of standards and investment in digital health; health-related policy issues in the G20/G7 forums and other multilateral forums; support for improving access to health products and technologies globally, including via regulatory alignment, addressing trade barriers, strengthening the global supply chain, and raising awareness on potential pitfalls of local manufacturing; combatting anti-microbial resistance; support for continued and reformed U.S. foreign assistance, including in global health
Association Health Plans Act
Client: CHAMBER OF COMMERCE OF THE U.S.A. · Firm: CHAMBER OF COMMERCE OF THE U.S.A.
H.R. 1, One Big Beautiful Bill Act H.R. 661, MIRACLE Medical Technology Act of 2025 H.R. 919, Chronic Disease Flexible Coverage Act H.R. 1650/S. 763, Telehealth Expansion Act of 2025 H.R. 2028/S. 1847, the Association Health Plans Act H.R. 2213/S. 998, Medical Supply Chain Resiliency Act H.R. 2270, Empowering Employer Child and Elder Care Solutions Act H.R. 2528/S. 1847, Association Health Plans Act H.R. 2571, Self-Insurance Protection Act S. 763, Telehealth Expansion Act of 2025 S. 1096, Preserve Access to Affordable Generics and Biosimilars Act Final Rule, Mental Health Parity and Addiction Equity Act (89 Fed. Reg. 77,586-77,751, September 23, 2024) Request for Information, Ultra Processed Foods (90 Fed. Reg. 35,305-35,309, July 25, 2025) Request for Information, NIH Artificial Intelligence Strategy (Response to NIH RFI NOT-OD-25-117), July 15, 2025 Request for Information, Ensuring Lawful Regulation and Unleashing Innovation to Make America Healthy Again (90 Fed. Reg. 20,478-20,481, July 14, 2025) Various issues relating to the employer-sponsored health care system, implementation of regulatory process, provider network adequacy, health savings account (HSAs), health reimbursement account (HRAs), employer mandate; implementation of the Inflation Reduction Act (P.L. 117-169); implementation of the One Big Beautiful Bill Act, (P.L. 119-21); balance or surprise billing and related issues; single-payer health care options; Affordable Care Act tax credit expiration; health reimbursement arrangements and other account-based group health plans; Health and Human Services international pricing index (IPI) model; mental health parity; COBRA subsidies; Federal Trade Commissions multilateral pharmaceutical merger taskforce; telehealth, including coverage of telehealth under High-Deductible Health Plans (HDHPs) and expanding telehealth options for employees; impact of Pharmacy Benefit Managers Practices; FTC-2022-0015; petition to HHS to grant march-in rights for the patents on the drug Xtandi; legislative proposals to tax employer-provided health care coverage; artificial price caps on providing insulin; Reasonable Price Clause in reauthorization draft of the Pandemic and All Hazards Preparedness Act (PAHPA, P.L. 109-417); ERISA preemption protections including information on constructive changes/modifications to ERISA; expansion of the list of preventive care benefits that may be provided by a high-deductible health plan (HDHP); efforts to reform the World Health Organizations (WHO) engagement with private sector; continued U.S. membership to the World Health Organization (WHO); support for necessary market conditions to incentivize health sector investment from private sector; support for private sector involvement in health systems strengthening; promote greater harmonization of standards and investment in digital health; health-related policy issues in the G20/G7 forums and other multilateral forums; support for improving access to health products and technologies globally, including via regulatory alignment, addressing trade barriers, strengthening the global supply chain, and raising awareness on potential pitfalls of local manufacturing; combatting anti-microbial resistance infectious diseases, and non-communicable diseases; support for continued and reformed U.S. foreign assistance, including in global health
Self-Insurance Protection Act
Client: CHAMBER OF COMMERCE OF THE U.S.A. · Firm: CHAMBER OF COMMERCE OF THE U.S.A.
H.R. 1, One Big Beautiful Bill Act H.R. 661, MIRACLE Medical Technology Act of 2025 H.R. 919, Chronic Disease Flexible Coverage Act H.R. 1650/S. 763, Telehealth Expansion Act of 2025 H.R. 2213/S. 998, Medical Supply Chain Resiliency Act H.R. 2270, Empowering Employer Child and Elder Care Solutions Act H.R. 2528, Association Health Plans Act H.R. 2571, Self-Insurance Protection Act S. 1096, Preserve Access to Affordable Generics and Biosimilars Act S. 763, Telehealth Expansion Act of 2025 Potential legislation similar to H.R. 9029, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2025 Final Rule, Mental Health Parity and Addiction Equity Act (89 Fed. Reg. 77,586-77,751, September 23, 2024) Advance Notice of Methodological Changes for Calendar Year (CY) 2025 for Medicare Advantage (MA) Capitation Rates and Part C and Part D Payment Policies, U.S. Centers for Medicare & Medicaid Services, U.S. Department of Health and Human Services (2025 Advance Notice, January 31, 2024); Various issues relating to the employer-sponsored health care system, implementation of regulatory process, provider network adequacy, health savings account (HSAs), health reimbursement account (HRAs), employer mandate; implementation of the American Rescue Plan Act (P.L. 117-2); implementation of the Inflation Reduction Act (P.L. 117-169); balance or surprise billing and related issues; single-payer health care options; health reimbursement arrangements and other account-based group health plans; Health and Human Services international pricing index (IPI) model; mental health parity; drug pricing; COBRA subsidies; Federal Trade Commissions multilateral pharmaceutical merger taskforce; telehealth, including coverage of telehealth under High-Deductible Health Plans (HDHPs) and expanding telehealth options for employees; impact of Pharmacy Benefit Managers Practices; FTC-2022-0015; petition to HHS to grant march-in rights for the patents on the drug Xtandi; legislative proposals to tax employer-provided health care coverage; artificial price caps on providing insulin; Reasonable Price Clause in reauthorization draft of the Pandemic and All Hazards Preparedness Act (PAHPA, P.L. 109-417); ERISA preemption protections including information on constructive changes/modifications to ERISA; expansion of the list of preventive care benefits that may be provided by a high-deductible health plan (HDHP); efforts to reform the World Health Organizations (WHO) engagement with private sector; continued U.S. membership to the World Health Organization (WHO); support for necessary market conditions to incentivize health sector investment from private sector; support for private sector involvement in health systems strengthening; promote greater harmonization of standards and investment in digital health; health-related policy issues in the G20/G7 forums and other multilateral forums; support for improving access to health products and technologies globally, including via regulatory alignment, addressing trade barriers, strengthening the global supply chain, and raising awareness on potential pitfalls of local manufacturing; combatting anti-microbial resistance; support for continued and reformed U.S. foreign assistance, including in global health
Self-Insurance Protection Act
Client: CHAMBER OF COMMERCE OF THE U.S.A. · Firm: CHAMBER OF COMMERCE OF THE U.S.A.
H.R. 1, One Big Beautiful Bill Act H.R. 661, MIRACLE Medical Technology Act of 2025 H.R. 919, Chronic Disease Flexible Coverage Act H.R. 1650/S. 763, Telehealth Expansion Act of 2025 H.R. 2028/S. 1847, the Association Health Plans Act H.R. 2213/S. 998, Medical Supply Chain Resiliency Act H.R. 2270, Empowering Employer Child and Elder Care Solutions Act H.R. 2528/S. 1847, Association Health Plans Act H.R. 2571, Self-Insurance Protection Act S. 763, Telehealth Expansion Act of 2025 S. 1096, Preserve Access to Affordable Generics and Biosimilars Act Final Rule, Mental Health Parity and Addiction Equity Act (89 Fed. Reg. 77,586-77,751, September 23, 2024) Request for Information, Ultra Processed Foods (90 Fed. Reg. 35,305-35,309, July 25, 2025) Request for Information, NIH Artificial Intelligence Strategy (Response to NIH RFI NOT-OD-25-117), July 15, 2025 Request for Information, Ensuring Lawful Regulation and Unleashing Innovation to Make America Healthy Again (90 Fed. Reg. 20,478-20,481, July 14, 2025) Various issues relating to the employer-sponsored health care system, implementation of regulatory process, provider network adequacy, health savings account (HSAs), health reimbursement account (HRAs), employer mandate; implementation of the Inflation Reduction Act (P.L. 117-169); implementation of the One Big Beautiful Bill Act, (P.L. 119-21); balance or surprise billing and related issues; single-payer health care options; Affordable Care Act tax credit expiration; health reimbursement arrangements and other account-based group health plans; Health and Human Services international pricing index (IPI) model; mental health parity; COBRA subsidies; Federal Trade Commissions multilateral pharmaceutical merger taskforce; telehealth, including coverage of telehealth under High-Deductible Health Plans (HDHPs) and expanding telehealth options for employees; impact of Pharmacy Benefit Managers Practices; FTC-2022-0015; petition to HHS to grant march-in rights for the patents on the drug Xtandi; legislative proposals to tax employer-provided health care coverage; artificial price caps on providing insulin; Reasonable Price Clause in reauthorization draft of the Pandemic and All Hazards Preparedness Act (PAHPA, P.L. 109-417); ERISA preemption protections including information on constructive changes/modifications to ERISA; expansion of the list of preventive care benefits that may be provided by a high-deductible health plan (HDHP); efforts to reform the World Health Organizations (WHO) engagement with private sector; continued U.S. membership to the World Health Organization (WHO); support for necessary market conditions to incentivize health sector investment from private sector; support for private sector involvement in health systems strengthening; promote greater harmonization of standards and investment in digital health; health-related policy issues in the G20/G7 forums and other multilateral forums; support for improving access to health products and technologies globally, including via regulatory alignment, addressing trade barriers, strengthening the global supply chain, and raising awareness on potential pitfalls of local manufacturing; combatting anti-microbial resistance infectious diseases, and non-communicable diseases; support for continued and reformed U.S. foreign assistance, including in global health
MIRACLE Medical Technology Act of 2025
Client: CHAMBER OF COMMERCE OF THE U.S.A. · Firm: CHAMBER OF COMMERCE OF THE U.S.A.
H.R. 1, One Big Beautiful Bill Act H.R. 661, MIRACLE Medical Technology Act of 2025 H.R. 919, Chronic Disease Flexible Coverage Act H.R. 1650/S. 763, Telehealth Expansion Act of 2025 H.R. 2213/S. 998, Medical Supply Chain Resiliency Act H.R. 2270, Empowering Employer Child and Elder Care Solutions Act H.R. 2528, Association Health Plans Act H.R. 2571, Self-Insurance Protection Act S. 1096, Preserve Access to Affordable Generics and Biosimilars Act S. 763, Telehealth Expansion Act of 2025 Potential legislation similar to H.R. 9029, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2025 Final Rule, Mental Health Parity and Addiction Equity Act (89 Fed. Reg. 77,586-77,751, September 23, 2024) Advance Notice of Methodological Changes for Calendar Year (CY) 2025 for Medicare Advantage (MA) Capitation Rates and Part C and Part D Payment Policies, U.S. Centers for Medicare & Medicaid Services, U.S. Department of Health and Human Services (2025 Advance Notice, January 31, 2024); Various issues relating to the employer-sponsored health care system, implementation of regulatory process, provider network adequacy, health savings account (HSAs), health reimbursement account (HRAs), employer mandate; implementation of the American Rescue Plan Act (P.L. 117-2); implementation of the Inflation Reduction Act (P.L. 117-169); balance or surprise billing and related issues; single-payer health care options; health reimbursement arrangements and other account-based group health plans; Health and Human Services international pricing index (IPI) model; mental health parity; drug pricing; COBRA subsidies; Federal Trade Commissions multilateral pharmaceutical merger taskforce; telehealth, including coverage of telehealth under High-Deductible Health Plans (HDHPs) and expanding telehealth options for employees; impact of Pharmacy Benefit Managers Practices; FTC-2022-0015; petition to HHS to grant march-in rights for the patents on the drug Xtandi; legislative proposals to tax employer-provided health care coverage; artificial price caps on providing insulin; Reasonable Price Clause in reauthorization draft of the Pandemic and All Hazards Preparedness Act (PAHPA, P.L. 109-417); ERISA preemption protections including information on constructive changes/modifications to ERISA; expansion of the list of preventive care benefits that may be provided by a high-deductible health plan (HDHP); efforts to reform the World Health Organizations (WHO) engagement with private sector; continued U.S. membership to the World Health Organization (WHO); support for necessary market conditions to incentivize health sector investment from private sector; support for private sector involvement in health systems strengthening; promote greater harmonization of standards and investment in digital health; health-related policy issues in the G20/G7 forums and other multilateral forums; support for improving access to health products and technologies globally, including via regulatory alignment, addressing trade barriers, strengthening the global supply chain, and raising awareness on potential pitfalls of local manufacturing; combatting anti-microbial resistance; support for continued and reformed U.S. foreign assistance, including in global health
MIRACLE Medical Technology Act of 2025
Client: CHAMBER OF COMMERCE OF THE U.S.A. · Firm: CHAMBER OF COMMERCE OF THE U.S.A.
H.R. 1, One Big Beautiful Bill Act H.R. 661, MIRACLE Medical Technology Act of 2025 H.R. 919, Chronic Disease Flexible Coverage Act H.R. 1650/S. 763, Telehealth Expansion Act of 2025 H.R. 2028/S. 1847, the Association Health Plans Act H.R. 2213/S. 998, Medical Supply Chain Resiliency Act H.R. 2270, Empowering Employer Child and Elder Care Solutions Act H.R. 2528/S. 1847, Association Health Plans Act H.R. 2571, Self-Insurance Protection Act S. 763, Telehealth Expansion Act of 2025 S. 1096, Preserve Access to Affordable Generics and Biosimilars Act Final Rule, Mental Health Parity and Addiction Equity Act (89 Fed. Reg. 77,586-77,751, September 23, 2024) Request for Information, Ultra Processed Foods (90 Fed. Reg. 35,305-35,309, July 25, 2025) Request for Information, NIH Artificial Intelligence Strategy (Response to NIH RFI NOT-OD-25-117), July 15, 2025 Request for Information, Ensuring Lawful Regulation and Unleashing Innovation to Make America Healthy Again (90 Fed. Reg. 20,478-20,481, July 14, 2025) Various issues relating to the employer-sponsored health care system, implementation of regulatory process, provider network adequacy, health savings account (HSAs), health reimbursement account (HRAs), employer mandate; implementation of the Inflation Reduction Act (P.L. 117-169); implementation of the One Big Beautiful Bill Act, (P.L. 119-21); balance or surprise billing and related issues; single-payer health care options; Affordable Care Act tax credit expiration; health reimbursement arrangements and other account-based group health plans; Health and Human Services international pricing index (IPI) model; mental health parity; COBRA subsidies; Federal Trade Commissions multilateral pharmaceutical merger taskforce; telehealth, including coverage of telehealth under High-Deductible Health Plans (HDHPs) and expanding telehealth options for employees; impact of Pharmacy Benefit Managers Practices; FTC-2022-0015; petition to HHS to grant march-in rights for the patents on the drug Xtandi; legislative proposals to tax employer-provided health care coverage; artificial price caps on providing insulin; Reasonable Price Clause in reauthorization draft of the Pandemic and All Hazards Preparedness Act (PAHPA, P.L. 109-417); ERISA preemption protections including information on constructive changes/modifications to ERISA; expansion of the list of preventive care benefits that may be provided by a high-deductible health plan (HDHP); efforts to reform the World Health Organizations (WHO) engagement with private sector; continued U.S. membership to the World Health Organization (WHO); support for necessary market conditions to incentivize health sector investment from private sector; support for private sector involvement in health systems strengthening; promote greater harmonization of standards and investment in digital health; health-related policy issues in the G20/G7 forums and other multilateral forums; support for improving access to health products and technologies globally, including via regulatory alignment, addressing trade barriers, strengthening the global supply chain, and raising awareness on potential pitfalls of local manufacturing; combatting anti-microbial resistance infectious diseases, and non-communicable diseases; support for continued and reformed U.S. foreign assistance, including in global health
MIRACLE Medical Technology Act of 2025
Client: CHAMBER OF COMMERCE OF THE U.S.A. · Firm: CHAMBER OF COMMERCE OF THE U.S.A.
H.R. 661, MIRACLE Medical Technology Act of 2025 H.R. 1650/S. 763, Telehealth Expansion Act of 2025 H.R. 2213/S. 998, Medical Supply Chain Resiliency Act H.R. 2270, Empowering Employer Child and Elder Care Solutions Act H.R. 2528/S. 1847, Association Health Plans Act H.R. 6703, Lower Health Care Premiums for All Americans Act, including provisions excluding PBM transparency reform S. 2828, Child Care Modernization Act of 2025 Various issues relating to the employer-sponsored health care system, implementation of regulatory process, provider network adequacy, health savings account (HSAs), health reimbursement account (HRAs), association health plans (AHPs), cost sharing reduction payments (CSRs), individual health reimbursement arrangements (ICHRAs), employer mandates; implementation of the Inflation Reduction Act (P.L. 117-169); implementation of the One Big Beautiful Bill Act, (P.L. 119-21); balance or surprise billing and related issues; single-payer health care options; Affordable Care Act tax credits; health reimbursement arrangements and other account-based group health plans; Health and Human Services international pricing index (IPI) model; mental health parity; COBRA subsidies; Federal Trade Commissions multilateral pharmaceutical merger taskforce; telehealth, including coverage of telehealth under High-Deductible Health Plans (HDHPs) and expanding telehealth options for employees; impact of Pharmacy Benefit Managers Practices; FTC-2022-0015; petition to HHS to grant march-in rights for the patents on the drug Xtandi; legislative proposals to tax employer-provided health care coverage; artificial price caps on providing insulin; Reasonable Price Clause in reauthorization draft of the Pandemic and All Hazards Preparedness Act (PAHPA, P.L. 109-417); ERISA preemption protections including information on constructive changes/modifications to ERISA; expansion of the list of preventive care benefits that may be provided by a high-deductible health plan (HDHP); efforts to reform the World Health Organizations (WHO) engagement with private sector; continued U.S. membership to the World Health Organization (WHO); support for necessary market conditions to incentivize health sector investment from private sector; support for private sector involvement in health systems strengthening; promote greater harmonization of standards and investment in digital health; health-related policy issues in the G20/G7 forums and other multilateral forums; support for improving access to health products and technologies globally, including via regulatory alignment, addressing trade barriers, strengthening the global supply chain, pooled procurement mechanisms, and raising awareness on potential pitfalls of local manufacturing; combatting anti-microbial resistance infectious diseases, and non-communicable diseases; support for continued and reformed U.S. foreign assistance, including in global health
MIRACLE Medical Technology Act of 2025
Client: CHAMBER OF COMMERCE OF THE U.S.A. · Firm: CHAMBER OF COMMERCE OF THE U.S.A.
H.R. 661, MIRACLE Medical Technology Act of 2025 H.R. 1650/S. 763, Telehealth Expansion Act of 2025 Potential legislation similar to H.R. 1843/S. 1001, Telehealth Expansion Act of 2023 Potential legislation similar to H.R. 2868, Association Health Plans Act Potential legislation similar to H.R. 3800, Chronic Disease Flexible Coverage Act Potential legislation similar to H.R. 4307/S. 2115, Medical Supply Chain Resiliency Act Potential legislation similar to H.R. 6363, Further Continuing Appropriations and Other Extensions Act of 2024, and issues pertaining to H.R. 1843/S. 1001, The Telehealth Expansion Act of 2023 Potential legislation similar to H.R. 6860, Restore Protections for Dialysis Patients Act Potential legislation similar to H.R. 9029, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2025 Potential legislation similar to S. 142, Preserve Access to Affordable Generics and Biosimilars Act Potential legislation similar to S. 150, Affordable Prescriptions for Patients Act of 2023 Potential legislation similar to S. 1067, Ensuring Timely Access to Generics Act of 2023 Potential legislation similar to S. 1114, Expanding Access to Low-Cost Generics Act of 2023 Potential legislation similar to S. 2624, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2024 Potential legislation similar to S. 2780, The Medication Affordability and Patent Integrity Act Final Rule, Mental Health Parity and Addiction Equity Act (89 Fed. Reg. 77,586-77,751, September 23, 2024) Various issues relating to the employer-sponsored health care system, implementation of regulatory process, provider network adequacy, health savings account (HSAs), health reimbursement account (HRAs), employer mandate; implementation of the American Rescue Plan Act (P.L. 117-2); implementation of the Inflation Reduction Act (P.L. 117-169); balance or surprise billing and related issues; single-payer health care options; health reimbursement arrangements and other account-based group health plans; Health and Human Services international pricing index (IPI) model; mental health parity; drug pricing; COBRA subsidies; Federal Trade Commissions multilateral pharmaceutical merger taskforce; telehealth, including coverage of telehealth under High Deductible Health Plans (HDHPs) and expanding telehealth options for employees; impact of Pharmacy Benefit Managers Practices; FTC-2022-0015; petition to HHS to grant march-in rights for the patents on the drug Xtandi; legislative proposals to tax employer-provided health care coverage; artificial price caps on providing insulin; Reasonable Price Clause in reauthorization draft of the Pandemic and All Hazards Preparedness Act (PAHPA, P.L. 109-417); ERISA preemption protections including information on constructive changes/modifications to ERISA; efforts to reform the World Health Organizations (WHO) engagement with private sector; continued U.S. membership to the World Health Organization (WHO); support for necessary market conditions to incentivize health sector investment from private sector; support for private sector involvement in health systems strengthening; promote greater harmonization of standards and investment in digital health; health-related policy issues in the G20/G7 forums and other multilateral forums; support for improving access to health products and technologies globally, including via regulatory alignment, addressing trade barriers, strengthening the global supply chain, and raising awareness on potential pitfalls of local manufacturing; combatting anti-microbial resistance; support for continued and reformed U.S. foreign assistance, including in global health; Advance Notice of Methodological Changes for Calendar Year (CY) 2025 for Medicare Advantage (MA) Capitation Rates and Part C and Part D Payment Policies, U.S. Centers for Medicare & Medicaid Services, U.S. Department of Health and Human Services (2025 Advance Notice, January 31, 2024)
Lower Health Care Premiums for All Americans Act
Client: CHAMBER OF COMMERCE OF THE U.S.A. · Firm: CHAMBER OF COMMERCE OF THE U.S.A.
H.R. 661, MIRACLE Medical Technology Act of 2025 H.R. 1650/S. 763, Telehealth Expansion Act of 2025 H.R. 2213/S. 998, Medical Supply Chain Resiliency Act H.R. 2270, Empowering Employer Child and Elder Care Solutions Act H.R. 2528/S. 1847, Association Health Plans Act H.R. 6703, Lower Health Care Premiums for All Americans Act, including provisions excluding PBM transparency reform S. 2828, Child Care Modernization Act of 2025 Various issues relating to the employer-sponsored health care system, implementation of regulatory process, provider network adequacy, health savings account (HSAs), health reimbursement account (HRAs), association health plans (AHPs), cost sharing reduction payments (CSRs), individual health reimbursement arrangements (ICHRAs), employer mandates; implementation of the Inflation Reduction Act (P.L. 117-169); implementation of the One Big Beautiful Bill Act, (P.L. 119-21); balance or surprise billing and related issues; single-payer health care options; Affordable Care Act tax credits; health reimbursement arrangements and other account-based group health plans; Health and Human Services international pricing index (IPI) model; mental health parity; COBRA subsidies; Federal Trade Commissions multilateral pharmaceutical merger taskforce; telehealth, including coverage of telehealth under High-Deductible Health Plans (HDHPs) and expanding telehealth options for employees; impact of Pharmacy Benefit Managers Practices; FTC-2022-0015; petition to HHS to grant march-in rights for the patents on the drug Xtandi; legislative proposals to tax employer-provided health care coverage; artificial price caps on providing insulin; Reasonable Price Clause in reauthorization draft of the Pandemic and All Hazards Preparedness Act (PAHPA, P.L. 109-417); ERISA preemption protections including information on constructive changes/modifications to ERISA; expansion of the list of preventive care benefits that may be provided by a high-deductible health plan (HDHP); efforts to reform the World Health Organizations (WHO) engagement with private sector; continued U.S. membership to the World Health Organization (WHO); support for necessary market conditions to incentivize health sector investment from private sector; support for private sector involvement in health systems strengthening; promote greater harmonization of standards and investment in digital health; health-related policy issues in the G20/G7 forums and other multilateral forums; support for improving access to health products and technologies globally, including via regulatory alignment, addressing trade barriers, strengthening the global supply chain, pooled procurement mechanisms, and raising awareness on potential pitfalls of local manufacturing; combatting anti-microbial resistance infectious diseases, and non-communicable diseases; support for continued and reformed U.S. foreign assistance, including in global health
Coal Cleanup Taxpayer Protection Act of 2026
Client: CHAMBER OF COMMERCE OF THE U.S.A. · Firm: CHAMBER OF COMMERCE OF THE U.S.A.
H.R. 1, One Big Beautiful Bill Act H.R. 661, MIRACLE Medical Technology Act of 2025 H.R. 919, Chronic Disease Flexible Coverage Act H.R. 1650/S. 763, Telehealth Expansion Act of 2025 H.R. 2213/S. 998, Medical Supply Chain Resiliency Act H.R. 2270, Empowering Employer Child and Elder Care Solutions Act H.R. 2528, Association Health Plans Act H.R. 2571, Self-Insurance Protection Act S. 1096, Preserve Access to Affordable Generics and Biosimilars Act S. 763, Telehealth Expansion Act of 2025 Potential legislation similar to H.R. 9029, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2025 Final Rule, Mental Health Parity and Addiction Equity Act (89 Fed. Reg. 77,586-77,751, September 23, 2024) Advance Notice of Methodological Changes for Calendar Year (CY) 2025 for Medicare Advantage (MA) Capitation Rates and Part C and Part D Payment Policies, U.S. Centers for Medicare & Medicaid Services, U.S. Department of Health and Human Services (2025 Advance Notice, January 31, 2024); Various issues relating to the employer-sponsored health care system, implementation of regulatory process, provider network adequacy, health savings account (HSAs), health reimbursement account (HRAs), employer mandate; implementation of the American Rescue Plan Act (P.L. 117-2); implementation of the Inflation Reduction Act (P.L. 117-169); balance or surprise billing and related issues; single-payer health care options; health reimbursement arrangements and other account-based group health plans; Health and Human Services international pricing index (IPI) model; mental health parity; drug pricing; COBRA subsidies; Federal Trade Commissions multilateral pharmaceutical merger taskforce; telehealth, including coverage of telehealth under High-Deductible Health Plans (HDHPs) and expanding telehealth options for employees; impact of Pharmacy Benefit Managers Practices; FTC-2022-0015; petition to HHS to grant march-in rights for the patents on the drug Xtandi; legislative proposals to tax employer-provided health care coverage; artificial price caps on providing insulin; Reasonable Price Clause in reauthorization draft of the Pandemic and All Hazards Preparedness Act (PAHPA, P.L. 109-417); ERISA preemption protections including information on constructive changes/modifications to ERISA; expansion of the list of preventive care benefits that may be provided by a high-deductible health plan (HDHP); efforts to reform the World Health Organizations (WHO) engagement with private sector; continued U.S. membership to the World Health Organization (WHO); support for necessary market conditions to incentivize health sector investment from private sector; support for private sector involvement in health systems strengthening; promote greater harmonization of standards and investment in digital health; health-related policy issues in the G20/G7 forums and other multilateral forums; support for improving access to health products and technologies globally, including via regulatory alignment, addressing trade barriers, strengthening the global supply chain, and raising awareness on potential pitfalls of local manufacturing; combatting anti-microbial resistance; support for continued and reformed U.S. foreign assistance, including in global health
Chronic Disease Flexible Coverage Act
Client: CHAMBER OF COMMERCE OF THE U.S.A. · Firm: CHAMBER OF COMMERCE OF THE U.S.A.
H.R. 1, One Big Beautiful Bill Act H.R. 661, MIRACLE Medical Technology Act of 2025 H.R. 919, Chronic Disease Flexible Coverage Act H.R. 1650/S. 763, Telehealth Expansion Act of 2025 H.R. 2213/S. 998, Medical Supply Chain Resiliency Act H.R. 2270, Empowering Employer Child and Elder Care Solutions Act H.R. 2528, Association Health Plans Act H.R. 2571, Self-Insurance Protection Act S. 1096, Preserve Access to Affordable Generics and Biosimilars Act S. 763, Telehealth Expansion Act of 2025 Potential legislation similar to H.R. 9029, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2025 Final Rule, Mental Health Parity and Addiction Equity Act (89 Fed. Reg. 77,586-77,751, September 23, 2024) Advance Notice of Methodological Changes for Calendar Year (CY) 2025 for Medicare Advantage (MA) Capitation Rates and Part C and Part D Payment Policies, U.S. Centers for Medicare & Medicaid Services, U.S. Department of Health and Human Services (2025 Advance Notice, January 31, 2024); Various issues relating to the employer-sponsored health care system, implementation of regulatory process, provider network adequacy, health savings account (HSAs), health reimbursement account (HRAs), employer mandate; implementation of the American Rescue Plan Act (P.L. 117-2); implementation of the Inflation Reduction Act (P.L. 117-169); balance or surprise billing and related issues; single-payer health care options; health reimbursement arrangements and other account-based group health plans; Health and Human Services international pricing index (IPI) model; mental health parity; drug pricing; COBRA subsidies; Federal Trade Commissions multilateral pharmaceutical merger taskforce; telehealth, including coverage of telehealth under High-Deductible Health Plans (HDHPs) and expanding telehealth options for employees; impact of Pharmacy Benefit Managers Practices; FTC-2022-0015; petition to HHS to grant march-in rights for the patents on the drug Xtandi; legislative proposals to tax employer-provided health care coverage; artificial price caps on providing insulin; Reasonable Price Clause in reauthorization draft of the Pandemic and All Hazards Preparedness Act (PAHPA, P.L. 109-417); ERISA preemption protections including information on constructive changes/modifications to ERISA; expansion of the list of preventive care benefits that may be provided by a high-deductible health plan (HDHP); efforts to reform the World Health Organizations (WHO) engagement with private sector; continued U.S. membership to the World Health Organization (WHO); support for necessary market conditions to incentivize health sector investment from private sector; support for private sector involvement in health systems strengthening; promote greater harmonization of standards and investment in digital health; health-related policy issues in the G20/G7 forums and other multilateral forums; support for improving access to health products and technologies globally, including via regulatory alignment, addressing trade barriers, strengthening the global supply chain, and raising awareness on potential pitfalls of local manufacturing; combatting anti-microbial resistance; support for continued and reformed U.S. foreign assistance, including in global health
Chronic Disease Flexible Coverage Act
Client: CHAMBER OF COMMERCE OF THE U.S.A. · Firm: CHAMBER OF COMMERCE OF THE U.S.A.
H.R. 1, One Big Beautiful Bill Act H.R. 661, MIRACLE Medical Technology Act of 2025 H.R. 919, Chronic Disease Flexible Coverage Act H.R. 1650/S. 763, Telehealth Expansion Act of 2025 H.R. 2028/S. 1847, the Association Health Plans Act H.R. 2213/S. 998, Medical Supply Chain Resiliency Act H.R. 2270, Empowering Employer Child and Elder Care Solutions Act H.R. 2528/S. 1847, Association Health Plans Act H.R. 2571, Self-Insurance Protection Act S. 763, Telehealth Expansion Act of 2025 S. 1096, Preserve Access to Affordable Generics and Biosimilars Act Final Rule, Mental Health Parity and Addiction Equity Act (89 Fed. Reg. 77,586-77,751, September 23, 2024) Request for Information, Ultra Processed Foods (90 Fed. Reg. 35,305-35,309, July 25, 2025) Request for Information, NIH Artificial Intelligence Strategy (Response to NIH RFI NOT-OD-25-117), July 15, 2025 Request for Information, Ensuring Lawful Regulation and Unleashing Innovation to Make America Healthy Again (90 Fed. Reg. 20,478-20,481, July 14, 2025) Various issues relating to the employer-sponsored health care system, implementation of regulatory process, provider network adequacy, health savings account (HSAs), health reimbursement account (HRAs), employer mandate; implementation of the Inflation Reduction Act (P.L. 117-169); implementation of the One Big Beautiful Bill Act, (P.L. 119-21); balance or surprise billing and related issues; single-payer health care options; Affordable Care Act tax credit expiration; health reimbursement arrangements and other account-based group health plans; Health and Human Services international pricing index (IPI) model; mental health parity; COBRA subsidies; Federal Trade Commissions multilateral pharmaceutical merger taskforce; telehealth, including coverage of telehealth under High-Deductible Health Plans (HDHPs) and expanding telehealth options for employees; impact of Pharmacy Benefit Managers Practices; FTC-2022-0015; petition to HHS to grant march-in rights for the patents on the drug Xtandi; legislative proposals to tax employer-provided health care coverage; artificial price caps on providing insulin; Reasonable Price Clause in reauthorization draft of the Pandemic and All Hazards Preparedness Act (PAHPA, P.L. 109-417); ERISA preemption protections including information on constructive changes/modifications to ERISA; expansion of the list of preventive care benefits that may be provided by a high-deductible health plan (HDHP); efforts to reform the World Health Organizations (WHO) engagement with private sector; continued U.S. membership to the World Health Organization (WHO); support for necessary market conditions to incentivize health sector investment from private sector; support for private sector involvement in health systems strengthening; promote greater harmonization of standards and investment in digital health; health-related policy issues in the G20/G7 forums and other multilateral forums; support for improving access to health products and technologies globally, including via regulatory alignment, addressing trade barriers, strengthening the global supply chain, and raising awareness on potential pitfalls of local manufacturing; combatting anti-microbial resistance infectious diseases, and non-communicable diseases; support for continued and reformed U.S. foreign assistance, including in global health
Preserve Access to Affordable Generics and Biosimilars Act
Client: CHAMBER OF COMMERCE OF THE U.S.A. · Firm: CHAMBER OF COMMERCE OF THE U.S.A.
H.R. 1, One Big Beautiful Bill Act H.R. 661, MIRACLE Medical Technology Act of 2025 H.R. 919, Chronic Disease Flexible Coverage Act H.R. 1650/S. 763, Telehealth Expansion Act of 2025 H.R. 2213/S. 998, Medical Supply Chain Resiliency Act H.R. 2270, Empowering Employer Child and Elder Care Solutions Act H.R. 2528, Association Health Plans Act H.R. 2571, Self-Insurance Protection Act S. 1096, Preserve Access to Affordable Generics and Biosimilars Act S. 763, Telehealth Expansion Act of 2025 Potential legislation similar to H.R. 9029, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2025 Final Rule, Mental Health Parity and Addiction Equity Act (89 Fed. Reg. 77,586-77,751, September 23, 2024) Advance Notice of Methodological Changes for Calendar Year (CY) 2025 for Medicare Advantage (MA) Capitation Rates and Part C and Part D Payment Policies, U.S. Centers for Medicare & Medicaid Services, U.S. Department of Health and Human Services (2025 Advance Notice, January 31, 2024); Various issues relating to the employer-sponsored health care system, implementation of regulatory process, provider network adequacy, health savings account (HSAs), health reimbursement account (HRAs), employer mandate; implementation of the American Rescue Plan Act (P.L. 117-2); implementation of the Inflation Reduction Act (P.L. 117-169); balance or surprise billing and related issues; single-payer health care options; health reimbursement arrangements and other account-based group health plans; Health and Human Services international pricing index (IPI) model; mental health parity; drug pricing; COBRA subsidies; Federal Trade Commissions multilateral pharmaceutical merger taskforce; telehealth, including coverage of telehealth under High-Deductible Health Plans (HDHPs) and expanding telehealth options for employees; impact of Pharmacy Benefit Managers Practices; FTC-2022-0015; petition to HHS to grant march-in rights for the patents on the drug Xtandi; legislative proposals to tax employer-provided health care coverage; artificial price caps on providing insulin; Reasonable Price Clause in reauthorization draft of the Pandemic and All Hazards Preparedness Act (PAHPA, P.L. 109-417); ERISA preemption protections including information on constructive changes/modifications to ERISA; expansion of the list of preventive care benefits that may be provided by a high-deductible health plan (HDHP); efforts to reform the World Health Organizations (WHO) engagement with private sector; continued U.S. membership to the World Health Organization (WHO); support for necessary market conditions to incentivize health sector investment from private sector; support for private sector involvement in health systems strengthening; promote greater harmonization of standards and investment in digital health; health-related policy issues in the G20/G7 forums and other multilateral forums; support for improving access to health products and technologies globally, including via regulatory alignment, addressing trade barriers, strengthening the global supply chain, and raising awareness on potential pitfalls of local manufacturing; combatting anti-microbial resistance; support for continued and reformed U.S. foreign assistance, including in global health
Preserve Access to Affordable Generics and Biosimilars Act
Client: CHAMBER OF COMMERCE OF THE U.S.A. · Firm: CHAMBER OF COMMERCE OF THE U.S.A.
H.R. 1, One Big Beautiful Bill Act H.R. 661, MIRACLE Medical Technology Act of 2025 H.R. 919, Chronic Disease Flexible Coverage Act H.R. 1650/S. 763, Telehealth Expansion Act of 2025 H.R. 2028/S. 1847, the Association Health Plans Act H.R. 2213/S. 998, Medical Supply Chain Resiliency Act H.R. 2270, Empowering Employer Child and Elder Care Solutions Act H.R. 2528/S. 1847, Association Health Plans Act H.R. 2571, Self-Insurance Protection Act S. 763, Telehealth Expansion Act of 2025 S. 1096, Preserve Access to Affordable Generics and Biosimilars Act Final Rule, Mental Health Parity and Addiction Equity Act (89 Fed. Reg. 77,586-77,751, September 23, 2024) Request for Information, Ultra Processed Foods (90 Fed. Reg. 35,305-35,309, July 25, 2025) Request for Information, NIH Artificial Intelligence Strategy (Response to NIH RFI NOT-OD-25-117), July 15, 2025 Request for Information, Ensuring Lawful Regulation and Unleashing Innovation to Make America Healthy Again (90 Fed. Reg. 20,478-20,481, July 14, 2025) Various issues relating to the employer-sponsored health care system, implementation of regulatory process, provider network adequacy, health savings account (HSAs), health reimbursement account (HRAs), employer mandate; implementation of the Inflation Reduction Act (P.L. 117-169); implementation of the One Big Beautiful Bill Act, (P.L. 119-21); balance or surprise billing and related issues; single-payer health care options; Affordable Care Act tax credit expiration; health reimbursement arrangements and other account-based group health plans; Health and Human Services international pricing index (IPI) model; mental health parity; COBRA subsidies; Federal Trade Commissions multilateral pharmaceutical merger taskforce; telehealth, including coverage of telehealth under High-Deductible Health Plans (HDHPs) and expanding telehealth options for employees; impact of Pharmacy Benefit Managers Practices; FTC-2022-0015; petition to HHS to grant march-in rights for the patents on the drug Xtandi; legislative proposals to tax employer-provided health care coverage; artificial price caps on providing insulin; Reasonable Price Clause in reauthorization draft of the Pandemic and All Hazards Preparedness Act (PAHPA, P.L. 109-417); ERISA preemption protections including information on constructive changes/modifications to ERISA; expansion of the list of preventive care benefits that may be provided by a high-deductible health plan (HDHP); efforts to reform the World Health Organizations (WHO) engagement with private sector; continued U.S. membership to the World Health Organization (WHO); support for necessary market conditions to incentivize health sector investment from private sector; support for private sector involvement in health systems strengthening; promote greater harmonization of standards and investment in digital health; health-related policy issues in the G20/G7 forums and other multilateral forums; support for improving access to health products and technologies globally, including via regulatory alignment, addressing trade barriers, strengthening the global supply chain, and raising awareness on potential pitfalls of local manufacturing; combatting anti-microbial resistance infectious diseases, and non-communicable diseases; support for continued and reformed U.S. foreign assistance, including in global health
Association Health Plans Act
Client: CHAMBER OF COMMERCE OF THE U.S.A. · Firm: CHAMBER OF COMMERCE OF THE U.S.A.
H.R. 661, MIRACLE Medical Technology Act of 2025 H.R. 1650/S. 763, Telehealth Expansion Act of 2025 H.R. 2213/S. 998, Medical Supply Chain Resiliency Act H.R. 2270, Empowering Employer Child and Elder Care Solutions Act H.R. 2528/S. 1847, Association Health Plans Act H.R. 6703, Lower Health Care Premiums for All Americans Act, including provisions excluding PBM transparency reform S. 2828, Child Care Modernization Act of 2025 Various issues relating to the employer-sponsored health care system, implementation of regulatory process, provider network adequacy, health savings account (HSAs), health reimbursement account (HRAs), association health plans (AHPs), cost sharing reduction payments (CSRs), individual health reimbursement arrangements (ICHRAs), employer mandates; implementation of the Inflation Reduction Act (P.L. 117-169); implementation of the One Big Beautiful Bill Act, (P.L. 119-21); balance or surprise billing and related issues; single-payer health care options; Affordable Care Act tax credits; health reimbursement arrangements and other account-based group health plans; Health and Human Services international pricing index (IPI) model; mental health parity; COBRA subsidies; Federal Trade Commissions multilateral pharmaceutical merger taskforce; telehealth, including coverage of telehealth under High-Deductible Health Plans (HDHPs) and expanding telehealth options for employees; impact of Pharmacy Benefit Managers Practices; FTC-2022-0015; petition to HHS to grant march-in rights for the patents on the drug Xtandi; legislative proposals to tax employer-provided health care coverage; artificial price caps on providing insulin; Reasonable Price Clause in reauthorization draft of the Pandemic and All Hazards Preparedness Act (PAHPA, P.L. 109-417); ERISA preemption protections including information on constructive changes/modifications to ERISA; expansion of the list of preventive care benefits that may be provided by a high-deductible health plan (HDHP); efforts to reform the World Health Organizations (WHO) engagement with private sector; continued U.S. membership to the World Health Organization (WHO); support for necessary market conditions to incentivize health sector investment from private sector; support for private sector involvement in health systems strengthening; promote greater harmonization of standards and investment in digital health; health-related policy issues in the G20/G7 forums and other multilateral forums; support for improving access to health products and technologies globally, including via regulatory alignment, addressing trade barriers, strengthening the global supply chain, pooled procurement mechanisms, and raising awareness on potential pitfalls of local manufacturing; combatting anti-microbial resistance infectious diseases, and non-communicable diseases; support for continued and reformed U.S. foreign assistance, including in global health
Association Health Plans Act
Client: CHAMBER OF COMMERCE OF THE U.S.A. · Firm: CHAMBER OF COMMERCE OF THE U.S.A.
H.R. 1, One Big Beautiful Bill Act H.R. 661, MIRACLE Medical Technology Act of 2025 H.R. 919, Chronic Disease Flexible Coverage Act H.R. 1650/S. 763, Telehealth Expansion Act of 2025 H.R. 2028/S. 1847, the Association Health Plans Act H.R. 2213/S. 998, Medical Supply Chain Resiliency Act H.R. 2270, Empowering Employer Child and Elder Care Solutions Act H.R. 2528/S. 1847, Association Health Plans Act H.R. 2571, Self-Insurance Protection Act S. 763, Telehealth Expansion Act of 2025 S. 1096, Preserve Access to Affordable Generics and Biosimilars Act Final Rule, Mental Health Parity and Addiction Equity Act (89 Fed. Reg. 77,586-77,751, September 23, 2024) Request for Information, Ultra Processed Foods (90 Fed. Reg. 35,305-35,309, July 25, 2025) Request for Information, NIH Artificial Intelligence Strategy (Response to NIH RFI NOT-OD-25-117), July 15, 2025 Request for Information, Ensuring Lawful Regulation and Unleashing Innovation to Make America Healthy Again (90 Fed. Reg. 20,478-20,481, July 14, 2025) Various issues relating to the employer-sponsored health care system, implementation of regulatory process, provider network adequacy, health savings account (HSAs), health reimbursement account (HRAs), employer mandate; implementation of the Inflation Reduction Act (P.L. 117-169); implementation of the One Big Beautiful Bill Act, (P.L. 119-21); balance or surprise billing and related issues; single-payer health care options; Affordable Care Act tax credit expiration; health reimbursement arrangements and other account-based group health plans; Health and Human Services international pricing index (IPI) model; mental health parity; COBRA subsidies; Federal Trade Commissions multilateral pharmaceutical merger taskforce; telehealth, including coverage of telehealth under High-Deductible Health Plans (HDHPs) and expanding telehealth options for employees; impact of Pharmacy Benefit Managers Practices; FTC-2022-0015; petition to HHS to grant march-in rights for the patents on the drug Xtandi; legislative proposals to tax employer-provided health care coverage; artificial price caps on providing insulin; Reasonable Price Clause in reauthorization draft of the Pandemic and All Hazards Preparedness Act (PAHPA, P.L. 109-417); ERISA preemption protections including information on constructive changes/modifications to ERISA; expansion of the list of preventive care benefits that may be provided by a high-deductible health plan (HDHP); efforts to reform the World Health Organizations (WHO) engagement with private sector; continued U.S. membership to the World Health Organization (WHO); support for necessary market conditions to incentivize health sector investment from private sector; support for private sector involvement in health systems strengthening; promote greater harmonization of standards and investment in digital health; health-related policy issues in the G20/G7 forums and other multilateral forums; support for improving access to health products and technologies globally, including via regulatory alignment, addressing trade barriers, strengthening the global supply chain, and raising awareness on potential pitfalls of local manufacturing; combatting anti-microbial resistance infectious diseases, and non-communicable diseases; support for continued and reformed U.S. foreign assistance, including in global health
Child Care Modernization Act of 2025
Client: CHAMBER OF COMMERCE OF THE U.S.A. · Firm: CHAMBER OF COMMERCE OF THE U.S.A.
H.R. 661, MIRACLE Medical Technology Act of 2025 H.R. 1650/S. 763, Telehealth Expansion Act of 2025 H.R. 2213/S. 998, Medical Supply Chain Resiliency Act H.R. 2270, Empowering Employer Child and Elder Care Solutions Act H.R. 2528/S. 1847, Association Health Plans Act H.R. 6703, Lower Health Care Premiums for All Americans Act, including provisions excluding PBM transparency reform S. 2828, Child Care Modernization Act of 2025 Various issues relating to the employer-sponsored health care system, implementation of regulatory process, provider network adequacy, health savings account (HSAs), health reimbursement account (HRAs), association health plans (AHPs), cost sharing reduction payments (CSRs), individual health reimbursement arrangements (ICHRAs), employer mandates; implementation of the Inflation Reduction Act (P.L. 117-169); implementation of the One Big Beautiful Bill Act, (P.L. 119-21); balance or surprise billing and related issues; single-payer health care options; Affordable Care Act tax credits; health reimbursement arrangements and other account-based group health plans; Health and Human Services international pricing index (IPI) model; mental health parity; COBRA subsidies; Federal Trade Commissions multilateral pharmaceutical merger taskforce; telehealth, including coverage of telehealth under High-Deductible Health Plans (HDHPs) and expanding telehealth options for employees; impact of Pharmacy Benefit Managers Practices; FTC-2022-0015; petition to HHS to grant march-in rights for the patents on the drug Xtandi; legislative proposals to tax employer-provided health care coverage; artificial price caps on providing insulin; Reasonable Price Clause in reauthorization draft of the Pandemic and All Hazards Preparedness Act (PAHPA, P.L. 109-417); ERISA preemption protections including information on constructive changes/modifications to ERISA; expansion of the list of preventive care benefits that may be provided by a high-deductible health plan (HDHP); efforts to reform the World Health Organizations (WHO) engagement with private sector; continued U.S. membership to the World Health Organization (WHO); support for necessary market conditions to incentivize health sector investment from private sector; support for private sector involvement in health systems strengthening; promote greater harmonization of standards and investment in digital health; health-related policy issues in the G20/G7 forums and other multilateral forums; support for improving access to health products and technologies globally, including via regulatory alignment, addressing trade barriers, strengthening the global supply chain, pooled procurement mechanisms, and raising awareness on potential pitfalls of local manufacturing; combatting anti-microbial resistance infectious diseases, and non-communicable diseases; support for continued and reformed U.S. foreign assistance, including in global health
Telehealth Expansion Act of 2025
Client: CHAMBER OF COMMERCE OF THE U.S.A. · Firm: CHAMBER OF COMMERCE OF THE U.S.A.
H.R. 661, MIRACLE Medical Technology Act of 2025 H.R. 1650/S. 763, Telehealth Expansion Act of 2025 H.R. 2213/S. 998, Medical Supply Chain Resiliency Act H.R. 2270, Empowering Employer Child and Elder Care Solutions Act H.R. 2528/S. 1847, Association Health Plans Act H.R. 6703, Lower Health Care Premiums for All Americans Act, including provisions excluding PBM transparency reform S. 2828, Child Care Modernization Act of 2025 Various issues relating to the employer-sponsored health care system, implementation of regulatory process, provider network adequacy, health savings account (HSAs), health reimbursement account (HRAs), association health plans (AHPs), cost sharing reduction payments (CSRs), individual health reimbursement arrangements (ICHRAs), employer mandates; implementation of the Inflation Reduction Act (P.L. 117-169); implementation of the One Big Beautiful Bill Act, (P.L. 119-21); balance or surprise billing and related issues; single-payer health care options; Affordable Care Act tax credits; health reimbursement arrangements and other account-based group health plans; Health and Human Services international pricing index (IPI) model; mental health parity; COBRA subsidies; Federal Trade Commissions multilateral pharmaceutical merger taskforce; telehealth, including coverage of telehealth under High-Deductible Health Plans (HDHPs) and expanding telehealth options for employees; impact of Pharmacy Benefit Managers Practices; FTC-2022-0015; petition to HHS to grant march-in rights for the patents on the drug Xtandi; legislative proposals to tax employer-provided health care coverage; artificial price caps on providing insulin; Reasonable Price Clause in reauthorization draft of the Pandemic and All Hazards Preparedness Act (PAHPA, P.L. 109-417); ERISA preemption protections including information on constructive changes/modifications to ERISA; expansion of the list of preventive care benefits that may be provided by a high-deductible health plan (HDHP); efforts to reform the World Health Organizations (WHO) engagement with private sector; continued U.S. membership to the World Health Organization (WHO); support for necessary market conditions to incentivize health sector investment from private sector; support for private sector involvement in health systems strengthening; promote greater harmonization of standards and investment in digital health; health-related policy issues in the G20/G7 forums and other multilateral forums; support for improving access to health products and technologies globally, including via regulatory alignment, addressing trade barriers, strengthening the global supply chain, pooled procurement mechanisms, and raising awareness on potential pitfalls of local manufacturing; combatting anti-microbial resistance infectious diseases, and non-communicable diseases; support for continued and reformed U.S. foreign assistance, including in global health
Telehealth Expansion Act of 2025
Client: CHAMBER OF COMMERCE OF THE U.S.A. · Firm: CHAMBER OF COMMERCE OF THE U.S.A.
H.R. 1, One Big Beautiful Bill Act H.R. 661, MIRACLE Medical Technology Act of 2025 H.R. 919, Chronic Disease Flexible Coverage Act H.R. 1650/S. 763, Telehealth Expansion Act of 2025 H.R. 2028/S. 1847, the Association Health Plans Act H.R. 2213/S. 998, Medical Supply Chain Resiliency Act H.R. 2270, Empowering Employer Child and Elder Care Solutions Act H.R. 2528/S. 1847, Association Health Plans Act H.R. 2571, Self-Insurance Protection Act S. 763, Telehealth Expansion Act of 2025 S. 1096, Preserve Access to Affordable Generics and Biosimilars Act Final Rule, Mental Health Parity and Addiction Equity Act (89 Fed. Reg. 77,586-77,751, September 23, 2024) Request for Information, Ultra Processed Foods (90 Fed. Reg. 35,305-35,309, July 25, 2025) Request for Information, NIH Artificial Intelligence Strategy (Response to NIH RFI NOT-OD-25-117), July 15, 2025 Request for Information, Ensuring Lawful Regulation and Unleashing Innovation to Make America Healthy Again (90 Fed. Reg. 20,478-20,481, July 14, 2025) Various issues relating to the employer-sponsored health care system, implementation of regulatory process, provider network adequacy, health savings account (HSAs), health reimbursement account (HRAs), employer mandate; implementation of the Inflation Reduction Act (P.L. 117-169); implementation of the One Big Beautiful Bill Act, (P.L. 119-21); balance or surprise billing and related issues; single-payer health care options; Affordable Care Act tax credit expiration; health reimbursement arrangements and other account-based group health plans; Health and Human Services international pricing index (IPI) model; mental health parity; COBRA subsidies; Federal Trade Commissions multilateral pharmaceutical merger taskforce; telehealth, including coverage of telehealth under High-Deductible Health Plans (HDHPs) and expanding telehealth options for employees; impact of Pharmacy Benefit Managers Practices; FTC-2022-0015; petition to HHS to grant march-in rights for the patents on the drug Xtandi; legislative proposals to tax employer-provided health care coverage; artificial price caps on providing insulin; Reasonable Price Clause in reauthorization draft of the Pandemic and All Hazards Preparedness Act (PAHPA, P.L. 109-417); ERISA preemption protections including information on constructive changes/modifications to ERISA; expansion of the list of preventive care benefits that may be provided by a high-deductible health plan (HDHP); efforts to reform the World Health Organizations (WHO) engagement with private sector; continued U.S. membership to the World Health Organization (WHO); support for necessary market conditions to incentivize health sector investment from private sector; support for private sector involvement in health systems strengthening; promote greater harmonization of standards and investment in digital health; health-related policy issues in the G20/G7 forums and other multilateral forums; support for improving access to health products and technologies globally, including via regulatory alignment, addressing trade barriers, strengthening the global supply chain, and raising awareness on potential pitfalls of local manufacturing; combatting anti-microbial resistance infectious diseases, and non-communicable diseases; support for continued and reformed U.S. foreign assistance, including in global health
Telehealth Expansion Act of 2025
Client: CHAMBER OF COMMERCE OF THE U.S.A. · Firm: CHAMBER OF COMMERCE OF THE U.S.A.
H.R. 1, One Big Beautiful Bill Act H.R. 661, MIRACLE Medical Technology Act of 2025 H.R. 919, Chronic Disease Flexible Coverage Act H.R. 1650/S. 763, Telehealth Expansion Act of 2025 H.R. 2213/S. 998, Medical Supply Chain Resiliency Act H.R. 2270, Empowering Employer Child and Elder Care Solutions Act H.R. 2528, Association Health Plans Act H.R. 2571, Self-Insurance Protection Act S. 1096, Preserve Access to Affordable Generics and Biosimilars Act S. 763, Telehealth Expansion Act of 2025 Potential legislation similar to H.R. 9029, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2025 Final Rule, Mental Health Parity and Addiction Equity Act (89 Fed. Reg. 77,586-77,751, September 23, 2024) Advance Notice of Methodological Changes for Calendar Year (CY) 2025 for Medicare Advantage (MA) Capitation Rates and Part C and Part D Payment Policies, U.S. Centers for Medicare & Medicaid Services, U.S. Department of Health and Human Services (2025 Advance Notice, January 31, 2024); Various issues relating to the employer-sponsored health care system, implementation of regulatory process, provider network adequacy, health savings account (HSAs), health reimbursement account (HRAs), employer mandate; implementation of the American Rescue Plan Act (P.L. 117-2); implementation of the Inflation Reduction Act (P.L. 117-169); balance or surprise billing and related issues; single-payer health care options; health reimbursement arrangements and other account-based group health plans; Health and Human Services international pricing index (IPI) model; mental health parity; drug pricing; COBRA subsidies; Federal Trade Commissions multilateral pharmaceutical merger taskforce; telehealth, including coverage of telehealth under High-Deductible Health Plans (HDHPs) and expanding telehealth options for employees; impact of Pharmacy Benefit Managers Practices; FTC-2022-0015; petition to HHS to grant march-in rights for the patents on the drug Xtandi; legislative proposals to tax employer-provided health care coverage; artificial price caps on providing insulin; Reasonable Price Clause in reauthorization draft of the Pandemic and All Hazards Preparedness Act (PAHPA, P.L. 109-417); ERISA preemption protections including information on constructive changes/modifications to ERISA; expansion of the list of preventive care benefits that may be provided by a high-deductible health plan (HDHP); efforts to reform the World Health Organizations (WHO) engagement with private sector; continued U.S. membership to the World Health Organization (WHO); support for necessary market conditions to incentivize health sector investment from private sector; support for private sector involvement in health systems strengthening; promote greater harmonization of standards and investment in digital health; health-related policy issues in the G20/G7 forums and other multilateral forums; support for improving access to health products and technologies globally, including via regulatory alignment, addressing trade barriers, strengthening the global supply chain, and raising awareness on potential pitfalls of local manufacturing; combatting anti-microbial resistance; support for continued and reformed U.S. foreign assistance, including in global health
Telehealth Expansion Act of 2025
Client: CHAMBER OF COMMERCE OF THE U.S.A. · Firm: CHAMBER OF COMMERCE OF THE U.S.A.
H.R. 661, MIRACLE Medical Technology Act of 2025 H.R. 1650/S. 763, Telehealth Expansion Act of 2025 Potential legislation similar to H.R. 1843/S. 1001, Telehealth Expansion Act of 2023 Potential legislation similar to H.R. 2868, Association Health Plans Act Potential legislation similar to H.R. 3800, Chronic Disease Flexible Coverage Act Potential legislation similar to H.R. 4307/S. 2115, Medical Supply Chain Resiliency Act Potential legislation similar to H.R. 6363, Further Continuing Appropriations and Other Extensions Act of 2024, and issues pertaining to H.R. 1843/S. 1001, The Telehealth Expansion Act of 2023 Potential legislation similar to H.R. 6860, Restore Protections for Dialysis Patients Act Potential legislation similar to H.R. 9029, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2025 Potential legislation similar to S. 142, Preserve Access to Affordable Generics and Biosimilars Act Potential legislation similar to S. 150, Affordable Prescriptions for Patients Act of 2023 Potential legislation similar to S. 1067, Ensuring Timely Access to Generics Act of 2023 Potential legislation similar to S. 1114, Expanding Access to Low-Cost Generics Act of 2023 Potential legislation similar to S. 2624, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2024 Potential legislation similar to S. 2780, The Medication Affordability and Patent Integrity Act Final Rule, Mental Health Parity and Addiction Equity Act (89 Fed. Reg. 77,586-77,751, September 23, 2024) Various issues relating to the employer-sponsored health care system, implementation of regulatory process, provider network adequacy, health savings account (HSAs), health reimbursement account (HRAs), employer mandate; implementation of the American Rescue Plan Act (P.L. 117-2); implementation of the Inflation Reduction Act (P.L. 117-169); balance or surprise billing and related issues; single-payer health care options; health reimbursement arrangements and other account-based group health plans; Health and Human Services international pricing index (IPI) model; mental health parity; drug pricing; COBRA subsidies; Federal Trade Commissions multilateral pharmaceutical merger taskforce; telehealth, including coverage of telehealth under High Deductible Health Plans (HDHPs) and expanding telehealth options for employees; impact of Pharmacy Benefit Managers Practices; FTC-2022-0015; petition to HHS to grant march-in rights for the patents on the drug Xtandi; legislative proposals to tax employer-provided health care coverage; artificial price caps on providing insulin; Reasonable Price Clause in reauthorization draft of the Pandemic and All Hazards Preparedness Act (PAHPA, P.L. 109-417); ERISA preemption protections including information on constructive changes/modifications to ERISA; efforts to reform the World Health Organizations (WHO) engagement with private sector; continued U.S. membership to the World Health Organization (WHO); support for necessary market conditions to incentivize health sector investment from private sector; support for private sector involvement in health systems strengthening; promote greater harmonization of standards and investment in digital health; health-related policy issues in the G20/G7 forums and other multilateral forums; support for improving access to health products and technologies globally, including via regulatory alignment, addressing trade barriers, strengthening the global supply chain, and raising awareness on potential pitfalls of local manufacturing; combatting anti-microbial resistance; support for continued and reformed U.S. foreign assistance, including in global health; Advance Notice of Methodological Changes for Calendar Year (CY) 2025 for Medicare Advantage (MA) Capitation Rates and Part C and Part D Payment Policies, U.S. Centers for Medicare & Medicaid Services, U.S. Department of Health and Human Services (2025 Advance Notice, January 31, 2024)
Medical Supply Chain Resiliency Act
Client: CHAMBER OF COMMERCE OF THE U.S.A. · Firm: CHAMBER OF COMMERCE OF THE U.S.A.
H.R. 661, MIRACLE Medical Technology Act of 2025 H.R. 1650/S. 763, Telehealth Expansion Act of 2025 H.R. 2213/S. 998, Medical Supply Chain Resiliency Act H.R. 2270, Empowering Employer Child and Elder Care Solutions Act H.R. 2528/S. 1847, Association Health Plans Act H.R. 6703, Lower Health Care Premiums for All Americans Act, including provisions excluding PBM transparency reform S. 2828, Child Care Modernization Act of 2025 Various issues relating to the employer-sponsored health care system, implementation of regulatory process, provider network adequacy, health savings account (HSAs), health reimbursement account (HRAs), association health plans (AHPs), cost sharing reduction payments (CSRs), individual health reimbursement arrangements (ICHRAs), employer mandates; implementation of the Inflation Reduction Act (P.L. 117-169); implementation of the One Big Beautiful Bill Act, (P.L. 119-21); balance or surprise billing and related issues; single-payer health care options; Affordable Care Act tax credits; health reimbursement arrangements and other account-based group health plans; Health and Human Services international pricing index (IPI) model; mental health parity; COBRA subsidies; Federal Trade Commissions multilateral pharmaceutical merger taskforce; telehealth, including coverage of telehealth under High-Deductible Health Plans (HDHPs) and expanding telehealth options for employees; impact of Pharmacy Benefit Managers Practices; FTC-2022-0015; petition to HHS to grant march-in rights for the patents on the drug Xtandi; legislative proposals to tax employer-provided health care coverage; artificial price caps on providing insulin; Reasonable Price Clause in reauthorization draft of the Pandemic and All Hazards Preparedness Act (PAHPA, P.L. 109-417); ERISA preemption protections including information on constructive changes/modifications to ERISA; expansion of the list of preventive care benefits that may be provided by a high-deductible health plan (HDHP); efforts to reform the World Health Organizations (WHO) engagement with private sector; continued U.S. membership to the World Health Organization (WHO); support for necessary market conditions to incentivize health sector investment from private sector; support for private sector involvement in health systems strengthening; promote greater harmonization of standards and investment in digital health; health-related policy issues in the G20/G7 forums and other multilateral forums; support for improving access to health products and technologies globally, including via regulatory alignment, addressing trade barriers, strengthening the global supply chain, pooled procurement mechanisms, and raising awareness on potential pitfalls of local manufacturing; combatting anti-microbial resistance infectious diseases, and non-communicable diseases; support for continued and reformed U.S. foreign assistance, including in global health
Medical Supply Chain Resiliency Act
Client: CHAMBER OF COMMERCE OF THE U.S.A. · Firm: CHAMBER OF COMMERCE OF THE U.S.A.
H.R. 1, One Big Beautiful Bill Act H.R. 661, MIRACLE Medical Technology Act of 2025 H.R. 919, Chronic Disease Flexible Coverage Act H.R. 1650/S. 763, Telehealth Expansion Act of 2025 H.R. 2028/S. 1847, the Association Health Plans Act H.R. 2213/S. 998, Medical Supply Chain Resiliency Act H.R. 2270, Empowering Employer Child and Elder Care Solutions Act H.R. 2528/S. 1847, Association Health Plans Act H.R. 2571, Self-Insurance Protection Act S. 763, Telehealth Expansion Act of 2025 S. 1096, Preserve Access to Affordable Generics and Biosimilars Act Final Rule, Mental Health Parity and Addiction Equity Act (89 Fed. Reg. 77,586-77,751, September 23, 2024) Request for Information, Ultra Processed Foods (90 Fed. Reg. 35,305-35,309, July 25, 2025) Request for Information, NIH Artificial Intelligence Strategy (Response to NIH RFI NOT-OD-25-117), July 15, 2025 Request for Information, Ensuring Lawful Regulation and Unleashing Innovation to Make America Healthy Again (90 Fed. Reg. 20,478-20,481, July 14, 2025) Various issues relating to the employer-sponsored health care system, implementation of regulatory process, provider network adequacy, health savings account (HSAs), health reimbursement account (HRAs), employer mandate; implementation of the Inflation Reduction Act (P.L. 117-169); implementation of the One Big Beautiful Bill Act, (P.L. 119-21); balance or surprise billing and related issues; single-payer health care options; Affordable Care Act tax credit expiration; health reimbursement arrangements and other account-based group health plans; Health and Human Services international pricing index (IPI) model; mental health parity; COBRA subsidies; Federal Trade Commissions multilateral pharmaceutical merger taskforce; telehealth, including coverage of telehealth under High-Deductible Health Plans (HDHPs) and expanding telehealth options for employees; impact of Pharmacy Benefit Managers Practices; FTC-2022-0015; petition to HHS to grant march-in rights for the patents on the drug Xtandi; legislative proposals to tax employer-provided health care coverage; artificial price caps on providing insulin; Reasonable Price Clause in reauthorization draft of the Pandemic and All Hazards Preparedness Act (PAHPA, P.L. 109-417); ERISA preemption protections including information on constructive changes/modifications to ERISA; expansion of the list of preventive care benefits that may be provided by a high-deductible health plan (HDHP); efforts to reform the World Health Organizations (WHO) engagement with private sector; continued U.S. membership to the World Health Organization (WHO); support for necessary market conditions to incentivize health sector investment from private sector; support for private sector involvement in health systems strengthening; promote greater harmonization of standards and investment in digital health; health-related policy issues in the G20/G7 forums and other multilateral forums; support for improving access to health products and technologies globally, including via regulatory alignment, addressing trade barriers, strengthening the global supply chain, and raising awareness on potential pitfalls of local manufacturing; combatting anti-microbial resistance infectious diseases, and non-communicable diseases; support for continued and reformed U.S. foreign assistance, including in global health
Medical Supply Chain Resiliency Act
Client: CHAMBER OF COMMERCE OF THE U.S.A. · Firm: CHAMBER OF COMMERCE OF THE U.S.A.
H.R. 1, One Big Beautiful Bill Act H.R. 661, MIRACLE Medical Technology Act of 2025 H.R. 919, Chronic Disease Flexible Coverage Act H.R. 1650/S. 763, Telehealth Expansion Act of 2025 H.R. 2213/S. 998, Medical Supply Chain Resiliency Act H.R. 2270, Empowering Employer Child and Elder Care Solutions Act H.R. 2528, Association Health Plans Act H.R. 2571, Self-Insurance Protection Act S. 1096, Preserve Access to Affordable Generics and Biosimilars Act S. 763, Telehealth Expansion Act of 2025 Potential legislation similar to H.R. 9029, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2025 Final Rule, Mental Health Parity and Addiction Equity Act (89 Fed. Reg. 77,586-77,751, September 23, 2024) Advance Notice of Methodological Changes for Calendar Year (CY) 2025 for Medicare Advantage (MA) Capitation Rates and Part C and Part D Payment Policies, U.S. Centers for Medicare & Medicaid Services, U.S. Department of Health and Human Services (2025 Advance Notice, January 31, 2024); Various issues relating to the employer-sponsored health care system, implementation of regulatory process, provider network adequacy, health savings account (HSAs), health reimbursement account (HRAs), employer mandate; implementation of the American Rescue Plan Act (P.L. 117-2); implementation of the Inflation Reduction Act (P.L. 117-169); balance or surprise billing and related issues; single-payer health care options; health reimbursement arrangements and other account-based group health plans; Health and Human Services international pricing index (IPI) model; mental health parity; drug pricing; COBRA subsidies; Federal Trade Commissions multilateral pharmaceutical merger taskforce; telehealth, including coverage of telehealth under High-Deductible Health Plans (HDHPs) and expanding telehealth options for employees; impact of Pharmacy Benefit Managers Practices; FTC-2022-0015; petition to HHS to grant march-in rights for the patents on the drug Xtandi; legislative proposals to tax employer-provided health care coverage; artificial price caps on providing insulin; Reasonable Price Clause in reauthorization draft of the Pandemic and All Hazards Preparedness Act (PAHPA, P.L. 109-417); ERISA preemption protections including information on constructive changes/modifications to ERISA; expansion of the list of preventive care benefits that may be provided by a high-deductible health plan (HDHP); efforts to reform the World Health Organizations (WHO) engagement with private sector; continued U.S. membership to the World Health Organization (WHO); support for necessary market conditions to incentivize health sector investment from private sector; support for private sector involvement in health systems strengthening; promote greater harmonization of standards and investment in digital health; health-related policy issues in the G20/G7 forums and other multilateral forums; support for improving access to health products and technologies globally, including via regulatory alignment, addressing trade barriers, strengthening the global supply chain, and raising awareness on potential pitfalls of local manufacturing; combatting anti-microbial resistance; support for continued and reformed U.S. foreign assistance, including in global health
Telehealth Expansion Act of 2023
Client: CHAMBER OF COMMERCE OF THE U.S.A. · Firm: CHAMBER OF COMMERCE OF THE U.S.A.
H.R. 661, MIRACLE Medical Technology Act of 2025 H.R. 1650/S. 763, Telehealth Expansion Act of 2025 Potential legislation similar to H.R. 1843/S. 1001, Telehealth Expansion Act of 2023 Potential legislation similar to H.R. 2868, Association Health Plans Act Potential legislation similar to H.R. 3800, Chronic Disease Flexible Coverage Act Potential legislation similar to H.R. 4307/S. 2115, Medical Supply Chain Resiliency Act Potential legislation similar to H.R. 6363, Further Continuing Appropriations and Other Extensions Act of 2024, and issues pertaining to H.R. 1843/S. 1001, The Telehealth Expansion Act of 2023 Potential legislation similar to H.R. 6860, Restore Protections for Dialysis Patients Act Potential legislation similar to H.R. 9029, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2025 Potential legislation similar to S. 142, Preserve Access to Affordable Generics and Biosimilars Act Potential legislation similar to S. 150, Affordable Prescriptions for Patients Act of 2023 Potential legislation similar to S. 1067, Ensuring Timely Access to Generics Act of 2023 Potential legislation similar to S. 1114, Expanding Access to Low-Cost Generics Act of 2023 Potential legislation similar to S. 2624, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2024 Potential legislation similar to S. 2780, The Medication Affordability and Patent Integrity Act Final Rule, Mental Health Parity and Addiction Equity Act (89 Fed. Reg. 77,586-77,751, September 23, 2024) Various issues relating to the employer-sponsored health care system, implementation of regulatory process, provider network adequacy, health savings account (HSAs), health reimbursement account (HRAs), employer mandate; implementation of the American Rescue Plan Act (P.L. 117-2); implementation of the Inflation Reduction Act (P.L. 117-169); balance or surprise billing and related issues; single-payer health care options; health reimbursement arrangements and other account-based group health plans; Health and Human Services international pricing index (IPI) model; mental health parity; drug pricing; COBRA subsidies; Federal Trade Commissions multilateral pharmaceutical merger taskforce; telehealth, including coverage of telehealth under High Deductible Health Plans (HDHPs) and expanding telehealth options for employees; impact of Pharmacy Benefit Managers Practices; FTC-2022-0015; petition to HHS to grant march-in rights for the patents on the drug Xtandi; legislative proposals to tax employer-provided health care coverage; artificial price caps on providing insulin; Reasonable Price Clause in reauthorization draft of the Pandemic and All Hazards Preparedness Act (PAHPA, P.L. 109-417); ERISA preemption protections including information on constructive changes/modifications to ERISA; efforts to reform the World Health Organizations (WHO) engagement with private sector; continued U.S. membership to the World Health Organization (WHO); support for necessary market conditions to incentivize health sector investment from private sector; support for private sector involvement in health systems strengthening; promote greater harmonization of standards and investment in digital health; health-related policy issues in the G20/G7 forums and other multilateral forums; support for improving access to health products and technologies globally, including via regulatory alignment, addressing trade barriers, strengthening the global supply chain, and raising awareness on potential pitfalls of local manufacturing; combatting anti-microbial resistance; support for continued and reformed U.S. foreign assistance, including in global health; Advance Notice of Methodological Changes for Calendar Year (CY) 2025 for Medicare Advantage (MA) Capitation Rates and Part C and Part D Payment Policies, U.S. Centers for Medicare & Medicaid Services, U.S. Department of Health and Human Services (2025 Advance Notice, January 31, 2024)
Association Health Plans Act
Client: CHAMBER OF COMMERCE OF THE U.S.A. · Firm: CHAMBER OF COMMERCE OF THE U.S.A.
H.R. 661, MIRACLE Medical Technology Act of 2025 H.R. 1650/S. 763, Telehealth Expansion Act of 2025 Potential legislation similar to H.R. 1843/S. 1001, Telehealth Expansion Act of 2023 Potential legislation similar to H.R. 2868, Association Health Plans Act Potential legislation similar to H.R. 3800, Chronic Disease Flexible Coverage Act Potential legislation similar to H.R. 4307/S. 2115, Medical Supply Chain Resiliency Act Potential legislation similar to H.R. 6363, Further Continuing Appropriations and Other Extensions Act of 2024, and issues pertaining to H.R. 1843/S. 1001, The Telehealth Expansion Act of 2023 Potential legislation similar to H.R. 6860, Restore Protections for Dialysis Patients Act Potential legislation similar to H.R. 9029, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2025 Potential legislation similar to S. 142, Preserve Access to Affordable Generics and Biosimilars Act Potential legislation similar to S. 150, Affordable Prescriptions for Patients Act of 2023 Potential legislation similar to S. 1067, Ensuring Timely Access to Generics Act of 2023 Potential legislation similar to S. 1114, Expanding Access to Low-Cost Generics Act of 2023 Potential legislation similar to S. 2624, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2024 Potential legislation similar to S. 2780, The Medication Affordability and Patent Integrity Act Final Rule, Mental Health Parity and Addiction Equity Act (89 Fed. Reg. 77,586-77,751, September 23, 2024) Various issues relating to the employer-sponsored health care system, implementation of regulatory process, provider network adequacy, health savings account (HSAs), health reimbursement account (HRAs), employer mandate; implementation of the American Rescue Plan Act (P.L. 117-2); implementation of the Inflation Reduction Act (P.L. 117-169); balance or surprise billing and related issues; single-payer health care options; health reimbursement arrangements and other account-based group health plans; Health and Human Services international pricing index (IPI) model; mental health parity; drug pricing; COBRA subsidies; Federal Trade Commissions multilateral pharmaceutical merger taskforce; telehealth, including coverage of telehealth under High Deductible Health Plans (HDHPs) and expanding telehealth options for employees; impact of Pharmacy Benefit Managers Practices; FTC-2022-0015; petition to HHS to grant march-in rights for the patents on the drug Xtandi; legislative proposals to tax employer-provided health care coverage; artificial price caps on providing insulin; Reasonable Price Clause in reauthorization draft of the Pandemic and All Hazards Preparedness Act (PAHPA, P.L. 109-417); ERISA preemption protections including information on constructive changes/modifications to ERISA; efforts to reform the World Health Organizations (WHO) engagement with private sector; continued U.S. membership to the World Health Organization (WHO); support for necessary market conditions to incentivize health sector investment from private sector; support for private sector involvement in health systems strengthening; promote greater harmonization of standards and investment in digital health; health-related policy issues in the G20/G7 forums and other multilateral forums; support for improving access to health products and technologies globally, including via regulatory alignment, addressing trade barriers, strengthening the global supply chain, and raising awareness on potential pitfalls of local manufacturing; combatting anti-microbial resistance; support for continued and reformed U.S. foreign assistance, including in global health; Advance Notice of Methodological Changes for Calendar Year (CY) 2025 for Medicare Advantage (MA) Capitation Rates and Part C and Part D Payment Policies, U.S. Centers for Medicare & Medicaid Services, U.S. Department of Health and Human Services (2025 Advance Notice, January 31, 2024)
Chronic Disease Flexible Coverage Act
Client: CHAMBER OF COMMERCE OF THE U.S.A. · Firm: CHAMBER OF COMMERCE OF THE U.S.A.
H.R. 661, MIRACLE Medical Technology Act of 2025 H.R. 1650/S. 763, Telehealth Expansion Act of 2025 Potential legislation similar to H.R. 1843/S. 1001, Telehealth Expansion Act of 2023 Potential legislation similar to H.R. 2868, Association Health Plans Act Potential legislation similar to H.R. 3800, Chronic Disease Flexible Coverage Act Potential legislation similar to H.R. 4307/S. 2115, Medical Supply Chain Resiliency Act Potential legislation similar to H.R. 6363, Further Continuing Appropriations and Other Extensions Act of 2024, and issues pertaining to H.R. 1843/S. 1001, The Telehealth Expansion Act of 2023 Potential legislation similar to H.R. 6860, Restore Protections for Dialysis Patients Act Potential legislation similar to H.R. 9029, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2025 Potential legislation similar to S. 142, Preserve Access to Affordable Generics and Biosimilars Act Potential legislation similar to S. 150, Affordable Prescriptions for Patients Act of 2023 Potential legislation similar to S. 1067, Ensuring Timely Access to Generics Act of 2023 Potential legislation similar to S. 1114, Expanding Access to Low-Cost Generics Act of 2023 Potential legislation similar to S. 2624, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2024 Potential legislation similar to S. 2780, The Medication Affordability and Patent Integrity Act Final Rule, Mental Health Parity and Addiction Equity Act (89 Fed. Reg. 77,586-77,751, September 23, 2024) Various issues relating to the employer-sponsored health care system, implementation of regulatory process, provider network adequacy, health savings account (HSAs), health reimbursement account (HRAs), employer mandate; implementation of the American Rescue Plan Act (P.L. 117-2); implementation of the Inflation Reduction Act (P.L. 117-169); balance or surprise billing and related issues; single-payer health care options; health reimbursement arrangements and other account-based group health plans; Health and Human Services international pricing index (IPI) model; mental health parity; drug pricing; COBRA subsidies; Federal Trade Commissions multilateral pharmaceutical merger taskforce; telehealth, including coverage of telehealth under High Deductible Health Plans (HDHPs) and expanding telehealth options for employees; impact of Pharmacy Benefit Managers Practices; FTC-2022-0015; petition to HHS to grant march-in rights for the patents on the drug Xtandi; legislative proposals to tax employer-provided health care coverage; artificial price caps on providing insulin; Reasonable Price Clause in reauthorization draft of the Pandemic and All Hazards Preparedness Act (PAHPA, P.L. 109-417); ERISA preemption protections including information on constructive changes/modifications to ERISA; efforts to reform the World Health Organizations (WHO) engagement with private sector; continued U.S. membership to the World Health Organization (WHO); support for necessary market conditions to incentivize health sector investment from private sector; support for private sector involvement in health systems strengthening; promote greater harmonization of standards and investment in digital health; health-related policy issues in the G20/G7 forums and other multilateral forums; support for improving access to health products and technologies globally, including via regulatory alignment, addressing trade barriers, strengthening the global supply chain, and raising awareness on potential pitfalls of local manufacturing; combatting anti-microbial resistance; support for continued and reformed U.S. foreign assistance, including in global health; Advance Notice of Methodological Changes for Calendar Year (CY) 2025 for Medicare Advantage (MA) Capitation Rates and Part C and Part D Payment Policies, U.S. Centers for Medicare & Medicaid Services, U.S. Department of Health and Human Services (2025 Advance Notice, January 31, 2024)
Medical Supply Chain Resiliency Act
Client: CHAMBER OF COMMERCE OF THE U.S.A. · Firm: CHAMBER OF COMMERCE OF THE U.S.A.
H.R. 661, MIRACLE Medical Technology Act of 2025 H.R. 1650/S. 763, Telehealth Expansion Act of 2025 Potential legislation similar to H.R. 1843/S. 1001, Telehealth Expansion Act of 2023 Potential legislation similar to H.R. 2868, Association Health Plans Act Potential legislation similar to H.R. 3800, Chronic Disease Flexible Coverage Act Potential legislation similar to H.R. 4307/S. 2115, Medical Supply Chain Resiliency Act Potential legislation similar to H.R. 6363, Further Continuing Appropriations and Other Extensions Act of 2024, and issues pertaining to H.R. 1843/S. 1001, The Telehealth Expansion Act of 2023 Potential legislation similar to H.R. 6860, Restore Protections for Dialysis Patients Act Potential legislation similar to H.R. 9029, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2025 Potential legislation similar to S. 142, Preserve Access to Affordable Generics and Biosimilars Act Potential legislation similar to S. 150, Affordable Prescriptions for Patients Act of 2023 Potential legislation similar to S. 1067, Ensuring Timely Access to Generics Act of 2023 Potential legislation similar to S. 1114, Expanding Access to Low-Cost Generics Act of 2023 Potential legislation similar to S. 2624, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2024 Potential legislation similar to S. 2780, The Medication Affordability and Patent Integrity Act Final Rule, Mental Health Parity and Addiction Equity Act (89 Fed. Reg. 77,586-77,751, September 23, 2024) Various issues relating to the employer-sponsored health care system, implementation of regulatory process, provider network adequacy, health savings account (HSAs), health reimbursement account (HRAs), employer mandate; implementation of the American Rescue Plan Act (P.L. 117-2); implementation of the Inflation Reduction Act (P.L. 117-169); balance or surprise billing and related issues; single-payer health care options; health reimbursement arrangements and other account-based group health plans; Health and Human Services international pricing index (IPI) model; mental health parity; drug pricing; COBRA subsidies; Federal Trade Commissions multilateral pharmaceutical merger taskforce; telehealth, including coverage of telehealth under High Deductible Health Plans (HDHPs) and expanding telehealth options for employees; impact of Pharmacy Benefit Managers Practices; FTC-2022-0015; petition to HHS to grant march-in rights for the patents on the drug Xtandi; legislative proposals to tax employer-provided health care coverage; artificial price caps on providing insulin; Reasonable Price Clause in reauthorization draft of the Pandemic and All Hazards Preparedness Act (PAHPA, P.L. 109-417); ERISA preemption protections including information on constructive changes/modifications to ERISA; efforts to reform the World Health Organizations (WHO) engagement with private sector; continued U.S. membership to the World Health Organization (WHO); support for necessary market conditions to incentivize health sector investment from private sector; support for private sector involvement in health systems strengthening; promote greater harmonization of standards and investment in digital health; health-related policy issues in the G20/G7 forums and other multilateral forums; support for improving access to health products and technologies globally, including via regulatory alignment, addressing trade barriers, strengthening the global supply chain, and raising awareness on potential pitfalls of local manufacturing; combatting anti-microbial resistance; support for continued and reformed U.S. foreign assistance, including in global health; Advance Notice of Methodological Changes for Calendar Year (CY) 2025 for Medicare Advantage (MA) Capitation Rates and Part C and Part D Payment Policies, U.S. Centers for Medicare & Medicaid Services, U.S. Department of Health and Human Services (2025 Advance Notice, January 31, 2024)
Further Continuing Appropriations and Other Extensions Act, 2024
Client: CHAMBER OF COMMERCE OF THE U.S.A. · Firm: CHAMBER OF COMMERCE OF THE U.S.A.
H.R. 661, MIRACLE Medical Technology Act of 2025 H.R. 1650/S. 763, Telehealth Expansion Act of 2025 Potential legislation similar to H.R. 1843/S. 1001, Telehealth Expansion Act of 2023 Potential legislation similar to H.R. 2868, Association Health Plans Act Potential legislation similar to H.R. 3800, Chronic Disease Flexible Coverage Act Potential legislation similar to H.R. 4307/S. 2115, Medical Supply Chain Resiliency Act Potential legislation similar to H.R. 6363, Further Continuing Appropriations and Other Extensions Act of 2024, and issues pertaining to H.R. 1843/S. 1001, The Telehealth Expansion Act of 2023 Potential legislation similar to H.R. 6860, Restore Protections for Dialysis Patients Act Potential legislation similar to H.R. 9029, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2025 Potential legislation similar to S. 142, Preserve Access to Affordable Generics and Biosimilars Act Potential legislation similar to S. 150, Affordable Prescriptions for Patients Act of 2023 Potential legislation similar to S. 1067, Ensuring Timely Access to Generics Act of 2023 Potential legislation similar to S. 1114, Expanding Access to Low-Cost Generics Act of 2023 Potential legislation similar to S. 2624, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2024 Potential legislation similar to S. 2780, The Medication Affordability and Patent Integrity Act Final Rule, Mental Health Parity and Addiction Equity Act (89 Fed. Reg. 77,586-77,751, September 23, 2024) Various issues relating to the employer-sponsored health care system, implementation of regulatory process, provider network adequacy, health savings account (HSAs), health reimbursement account (HRAs), employer mandate; implementation of the American Rescue Plan Act (P.L. 117-2); implementation of the Inflation Reduction Act (P.L. 117-169); balance or surprise billing and related issues; single-payer health care options; health reimbursement arrangements and other account-based group health plans; Health and Human Services international pricing index (IPI) model; mental health parity; drug pricing; COBRA subsidies; Federal Trade Commissions multilateral pharmaceutical merger taskforce; telehealth, including coverage of telehealth under High Deductible Health Plans (HDHPs) and expanding telehealth options for employees; impact of Pharmacy Benefit Managers Practices; FTC-2022-0015; petition to HHS to grant march-in rights for the patents on the drug Xtandi; legislative proposals to tax employer-provided health care coverage; artificial price caps on providing insulin; Reasonable Price Clause in reauthorization draft of the Pandemic and All Hazards Preparedness Act (PAHPA, P.L. 109-417); ERISA preemption protections including information on constructive changes/modifications to ERISA; efforts to reform the World Health Organizations (WHO) engagement with private sector; continued U.S. membership to the World Health Organization (WHO); support for necessary market conditions to incentivize health sector investment from private sector; support for private sector involvement in health systems strengthening; promote greater harmonization of standards and investment in digital health; health-related policy issues in the G20/G7 forums and other multilateral forums; support for improving access to health products and technologies globally, including via regulatory alignment, addressing trade barriers, strengthening the global supply chain, and raising awareness on potential pitfalls of local manufacturing; combatting anti-microbial resistance; support for continued and reformed U.S. foreign assistance, including in global health; Advance Notice of Methodological Changes for Calendar Year (CY) 2025 for Medicare Advantage (MA) Capitation Rates and Part C and Part D Payment Policies, U.S. Centers for Medicare & Medicaid Services, U.S. Department of Health and Human Services (2025 Advance Notice, January 31, 2024)
Restore Protections for Dialysis Patients Act
Client: CHAMBER OF COMMERCE OF THE U.S.A. · Firm: CHAMBER OF COMMERCE OF THE U.S.A.
H.R. 661, MIRACLE Medical Technology Act of 2025 H.R. 1650/S. 763, Telehealth Expansion Act of 2025 Potential legislation similar to H.R. 1843/S. 1001, Telehealth Expansion Act of 2023 Potential legislation similar to H.R. 2868, Association Health Plans Act Potential legislation similar to H.R. 3800, Chronic Disease Flexible Coverage Act Potential legislation similar to H.R. 4307/S. 2115, Medical Supply Chain Resiliency Act Potential legislation similar to H.R. 6363, Further Continuing Appropriations and Other Extensions Act of 2024, and issues pertaining to H.R. 1843/S. 1001, The Telehealth Expansion Act of 2023 Potential legislation similar to H.R. 6860, Restore Protections for Dialysis Patients Act Potential legislation similar to H.R. 9029, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2025 Potential legislation similar to S. 142, Preserve Access to Affordable Generics and Biosimilars Act Potential legislation similar to S. 150, Affordable Prescriptions for Patients Act of 2023 Potential legislation similar to S. 1067, Ensuring Timely Access to Generics Act of 2023 Potential legislation similar to S. 1114, Expanding Access to Low-Cost Generics Act of 2023 Potential legislation similar to S. 2624, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2024 Potential legislation similar to S. 2780, The Medication Affordability and Patent Integrity Act Final Rule, Mental Health Parity and Addiction Equity Act (89 Fed. Reg. 77,586-77,751, September 23, 2024) Various issues relating to the employer-sponsored health care system, implementation of regulatory process, provider network adequacy, health savings account (HSAs), health reimbursement account (HRAs), employer mandate; implementation of the American Rescue Plan Act (P.L. 117-2); implementation of the Inflation Reduction Act (P.L. 117-169); balance or surprise billing and related issues; single-payer health care options; health reimbursement arrangements and other account-based group health plans; Health and Human Services international pricing index (IPI) model; mental health parity; drug pricing; COBRA subsidies; Federal Trade Commissions multilateral pharmaceutical merger taskforce; telehealth, including coverage of telehealth under High Deductible Health Plans (HDHPs) and expanding telehealth options for employees; impact of Pharmacy Benefit Managers Practices; FTC-2022-0015; petition to HHS to grant march-in rights for the patents on the drug Xtandi; legislative proposals to tax employer-provided health care coverage; artificial price caps on providing insulin; Reasonable Price Clause in reauthorization draft of the Pandemic and All Hazards Preparedness Act (PAHPA, P.L. 109-417); ERISA preemption protections including information on constructive changes/modifications to ERISA; efforts to reform the World Health Organizations (WHO) engagement with private sector; continued U.S. membership to the World Health Organization (WHO); support for necessary market conditions to incentivize health sector investment from private sector; support for private sector involvement in health systems strengthening; promote greater harmonization of standards and investment in digital health; health-related policy issues in the G20/G7 forums and other multilateral forums; support for improving access to health products and technologies globally, including via regulatory alignment, addressing trade barriers, strengthening the global supply chain, and raising awareness on potential pitfalls of local manufacturing; combatting anti-microbial resistance; support for continued and reformed U.S. foreign assistance, including in global health; Advance Notice of Methodological Changes for Calendar Year (CY) 2025 for Medicare Advantage (MA) Capitation Rates and Part C and Part D Payment Policies, U.S. Centers for Medicare & Medicaid Services, U.S. Department of Health and Human Services (2025 Advance Notice, January 31, 2024)
Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2025
Client: CHAMBER OF COMMERCE OF THE U.S.A. · Firm: CHAMBER OF COMMERCE OF THE U.S.A.
H.R. 661, MIRACLE Medical Technology Act of 2025 H.R. 1650/S. 763, Telehealth Expansion Act of 2025 Potential legislation similar to H.R. 1843/S. 1001, Telehealth Expansion Act of 2023 Potential legislation similar to H.R. 2868, Association Health Plans Act Potential legislation similar to H.R. 3800, Chronic Disease Flexible Coverage Act Potential legislation similar to H.R. 4307/S. 2115, Medical Supply Chain Resiliency Act Potential legislation similar to H.R. 6363, Further Continuing Appropriations and Other Extensions Act of 2024, and issues pertaining to H.R. 1843/S. 1001, The Telehealth Expansion Act of 2023 Potential legislation similar to H.R. 6860, Restore Protections for Dialysis Patients Act Potential legislation similar to H.R. 9029, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2025 Potential legislation similar to S. 142, Preserve Access to Affordable Generics and Biosimilars Act Potential legislation similar to S. 150, Affordable Prescriptions for Patients Act of 2023 Potential legislation similar to S. 1067, Ensuring Timely Access to Generics Act of 2023 Potential legislation similar to S. 1114, Expanding Access to Low-Cost Generics Act of 2023 Potential legislation similar to S. 2624, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2024 Potential legislation similar to S. 2780, The Medication Affordability and Patent Integrity Act Final Rule, Mental Health Parity and Addiction Equity Act (89 Fed. Reg. 77,586-77,751, September 23, 2024) Various issues relating to the employer-sponsored health care system, implementation of regulatory process, provider network adequacy, health savings account (HSAs), health reimbursement account (HRAs), employer mandate; implementation of the American Rescue Plan Act (P.L. 117-2); implementation of the Inflation Reduction Act (P.L. 117-169); balance or surprise billing and related issues; single-payer health care options; health reimbursement arrangements and other account-based group health plans; Health and Human Services international pricing index (IPI) model; mental health parity; drug pricing; COBRA subsidies; Federal Trade Commissions multilateral pharmaceutical merger taskforce; telehealth, including coverage of telehealth under High Deductible Health Plans (HDHPs) and expanding telehealth options for employees; impact of Pharmacy Benefit Managers Practices; FTC-2022-0015; petition to HHS to grant march-in rights for the patents on the drug Xtandi; legislative proposals to tax employer-provided health care coverage; artificial price caps on providing insulin; Reasonable Price Clause in reauthorization draft of the Pandemic and All Hazards Preparedness Act (PAHPA, P.L. 109-417); ERISA preemption protections including information on constructive changes/modifications to ERISA; efforts to reform the World Health Organizations (WHO) engagement with private sector; continued U.S. membership to the World Health Organization (WHO); support for necessary market conditions to incentivize health sector investment from private sector; support for private sector involvement in health systems strengthening; promote greater harmonization of standards and investment in digital health; health-related policy issues in the G20/G7 forums and other multilateral forums; support for improving access to health products and technologies globally, including via regulatory alignment, addressing trade barriers, strengthening the global supply chain, and raising awareness on potential pitfalls of local manufacturing; combatting anti-microbial resistance; support for continued and reformed U.S. foreign assistance, including in global health; Advance Notice of Methodological Changes for Calendar Year (CY) 2025 for Medicare Advantage (MA) Capitation Rates and Part C and Part D Payment Policies, U.S. Centers for Medicare & Medicaid Services, U.S. Department of Health and Human Services (2025 Advance Notice, January 31, 2024)
Telehealth Expansion Act of 2023
Client: CHAMBER OF COMMERCE OF THE U.S.A. · Firm: CHAMBER OF COMMERCE OF THE U.S.A.
H.R. 661, MIRACLE Medical Technology Act of 2025 H.R. 1650/S. 763, Telehealth Expansion Act of 2025 Potential legislation similar to H.R. 1843/S. 1001, Telehealth Expansion Act of 2023 Potential legislation similar to H.R. 2868, Association Health Plans Act Potential legislation similar to H.R. 3800, Chronic Disease Flexible Coverage Act Potential legislation similar to H.R. 4307/S. 2115, Medical Supply Chain Resiliency Act Potential legislation similar to H.R. 6363, Further Continuing Appropriations and Other Extensions Act of 2024, and issues pertaining to H.R. 1843/S. 1001, The Telehealth Expansion Act of 2023 Potential legislation similar to H.R. 6860, Restore Protections for Dialysis Patients Act Potential legislation similar to H.R. 9029, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2025 Potential legislation similar to S. 142, Preserve Access to Affordable Generics and Biosimilars Act Potential legislation similar to S. 150, Affordable Prescriptions for Patients Act of 2023 Potential legislation similar to S. 1067, Ensuring Timely Access to Generics Act of 2023 Potential legislation similar to S. 1114, Expanding Access to Low-Cost Generics Act of 2023 Potential legislation similar to S. 2624, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2024 Potential legislation similar to S. 2780, The Medication Affordability and Patent Integrity Act Final Rule, Mental Health Parity and Addiction Equity Act (89 Fed. Reg. 77,586-77,751, September 23, 2024) Various issues relating to the employer-sponsored health care system, implementation of regulatory process, provider network adequacy, health savings account (HSAs), health reimbursement account (HRAs), employer mandate; implementation of the American Rescue Plan Act (P.L. 117-2); implementation of the Inflation Reduction Act (P.L. 117-169); balance or surprise billing and related issues; single-payer health care options; health reimbursement arrangements and other account-based group health plans; Health and Human Services international pricing index (IPI) model; mental health parity; drug pricing; COBRA subsidies; Federal Trade Commissions multilateral pharmaceutical merger taskforce; telehealth, including coverage of telehealth under High Deductible Health Plans (HDHPs) and expanding telehealth options for employees; impact of Pharmacy Benefit Managers Practices; FTC-2022-0015; petition to HHS to grant march-in rights for the patents on the drug Xtandi; legislative proposals to tax employer-provided health care coverage; artificial price caps on providing insulin; Reasonable Price Clause in reauthorization draft of the Pandemic and All Hazards Preparedness Act (PAHPA, P.L. 109-417); ERISA preemption protections including information on constructive changes/modifications to ERISA; efforts to reform the World Health Organizations (WHO) engagement with private sector; continued U.S. membership to the World Health Organization (WHO); support for necessary market conditions to incentivize health sector investment from private sector; support for private sector involvement in health systems strengthening; promote greater harmonization of standards and investment in digital health; health-related policy issues in the G20/G7 forums and other multilateral forums; support for improving access to health products and technologies globally, including via regulatory alignment, addressing trade barriers, strengthening the global supply chain, and raising awareness on potential pitfalls of local manufacturing; combatting anti-microbial resistance; support for continued and reformed U.S. foreign assistance, including in global health; Advance Notice of Methodological Changes for Calendar Year (CY) 2025 for Medicare Advantage (MA) Capitation Rates and Part C and Part D Payment Policies, U.S. Centers for Medicare & Medicaid Services, U.S. Department of Health and Human Services (2025 Advance Notice, January 31, 2024)
Ensuring Timely Access to Generics Act of 2023
Client: CHAMBER OF COMMERCE OF THE U.S.A. · Firm: CHAMBER OF COMMERCE OF THE U.S.A.
H.R. 661, MIRACLE Medical Technology Act of 2025 H.R. 1650/S. 763, Telehealth Expansion Act of 2025 Potential legislation similar to H.R. 1843/S. 1001, Telehealth Expansion Act of 2023 Potential legislation similar to H.R. 2868, Association Health Plans Act Potential legislation similar to H.R. 3800, Chronic Disease Flexible Coverage Act Potential legislation similar to H.R. 4307/S. 2115, Medical Supply Chain Resiliency Act Potential legislation similar to H.R. 6363, Further Continuing Appropriations and Other Extensions Act of 2024, and issues pertaining to H.R. 1843/S. 1001, The Telehealth Expansion Act of 2023 Potential legislation similar to H.R. 6860, Restore Protections for Dialysis Patients Act Potential legislation similar to H.R. 9029, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2025 Potential legislation similar to S. 142, Preserve Access to Affordable Generics and Biosimilars Act Potential legislation similar to S. 150, Affordable Prescriptions for Patients Act of 2023 Potential legislation similar to S. 1067, Ensuring Timely Access to Generics Act of 2023 Potential legislation similar to S. 1114, Expanding Access to Low-Cost Generics Act of 2023 Potential legislation similar to S. 2624, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2024 Potential legislation similar to S. 2780, The Medication Affordability and Patent Integrity Act Final Rule, Mental Health Parity and Addiction Equity Act (89 Fed. Reg. 77,586-77,751, September 23, 2024) Various issues relating to the employer-sponsored health care system, implementation of regulatory process, provider network adequacy, health savings account (HSAs), health reimbursement account (HRAs), employer mandate; implementation of the American Rescue Plan Act (P.L. 117-2); implementation of the Inflation Reduction Act (P.L. 117-169); balance or surprise billing and related issues; single-payer health care options; health reimbursement arrangements and other account-based group health plans; Health and Human Services international pricing index (IPI) model; mental health parity; drug pricing; COBRA subsidies; Federal Trade Commissions multilateral pharmaceutical merger taskforce; telehealth, including coverage of telehealth under High Deductible Health Plans (HDHPs) and expanding telehealth options for employees; impact of Pharmacy Benefit Managers Practices; FTC-2022-0015; petition to HHS to grant march-in rights for the patents on the drug Xtandi; legislative proposals to tax employer-provided health care coverage; artificial price caps on providing insulin; Reasonable Price Clause in reauthorization draft of the Pandemic and All Hazards Preparedness Act (PAHPA, P.L. 109-417); ERISA preemption protections including information on constructive changes/modifications to ERISA; efforts to reform the World Health Organizations (WHO) engagement with private sector; continued U.S. membership to the World Health Organization (WHO); support for necessary market conditions to incentivize health sector investment from private sector; support for private sector involvement in health systems strengthening; promote greater harmonization of standards and investment in digital health; health-related policy issues in the G20/G7 forums and other multilateral forums; support for improving access to health products and technologies globally, including via regulatory alignment, addressing trade barriers, strengthening the global supply chain, and raising awareness on potential pitfalls of local manufacturing; combatting anti-microbial resistance; support for continued and reformed U.S. foreign assistance, including in global health; Advance Notice of Methodological Changes for Calendar Year (CY) 2025 for Medicare Advantage (MA) Capitation Rates and Part C and Part D Payment Policies, U.S. Centers for Medicare & Medicaid Services, U.S. Department of Health and Human Services (2025 Advance Notice, January 31, 2024)
Expanding Access to Low-Cost Generics Act of 2023
Client: CHAMBER OF COMMERCE OF THE U.S.A. · Firm: CHAMBER OF COMMERCE OF THE U.S.A.
H.R. 661, MIRACLE Medical Technology Act of 2025 H.R. 1650/S. 763, Telehealth Expansion Act of 2025 Potential legislation similar to H.R. 1843/S. 1001, Telehealth Expansion Act of 2023 Potential legislation similar to H.R. 2868, Association Health Plans Act Potential legislation similar to H.R. 3800, Chronic Disease Flexible Coverage Act Potential legislation similar to H.R. 4307/S. 2115, Medical Supply Chain Resiliency Act Potential legislation similar to H.R. 6363, Further Continuing Appropriations and Other Extensions Act of 2024, and issues pertaining to H.R. 1843/S. 1001, The Telehealth Expansion Act of 2023 Potential legislation similar to H.R. 6860, Restore Protections for Dialysis Patients Act Potential legislation similar to H.R. 9029, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2025 Potential legislation similar to S. 142, Preserve Access to Affordable Generics and Biosimilars Act Potential legislation similar to S. 150, Affordable Prescriptions for Patients Act of 2023 Potential legislation similar to S. 1067, Ensuring Timely Access to Generics Act of 2023 Potential legislation similar to S. 1114, Expanding Access to Low-Cost Generics Act of 2023 Potential legislation similar to S. 2624, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2024 Potential legislation similar to S. 2780, The Medication Affordability and Patent Integrity Act Final Rule, Mental Health Parity and Addiction Equity Act (89 Fed. Reg. 77,586-77,751, September 23, 2024) Various issues relating to the employer-sponsored health care system, implementation of regulatory process, provider network adequacy, health savings account (HSAs), health reimbursement account (HRAs), employer mandate; implementation of the American Rescue Plan Act (P.L. 117-2); implementation of the Inflation Reduction Act (P.L. 117-169); balance or surprise billing and related issues; single-payer health care options; health reimbursement arrangements and other account-based group health plans; Health and Human Services international pricing index (IPI) model; mental health parity; drug pricing; COBRA subsidies; Federal Trade Commissions multilateral pharmaceutical merger taskforce; telehealth, including coverage of telehealth under High Deductible Health Plans (HDHPs) and expanding telehealth options for employees; impact of Pharmacy Benefit Managers Practices; FTC-2022-0015; petition to HHS to grant march-in rights for the patents on the drug Xtandi; legislative proposals to tax employer-provided health care coverage; artificial price caps on providing insulin; Reasonable Price Clause in reauthorization draft of the Pandemic and All Hazards Preparedness Act (PAHPA, P.L. 109-417); ERISA preemption protections including information on constructive changes/modifications to ERISA; efforts to reform the World Health Organizations (WHO) engagement with private sector; continued U.S. membership to the World Health Organization (WHO); support for necessary market conditions to incentivize health sector investment from private sector; support for private sector involvement in health systems strengthening; promote greater harmonization of standards and investment in digital health; health-related policy issues in the G20/G7 forums and other multilateral forums; support for improving access to health products and technologies globally, including via regulatory alignment, addressing trade barriers, strengthening the global supply chain, and raising awareness on potential pitfalls of local manufacturing; combatting anti-microbial resistance; support for continued and reformed U.S. foreign assistance, including in global health; Advance Notice of Methodological Changes for Calendar Year (CY) 2025 for Medicare Advantage (MA) Capitation Rates and Part C and Part D Payment Policies, U.S. Centers for Medicare & Medicaid Services, U.S. Department of Health and Human Services (2025 Advance Notice, January 31, 2024)
Preserve Access to Affordable Generics and Biosimilars Act
Client: CHAMBER OF COMMERCE OF THE U.S.A. · Firm: CHAMBER OF COMMERCE OF THE U.S.A.
H.R. 661, MIRACLE Medical Technology Act of 2025 H.R. 1650/S. 763, Telehealth Expansion Act of 2025 Potential legislation similar to H.R. 1843/S. 1001, Telehealth Expansion Act of 2023 Potential legislation similar to H.R. 2868, Association Health Plans Act Potential legislation similar to H.R. 3800, Chronic Disease Flexible Coverage Act Potential legislation similar to H.R. 4307/S. 2115, Medical Supply Chain Resiliency Act Potential legislation similar to H.R. 6363, Further Continuing Appropriations and Other Extensions Act of 2024, and issues pertaining to H.R. 1843/S. 1001, The Telehealth Expansion Act of 2023 Potential legislation similar to H.R. 6860, Restore Protections for Dialysis Patients Act Potential legislation similar to H.R. 9029, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2025 Potential legislation similar to S. 142, Preserve Access to Affordable Generics and Biosimilars Act Potential legislation similar to S. 150, Affordable Prescriptions for Patients Act of 2023 Potential legislation similar to S. 1067, Ensuring Timely Access to Generics Act of 2023 Potential legislation similar to S. 1114, Expanding Access to Low-Cost Generics Act of 2023 Potential legislation similar to S. 2624, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2024 Potential legislation similar to S. 2780, The Medication Affordability and Patent Integrity Act Final Rule, Mental Health Parity and Addiction Equity Act (89 Fed. Reg. 77,586-77,751, September 23, 2024) Various issues relating to the employer-sponsored health care system, implementation of regulatory process, provider network adequacy, health savings account (HSAs), health reimbursement account (HRAs), employer mandate; implementation of the American Rescue Plan Act (P.L. 117-2); implementation of the Inflation Reduction Act (P.L. 117-169); balance or surprise billing and related issues; single-payer health care options; health reimbursement arrangements and other account-based group health plans; Health and Human Services international pricing index (IPI) model; mental health parity; drug pricing; COBRA subsidies; Federal Trade Commissions multilateral pharmaceutical merger taskforce; telehealth, including coverage of telehealth under High Deductible Health Plans (HDHPs) and expanding telehealth options for employees; impact of Pharmacy Benefit Managers Practices; FTC-2022-0015; petition to HHS to grant march-in rights for the patents on the drug Xtandi; legislative proposals to tax employer-provided health care coverage; artificial price caps on providing insulin; Reasonable Price Clause in reauthorization draft of the Pandemic and All Hazards Preparedness Act (PAHPA, P.L. 109-417); ERISA preemption protections including information on constructive changes/modifications to ERISA; efforts to reform the World Health Organizations (WHO) engagement with private sector; continued U.S. membership to the World Health Organization (WHO); support for necessary market conditions to incentivize health sector investment from private sector; support for private sector involvement in health systems strengthening; promote greater harmonization of standards and investment in digital health; health-related policy issues in the G20/G7 forums and other multilateral forums; support for improving access to health products and technologies globally, including via regulatory alignment, addressing trade barriers, strengthening the global supply chain, and raising awareness on potential pitfalls of local manufacturing; combatting anti-microbial resistance; support for continued and reformed U.S. foreign assistance, including in global health; Advance Notice of Methodological Changes for Calendar Year (CY) 2025 for Medicare Advantage (MA) Capitation Rates and Part C and Part D Payment Policies, U.S. Centers for Medicare & Medicaid Services, U.S. Department of Health and Human Services (2025 Advance Notice, January 31, 2024)
Affordable Prescriptions for Patients Act of 2023
Client: CHAMBER OF COMMERCE OF THE U.S.A. · Firm: CHAMBER OF COMMERCE OF THE U.S.A.
H.R. 661, MIRACLE Medical Technology Act of 2025 H.R. 1650/S. 763, Telehealth Expansion Act of 2025 Potential legislation similar to H.R. 1843/S. 1001, Telehealth Expansion Act of 2023 Potential legislation similar to H.R. 2868, Association Health Plans Act Potential legislation similar to H.R. 3800, Chronic Disease Flexible Coverage Act Potential legislation similar to H.R. 4307/S. 2115, Medical Supply Chain Resiliency Act Potential legislation similar to H.R. 6363, Further Continuing Appropriations and Other Extensions Act of 2024, and issues pertaining to H.R. 1843/S. 1001, The Telehealth Expansion Act of 2023 Potential legislation similar to H.R. 6860, Restore Protections for Dialysis Patients Act Potential legislation similar to H.R. 9029, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2025 Potential legislation similar to S. 142, Preserve Access to Affordable Generics and Biosimilars Act Potential legislation similar to S. 150, Affordable Prescriptions for Patients Act of 2023 Potential legislation similar to S. 1067, Ensuring Timely Access to Generics Act of 2023 Potential legislation similar to S. 1114, Expanding Access to Low-Cost Generics Act of 2023 Potential legislation similar to S. 2624, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2024 Potential legislation similar to S. 2780, The Medication Affordability and Patent Integrity Act Final Rule, Mental Health Parity and Addiction Equity Act (89 Fed. Reg. 77,586-77,751, September 23, 2024) Various issues relating to the employer-sponsored health care system, implementation of regulatory process, provider network adequacy, health savings account (HSAs), health reimbursement account (HRAs), employer mandate; implementation of the American Rescue Plan Act (P.L. 117-2); implementation of the Inflation Reduction Act (P.L. 117-169); balance or surprise billing and related issues; single-payer health care options; health reimbursement arrangements and other account-based group health plans; Health and Human Services international pricing index (IPI) model; mental health parity; drug pricing; COBRA subsidies; Federal Trade Commissions multilateral pharmaceutical merger taskforce; telehealth, including coverage of telehealth under High Deductible Health Plans (HDHPs) and expanding telehealth options for employees; impact of Pharmacy Benefit Managers Practices; FTC-2022-0015; petition to HHS to grant march-in rights for the patents on the drug Xtandi; legislative proposals to tax employer-provided health care coverage; artificial price caps on providing insulin; Reasonable Price Clause in reauthorization draft of the Pandemic and All Hazards Preparedness Act (PAHPA, P.L. 109-417); ERISA preemption protections including information on constructive changes/modifications to ERISA; efforts to reform the World Health Organizations (WHO) engagement with private sector; continued U.S. membership to the World Health Organization (WHO); support for necessary market conditions to incentivize health sector investment from private sector; support for private sector involvement in health systems strengthening; promote greater harmonization of standards and investment in digital health; health-related policy issues in the G20/G7 forums and other multilateral forums; support for improving access to health products and technologies globally, including via regulatory alignment, addressing trade barriers, strengthening the global supply chain, and raising awareness on potential pitfalls of local manufacturing; combatting anti-microbial resistance; support for continued and reformed U.S. foreign assistance, including in global health; Advance Notice of Methodological Changes for Calendar Year (CY) 2025 for Medicare Advantage (MA) Capitation Rates and Part C and Part D Payment Policies, U.S. Centers for Medicare & Medicaid Services, U.S. Department of Health and Human Services (2025 Advance Notice, January 31, 2024)
Medical Supply Chain Resiliency Act
Client: CHAMBER OF COMMERCE OF THE U.S.A. · Firm: CHAMBER OF COMMERCE OF THE U.S.A.
H.R. 661, MIRACLE Medical Technology Act of 2025 H.R. 1650/S. 763, Telehealth Expansion Act of 2025 Potential legislation similar to H.R. 1843/S. 1001, Telehealth Expansion Act of 2023 Potential legislation similar to H.R. 2868, Association Health Plans Act Potential legislation similar to H.R. 3800, Chronic Disease Flexible Coverage Act Potential legislation similar to H.R. 4307/S. 2115, Medical Supply Chain Resiliency Act Potential legislation similar to H.R. 6363, Further Continuing Appropriations and Other Extensions Act of 2024, and issues pertaining to H.R. 1843/S. 1001, The Telehealth Expansion Act of 2023 Potential legislation similar to H.R. 6860, Restore Protections for Dialysis Patients Act Potential legislation similar to H.R. 9029, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2025 Potential legislation similar to S. 142, Preserve Access to Affordable Generics and Biosimilars Act Potential legislation similar to S. 150, Affordable Prescriptions for Patients Act of 2023 Potential legislation similar to S. 1067, Ensuring Timely Access to Generics Act of 2023 Potential legislation similar to S. 1114, Expanding Access to Low-Cost Generics Act of 2023 Potential legislation similar to S. 2624, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2024 Potential legislation similar to S. 2780, The Medication Affordability and Patent Integrity Act Final Rule, Mental Health Parity and Addiction Equity Act (89 Fed. Reg. 77,586-77,751, September 23, 2024) Various issues relating to the employer-sponsored health care system, implementation of regulatory process, provider network adequacy, health savings account (HSAs), health reimbursement account (HRAs), employer mandate; implementation of the American Rescue Plan Act (P.L. 117-2); implementation of the Inflation Reduction Act (P.L. 117-169); balance or surprise billing and related issues; single-payer health care options; health reimbursement arrangements and other account-based group health plans; Health and Human Services international pricing index (IPI) model; mental health parity; drug pricing; COBRA subsidies; Federal Trade Commissions multilateral pharmaceutical merger taskforce; telehealth, including coverage of telehealth under High Deductible Health Plans (HDHPs) and expanding telehealth options for employees; impact of Pharmacy Benefit Managers Practices; FTC-2022-0015; petition to HHS to grant march-in rights for the patents on the drug Xtandi; legislative proposals to tax employer-provided health care coverage; artificial price caps on providing insulin; Reasonable Price Clause in reauthorization draft of the Pandemic and All Hazards Preparedness Act (PAHPA, P.L. 109-417); ERISA preemption protections including information on constructive changes/modifications to ERISA; efforts to reform the World Health Organizations (WHO) engagement with private sector; continued U.S. membership to the World Health Organization (WHO); support for necessary market conditions to incentivize health sector investment from private sector; support for private sector involvement in health systems strengthening; promote greater harmonization of standards and investment in digital health; health-related policy issues in the G20/G7 forums and other multilateral forums; support for improving access to health products and technologies globally, including via regulatory alignment, addressing trade barriers, strengthening the global supply chain, and raising awareness on potential pitfalls of local manufacturing; combatting anti-microbial resistance; support for continued and reformed U.S. foreign assistance, including in global health; Advance Notice of Methodological Changes for Calendar Year (CY) 2025 for Medicare Advantage (MA) Capitation Rates and Part C and Part D Payment Policies, U.S. Centers for Medicare & Medicaid Services, U.S. Department of Health and Human Services (2025 Advance Notice, January 31, 2024)
Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2024
Client: CHAMBER OF COMMERCE OF THE U.S.A. · Firm: CHAMBER OF COMMERCE OF THE U.S.A.
H.R. 661, MIRACLE Medical Technology Act of 2025 H.R. 1650/S. 763, Telehealth Expansion Act of 2025 Potential legislation similar to H.R. 1843/S. 1001, Telehealth Expansion Act of 2023 Potential legislation similar to H.R. 2868, Association Health Plans Act Potential legislation similar to H.R. 3800, Chronic Disease Flexible Coverage Act Potential legislation similar to H.R. 4307/S. 2115, Medical Supply Chain Resiliency Act Potential legislation similar to H.R. 6363, Further Continuing Appropriations and Other Extensions Act of 2024, and issues pertaining to H.R. 1843/S. 1001, The Telehealth Expansion Act of 2023 Potential legislation similar to H.R. 6860, Restore Protections for Dialysis Patients Act Potential legislation similar to H.R. 9029, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2025 Potential legislation similar to S. 142, Preserve Access to Affordable Generics and Biosimilars Act Potential legislation similar to S. 150, Affordable Prescriptions for Patients Act of 2023 Potential legislation similar to S. 1067, Ensuring Timely Access to Generics Act of 2023 Potential legislation similar to S. 1114, Expanding Access to Low-Cost Generics Act of 2023 Potential legislation similar to S. 2624, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2024 Potential legislation similar to S. 2780, The Medication Affordability and Patent Integrity Act Final Rule, Mental Health Parity and Addiction Equity Act (89 Fed. Reg. 77,586-77,751, September 23, 2024) Various issues relating to the employer-sponsored health care system, implementation of regulatory process, provider network adequacy, health savings account (HSAs), health reimbursement account (HRAs), employer mandate; implementation of the American Rescue Plan Act (P.L. 117-2); implementation of the Inflation Reduction Act (P.L. 117-169); balance or surprise billing and related issues; single-payer health care options; health reimbursement arrangements and other account-based group health plans; Health and Human Services international pricing index (IPI) model; mental health parity; drug pricing; COBRA subsidies; Federal Trade Commissions multilateral pharmaceutical merger taskforce; telehealth, including coverage of telehealth under High Deductible Health Plans (HDHPs) and expanding telehealth options for employees; impact of Pharmacy Benefit Managers Practices; FTC-2022-0015; petition to HHS to grant march-in rights for the patents on the drug Xtandi; legislative proposals to tax employer-provided health care coverage; artificial price caps on providing insulin; Reasonable Price Clause in reauthorization draft of the Pandemic and All Hazards Preparedness Act (PAHPA, P.L. 109-417); ERISA preemption protections including information on constructive changes/modifications to ERISA; efforts to reform the World Health Organizations (WHO) engagement with private sector; continued U.S. membership to the World Health Organization (WHO); support for necessary market conditions to incentivize health sector investment from private sector; support for private sector involvement in health systems strengthening; promote greater harmonization of standards and investment in digital health; health-related policy issues in the G20/G7 forums and other multilateral forums; support for improving access to health products and technologies globally, including via regulatory alignment, addressing trade barriers, strengthening the global supply chain, and raising awareness on potential pitfalls of local manufacturing; combatting anti-microbial resistance; support for continued and reformed U.S. foreign assistance, including in global health; Advance Notice of Methodological Changes for Calendar Year (CY) 2025 for Medicare Advantage (MA) Capitation Rates and Part C and Part D Payment Policies, U.S. Centers for Medicare & Medicaid Services, U.S. Department of Health and Human Services (2025 Advance Notice, January 31, 2024)
Medication Affordability and Patent Integrity Act
Client: CHAMBER OF COMMERCE OF THE U.S.A. · Firm: CHAMBER OF COMMERCE OF THE U.S.A.
H.R. 661, MIRACLE Medical Technology Act of 2025 H.R. 1650/S. 763, Telehealth Expansion Act of 2025 Potential legislation similar to H.R. 1843/S. 1001, Telehealth Expansion Act of 2023 Potential legislation similar to H.R. 2868, Association Health Plans Act Potential legislation similar to H.R. 3800, Chronic Disease Flexible Coverage Act Potential legislation similar to H.R. 4307/S. 2115, Medical Supply Chain Resiliency Act Potential legislation similar to H.R. 6363, Further Continuing Appropriations and Other Extensions Act of 2024, and issues pertaining to H.R. 1843/S. 1001, The Telehealth Expansion Act of 2023 Potential legislation similar to H.R. 6860, Restore Protections for Dialysis Patients Act Potential legislation similar to H.R. 9029, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2025 Potential legislation similar to S. 142, Preserve Access to Affordable Generics and Biosimilars Act Potential legislation similar to S. 150, Affordable Prescriptions for Patients Act of 2023 Potential legislation similar to S. 1067, Ensuring Timely Access to Generics Act of 2023 Potential legislation similar to S. 1114, Expanding Access to Low-Cost Generics Act of 2023 Potential legislation similar to S. 2624, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2024 Potential legislation similar to S. 2780, The Medication Affordability and Patent Integrity Act Final Rule, Mental Health Parity and Addiction Equity Act (89 Fed. Reg. 77,586-77,751, September 23, 2024) Various issues relating to the employer-sponsored health care system, implementation of regulatory process, provider network adequacy, health savings account (HSAs), health reimbursement account (HRAs), employer mandate; implementation of the American Rescue Plan Act (P.L. 117-2); implementation of the Inflation Reduction Act (P.L. 117-169); balance or surprise billing and related issues; single-payer health care options; health reimbursement arrangements and other account-based group health plans; Health and Human Services international pricing index (IPI) model; mental health parity; drug pricing; COBRA subsidies; Federal Trade Commissions multilateral pharmaceutical merger taskforce; telehealth, including coverage of telehealth under High Deductible Health Plans (HDHPs) and expanding telehealth options for employees; impact of Pharmacy Benefit Managers Practices; FTC-2022-0015; petition to HHS to grant march-in rights for the patents on the drug Xtandi; legislative proposals to tax employer-provided health care coverage; artificial price caps on providing insulin; Reasonable Price Clause in reauthorization draft of the Pandemic and All Hazards Preparedness Act (PAHPA, P.L. 109-417); ERISA preemption protections including information on constructive changes/modifications to ERISA; efforts to reform the World Health Organizations (WHO) engagement with private sector; continued U.S. membership to the World Health Organization (WHO); support for necessary market conditions to incentivize health sector investment from private sector; support for private sector involvement in health systems strengthening; promote greater harmonization of standards and investment in digital health; health-related policy issues in the G20/G7 forums and other multilateral forums; support for improving access to health products and technologies globally, including via regulatory alignment, addressing trade barriers, strengthening the global supply chain, and raising awareness on potential pitfalls of local manufacturing; combatting anti-microbial resistance; support for continued and reformed U.S. foreign assistance, including in global health; Advance Notice of Methodological Changes for Calendar Year (CY) 2025 for Medicare Advantage (MA) Capitation Rates and Part C and Part D Payment Policies, U.S. Centers for Medicare & Medicaid Services, U.S. Department of Health and Human Services (2025 Advance Notice, January 31, 2024)
Commonsense Reporting Act of 2023
Client: CHAMBER OF COMMERCE OF THE U.S.A. · Firm: CHAMBER OF COMMERCE OF THE U.S.A.
H.R. 1264, Commonsense Reporting Act of 2023 H.R. 2813, Self-Insurance Protection Act H.R. 2868, Association Health Plans Act S. 127, Pharmacy Benefit Manager Transparency Act of 2023 S. 142, Preserve Access to Affordable Generics and Biosimilars Act S. 148, Stop Significant and Time-wasting Abuse Limiting Legitimate Innovation of New Generics (Stop STALLING) Act S. 150, Affordable Prescriptions for Patients Act of 2023 S. 1067, Ensuring Timely Access to Generics Act of 2023 S. 1114, Expanding Access to Low-Cost Generics Act of 2023 S. 1214, Retaining Access and Restoring Exclusivity (RARE) Act S. 1339, Pharmacy Benefit Manager Reform Act Various issues relating to the employer-sponsored health care system, implementation of regulatory process, provider network adequacy, health savings account (HSAs), health reimbursement account (HRAs), employer mandate; Medicare Drug Price Negotiation Program: Initial Memorandum, Implementation of Sections 1191 - 1198 of the Social Security Act for Initial Price Applicability Year 2026, and Solicitation of Comments; implementation of the American Rescue Plan Act (P.L. 117-2); implementation of the Inflation Reduction Act (P.L. 117-169); balance or surprise billing and related issues; single-payer health care options; health reimbursement arrangements and other account-based group health plans; Health and Human Services international pricing index (IPI) model; mental health parity; drug pricing; COBRA subsidies; Federal Trade Commissions multilateral pharmaceutical merger taskforce; telehealth, including coverage of telehealth under High Deductible Health Plans (HDHPs) and expanding telehealth options for employees; impact of Pharmacy Benefit Managers Practices; FTC-2022-0015; petition to HHS to grant march-in rights for the patents on the drug Xtandi; ERISA preemption protections; artificial price caps on providing insulin; efforts to reform the World Health Organizations (WHO) engagement with private sector; continued U.S. membership to the World Health Organization (WHO); support for necessary market conditions to incentivize health sector investment from private sector; support for private sector involvement in health systems strengthening; greater harmonization of standards and investment in digital health internationally; role of private sector related pandemic prevention, preparedness and response; oversight issues related to the U.S. Food and Drug Administration
Self-Insurance Protection Act
Client: CHAMBER OF COMMERCE OF THE U.S.A. · Firm: CHAMBER OF COMMERCE OF THE U.S.A.
H.R. 1264, Commonsense Reporting Act of 2023 H.R. 2813, Self-Insurance Protection Act H.R. 2868, Association Health Plans Act S. 127, Pharmacy Benefit Manager Transparency Act of 2023 S. 142, Preserve Access to Affordable Generics and Biosimilars Act S. 148, Stop Significant and Time-wasting Abuse Limiting Legitimate Innovation of New Generics (Stop STALLING) Act S. 150, Affordable Prescriptions for Patients Act of 2023 S. 1067, Ensuring Timely Access to Generics Act of 2023 S. 1114, Expanding Access to Low-Cost Generics Act of 2023 S. 1214, Retaining Access and Restoring Exclusivity (RARE) Act S. 1339, Pharmacy Benefit Manager Reform Act Various issues relating to the employer-sponsored health care system, implementation of regulatory process, provider network adequacy, health savings account (HSAs), health reimbursement account (HRAs), employer mandate; Medicare Drug Price Negotiation Program: Initial Memorandum, Implementation of Sections 1191 - 1198 of the Social Security Act for Initial Price Applicability Year 2026, and Solicitation of Comments; implementation of the American Rescue Plan Act (P.L. 117-2); implementation of the Inflation Reduction Act (P.L. 117-169); balance or surprise billing and related issues; single-payer health care options; health reimbursement arrangements and other account-based group health plans; Health and Human Services international pricing index (IPI) model; mental health parity; drug pricing; COBRA subsidies; Federal Trade Commissions multilateral pharmaceutical merger taskforce; telehealth, including coverage of telehealth under High Deductible Health Plans (HDHPs) and expanding telehealth options for employees; impact of Pharmacy Benefit Managers Practices; FTC-2022-0015; petition to HHS to grant march-in rights for the patents on the drug Xtandi; ERISA preemption protections; artificial price caps on providing insulin; efforts to reform the World Health Organizations (WHO) engagement with private sector; continued U.S. membership to the World Health Organization (WHO); support for necessary market conditions to incentivize health sector investment from private sector; support for private sector involvement in health systems strengthening; greater harmonization of standards and investment in digital health internationally; role of private sector related pandemic prevention, preparedness and response; oversight issues related to the U.S. Food and Drug Administration
Association Health Plans Act
Client: CHAMBER OF COMMERCE OF THE U.S.A. · Firm: CHAMBER OF COMMERCE OF THE U.S.A.
H.R. 1264, Commonsense Reporting Act of 2023 H.R. 2813, Self-Insurance Protection Act H.R. 2868, Association Health Plans Act S. 127, Pharmacy Benefit Manager Transparency Act of 2023 S. 142, Preserve Access to Affordable Generics and Biosimilars Act S. 148, Stop Significant and Time-wasting Abuse Limiting Legitimate Innovation of New Generics (Stop STALLING) Act S. 150, Affordable Prescriptions for Patients Act of 2023 S. 1067, Ensuring Timely Access to Generics Act of 2023 S. 1114, Expanding Access to Low-Cost Generics Act of 2023 S. 1214, Retaining Access and Restoring Exclusivity (RARE) Act S. 1339, Pharmacy Benefit Manager Reform Act Various issues relating to the employer-sponsored health care system, implementation of regulatory process, provider network adequacy, health savings account (HSAs), health reimbursement account (HRAs), employer mandate; Medicare Drug Price Negotiation Program: Initial Memorandum, Implementation of Sections 1191 - 1198 of the Social Security Act for Initial Price Applicability Year 2026, and Solicitation of Comments; implementation of the American Rescue Plan Act (P.L. 117-2); implementation of the Inflation Reduction Act (P.L. 117-169); balance or surprise billing and related issues; single-payer health care options; health reimbursement arrangements and other account-based group health plans; Health and Human Services international pricing index (IPI) model; mental health parity; drug pricing; COBRA subsidies; Federal Trade Commissions multilateral pharmaceutical merger taskforce; telehealth, including coverage of telehealth under High Deductible Health Plans (HDHPs) and expanding telehealth options for employees; impact of Pharmacy Benefit Managers Practices; FTC-2022-0015; petition to HHS to grant march-in rights for the patents on the drug Xtandi; ERISA preemption protections; artificial price caps on providing insulin; efforts to reform the World Health Organizations (WHO) engagement with private sector; continued U.S. membership to the World Health Organization (WHO); support for necessary market conditions to incentivize health sector investment from private sector; support for private sector involvement in health systems strengthening; greater harmonization of standards and investment in digital health internationally; role of private sector related pandemic prevention, preparedness and response; oversight issues related to the U.S. Food and Drug Administration
Ensuring Timely Access to Generics Act of 2023
Client: CHAMBER OF COMMERCE OF THE U.S.A. · Firm: CHAMBER OF COMMERCE OF THE U.S.A.
H.R. 1264, Commonsense Reporting Act of 2023 H.R. 2813, Self-Insurance Protection Act H.R. 2868, Association Health Plans Act S. 127, Pharmacy Benefit Manager Transparency Act of 2023 S. 142, Preserve Access to Affordable Generics and Biosimilars Act S. 148, Stop Significant and Time-wasting Abuse Limiting Legitimate Innovation of New Generics (Stop STALLING) Act S. 150, Affordable Prescriptions for Patients Act of 2023 S. 1067, Ensuring Timely Access to Generics Act of 2023 S. 1114, Expanding Access to Low-Cost Generics Act of 2023 S. 1214, Retaining Access and Restoring Exclusivity (RARE) Act S. 1339, Pharmacy Benefit Manager Reform Act Various issues relating to the employer-sponsored health care system, implementation of regulatory process, provider network adequacy, health savings account (HSAs), health reimbursement account (HRAs), employer mandate; Medicare Drug Price Negotiation Program: Initial Memorandum, Implementation of Sections 1191 - 1198 of the Social Security Act for Initial Price Applicability Year 2026, and Solicitation of Comments; implementation of the American Rescue Plan Act (P.L. 117-2); implementation of the Inflation Reduction Act (P.L. 117-169); balance or surprise billing and related issues; single-payer health care options; health reimbursement arrangements and other account-based group health plans; Health and Human Services international pricing index (IPI) model; mental health parity; drug pricing; COBRA subsidies; Federal Trade Commissions multilateral pharmaceutical merger taskforce; telehealth, including coverage of telehealth under High Deductible Health Plans (HDHPs) and expanding telehealth options for employees; impact of Pharmacy Benefit Managers Practices; FTC-2022-0015; petition to HHS to grant march-in rights for the patents on the drug Xtandi; ERISA preemption protections; artificial price caps on providing insulin; efforts to reform the World Health Organizations (WHO) engagement with private sector; continued U.S. membership to the World Health Organization (WHO); support for necessary market conditions to incentivize health sector investment from private sector; support for private sector involvement in health systems strengthening; greater harmonization of standards and investment in digital health internationally; role of private sector related pandemic prevention, preparedness and response; oversight issues related to the U.S. Food and Drug Administration
Expanding Access to Low-Cost Generics Act of 2023
Client: CHAMBER OF COMMERCE OF THE U.S.A. · Firm: CHAMBER OF COMMERCE OF THE U.S.A.
H.R. 1264, Commonsense Reporting Act of 2023 H.R. 2813, Self-Insurance Protection Act H.R. 2868, Association Health Plans Act S. 127, Pharmacy Benefit Manager Transparency Act of 2023 S. 142, Preserve Access to Affordable Generics and Biosimilars Act S. 148, Stop Significant and Time-wasting Abuse Limiting Legitimate Innovation of New Generics (Stop STALLING) Act S. 150, Affordable Prescriptions for Patients Act of 2023 S. 1067, Ensuring Timely Access to Generics Act of 2023 S. 1114, Expanding Access to Low-Cost Generics Act of 2023 S. 1214, Retaining Access and Restoring Exclusivity (RARE) Act S. 1339, Pharmacy Benefit Manager Reform Act Various issues relating to the employer-sponsored health care system, implementation of regulatory process, provider network adequacy, health savings account (HSAs), health reimbursement account (HRAs), employer mandate; Medicare Drug Price Negotiation Program: Initial Memorandum, Implementation of Sections 1191 - 1198 of the Social Security Act for Initial Price Applicability Year 2026, and Solicitation of Comments; implementation of the American Rescue Plan Act (P.L. 117-2); implementation of the Inflation Reduction Act (P.L. 117-169); balance or surprise billing and related issues; single-payer health care options; health reimbursement arrangements and other account-based group health plans; Health and Human Services international pricing index (IPI) model; mental health parity; drug pricing; COBRA subsidies; Federal Trade Commissions multilateral pharmaceutical merger taskforce; telehealth, including coverage of telehealth under High Deductible Health Plans (HDHPs) and expanding telehealth options for employees; impact of Pharmacy Benefit Managers Practices; FTC-2022-0015; petition to HHS to grant march-in rights for the patents on the drug Xtandi; ERISA preemption protections; artificial price caps on providing insulin; efforts to reform the World Health Organizations (WHO) engagement with private sector; continued U.S. membership to the World Health Organization (WHO); support for necessary market conditions to incentivize health sector investment from private sector; support for private sector involvement in health systems strengthening; greater harmonization of standards and investment in digital health internationally; role of private sector related pandemic prevention, preparedness and response; oversight issues related to the U.S. Food and Drug Administration
H.R. 1264, Commonsense Reporting Act of 2023 H.R. 2813, Self-Insurance Protection Act H.R. 2868, Association Health Plans Act S. 127, Pharmacy Benefit Manager Transparency Act of 2023 S. 142, Preserve Access to Affordable Generics and Biosimilars Act S. 148, Stop Significant and Time-wasting Abuse Limiting Legitimate Innovation of New Generics (Stop STALLING) Act S. 150, Affordable Prescriptions for Patients Act of 2023 S. 1067, Ensuring Timely Access to Generics Act of 2023 S. 1114, Expanding Access to Low-Cost Generics Act of 2023 S. 1214, Retaining Access and Restoring Exclusivity (RARE) Act S. 1339, Pharmacy Benefit Manager Reform Act Various issues relating to the employer-sponsored health care system, implementation of regulatory process, provider network adequacy, health savings account (HSAs), health reimbursement account (HRAs), employer mandate; Medicare Drug Price Negotiation Program: Initial Memorandum, Implementation of Sections 1191 - 1198 of the Social Security Act for Initial Price Applicability Year 2026, and Solicitation of Comments; implementation of the American Rescue Plan Act (P.L. 117-2); implementation of the Inflation Reduction Act (P.L. 117-169); balance or surprise billing and related issues; single-payer health care options; health reimbursement arrangements and other account-based group health plans; Health and Human Services international pricing index (IPI) model; mental health parity; drug pricing; COBRA subsidies; Federal Trade Commissions multilateral pharmaceutical merger taskforce; telehealth, including coverage of telehealth under High Deductible Health Plans (HDHPs) and expanding telehealth options for employees; impact of Pharmacy Benefit Managers Practices; FTC-2022-0015; petition to HHS to grant march-in rights for the patents on the drug Xtandi; ERISA preemption protections; artificial price caps on providing insulin; efforts to reform the World Health Organizations (WHO) engagement with private sector; continued U.S. membership to the World Health Organization (WHO); support for necessary market conditions to incentivize health sector investment from private sector; support for private sector involvement in health systems strengthening; greater harmonization of standards and investment in digital health internationally; role of private sector related pandemic prevention, preparedness and response; oversight issues related to the U.S. Food and Drug Administration
Pharmacy Benefit Manager Transparency Act of 2023
Client: CHAMBER OF COMMERCE OF THE U.S.A. · Firm: CHAMBER OF COMMERCE OF THE U.S.A.
S. 127, Pharmacy Benefit Manager Transparency Act of 2023 S. 142, Preserve Access to Affordable Generics and Biosimilars Act S. 148, Stop Significant and Time-wasting Abuse Limiting Legitimate Innovation of New Generics (Stop STALLING) Act S. 150, Affordable Prescriptions for Patients Act of 2023 Various issues relating to the employer-sponsored health care system, the "family glitch", implementation of regulatory process, provider network adequacy, health savings account (HSAs), health reimbursement account (HRAs), employer mandate; coronavirus pandemic; vaccine distribution, PPE, testing, medications and treatments, and vaccination incentives; digital health credentials; vaccine diplomacy; COVID-19 vaccine requirements, including a potential Emergency Temporary Standard from the Occupational Safety and Health Administration relating to employers with more than 100 employees; vaccine requirements for federal contractors; Executive Order 14042, Ensuring Adequate COVID Safety Protocols for Federal Contractors; implementation of the American Rescue Plan Act (P.L. 117-2); balance or surprise billing and related issues; single-payer health care options; health reimbursement arrangements and other account-based group health plans; Health and Human Services international pricing index (IPI) model; mental health parity; drug pricing; COBRA subsidies; Federal Trade Commissions multilateral pharmaceutical merger taskforce; telehealth, including coverage of telehealth under High Deductible Health Plans (HDHPs) and expanding telehealth options for employees; impact of Pharmacy Benefit Managers Practices; FTC-2022-0015; petition to HHS to grant march-in rights for the patents on the drug Xtandi; Centers for Medicare & Medicaid Services; Advance Notice of Methodological Changes for Calendar Year (CY) 2024 for Medicare Advantage (MA) Capitation Rates and Part C and Part D Payment Policies (February 1, 2023); comments on COVID-19 Telehealth Program Application Evaluation Metrics (WC Docket No. 20-89); efforts to reform the World Health Organizations (WHO) engagement with private sector; continued U.S. membership to the World Health Organization (WHO); support for necessary market conditions to incentivize health sector investment from private sector; support for private sector involvement in health systems strengthening; greater harmonization of standards and investment in digital health internationally; role of private sector related pandemic prevention, preparedness and response; request for input, United States Senate Committee on Health, Education, Labor, and Pensions; U.S. Healthcare Workforce Shortage RFI (March 2, 2023)
Pharmacy Benefit Manager Transparency Act of 2023
Client: CHAMBER OF COMMERCE OF THE U.S.A. · Firm: CHAMBER OF COMMERCE OF THE U.S.A.
H.R. 1264, Commonsense Reporting Act of 2023 H.R. 2813, Self-Insurance Protection Act H.R. 2868, Association Health Plans Act S. 127, Pharmacy Benefit Manager Transparency Act of 2023 S. 142, Preserve Access to Affordable Generics and Biosimilars Act S. 148, Stop Significant and Time-wasting Abuse Limiting Legitimate Innovation of New Generics (Stop STALLING) Act S. 150, Affordable Prescriptions for Patients Act of 2023 S. 1067, Ensuring Timely Access to Generics Act of 2023 S. 1114, Expanding Access to Low-Cost Generics Act of 2023 S. 1214, Retaining Access and Restoring Exclusivity (RARE) Act S. 1339, Pharmacy Benefit Manager Reform Act Various issues relating to the employer-sponsored health care system, implementation of regulatory process, provider network adequacy, health savings account (HSAs), health reimbursement account (HRAs), employer mandate; Medicare Drug Price Negotiation Program: Initial Memorandum, Implementation of Sections 1191 - 1198 of the Social Security Act for Initial Price Applicability Year 2026, and Solicitation of Comments; implementation of the American Rescue Plan Act (P.L. 117-2); implementation of the Inflation Reduction Act (P.L. 117-169); balance or surprise billing and related issues; single-payer health care options; health reimbursement arrangements and other account-based group health plans; Health and Human Services international pricing index (IPI) model; mental health parity; drug pricing; COBRA subsidies; Federal Trade Commissions multilateral pharmaceutical merger taskforce; telehealth, including coverage of telehealth under High Deductible Health Plans (HDHPs) and expanding telehealth options for employees; impact of Pharmacy Benefit Managers Practices; FTC-2022-0015; petition to HHS to grant march-in rights for the patents on the drug Xtandi; ERISA preemption protections; artificial price caps on providing insulin; efforts to reform the World Health Organizations (WHO) engagement with private sector; continued U.S. membership to the World Health Organization (WHO); support for necessary market conditions to incentivize health sector investment from private sector; support for private sector involvement in health systems strengthening; greater harmonization of standards and investment in digital health internationally; role of private sector related pandemic prevention, preparedness and response; oversight issues related to the U.S. Food and Drug Administration
Pharmacy Benefit Manager Transparency Act of 2023
Client: CHAMBER OF COMMERCE OF THE U.S.A. · Firm: CHAMBER OF COMMERCE OF THE U.S.A.
S. 127, Pharmacy Benefit Manager Transparency Act of 2023 S. 142, Preserve Access to Affordable Generics and Biosimilars Act S. 148, Stop Significant and Time-wasting Abuse Limiting Legitimate Innovation of New Generics (Stop STALLING) Act S. 150, Affordable Prescriptions for Patients Act of 2023 Various issues relating to the employer-sponsored health care system, the "family glitch", implementation of regulatory process, provider network adequacy, health savings account (HSAs), health reimbursement account (HRAs), employer mandate; coronavirus pandemic; vaccine distribution, PPE, testing, medications and treatments, and vaccination incentives; digital health credentials; vaccine diplomacy; COVID-19 vaccine requirements, including a potential Emergency Temporary Standard from the Occupational Safety and Health Administration relating to employers with more than 100 employees; vaccine requirements for federal contractors; Executive Order 14042, Ensuring Adequate COVID Safety Protocols for Federal Contractors; implementation of the American Rescue Plan Act (P.L. 117-2); balance or surprise billing and related issues; single-payer health care options; health reimbursement arrangements and other account-based group health plans; Health and Human Services international pricing index (IPI) model; mental health parity; drug pricing; COBRA subsidies; Federal Trade Commissions multilateral pharmaceutical merger taskforce; telehealth, including coverage of telehealth under High Deductible Health Plans (HDHPs) and expanding telehealth options for employees; impact of Pharmacy Benefit Managers Practices; FTC-2022-0015; petition to HHS to grant march-in rights for the patents on the drug Xtandi; Centers for Medicare & Medicaid Services; Advance Notice of Methodological Changes for Calendar Year (CY) 2024 for Medicare Advantage (MA) Capitation Rates and Part C and Part D Payment Policies (February 1, 2023); comments on COVID-19 Telehealth Program Application Evaluation Metrics (WC Docket No. 20-89); efforts to reform the World Health Organizations (WHO) engagement with private sector; continued U.S. membership to the World Health Organization (WHO); support for necessary market conditions to incentivize health sector investment from private sector; support for private sector involvement in health systems strengthening; greater harmonization of standards and investment in digital health internationally; role of private sector related pandemic prevention, preparedness and response; request for input, United States Senate Committee on Health, Education, Labor, and Pensions; U.S. Healthcare Workforce Shortage RFI (March 2, 2023)
Pharmacy Benefit Manager Reform Act
Client: CHAMBER OF COMMERCE OF THE U.S.A. · Firm: CHAMBER OF COMMERCE OF THE U.S.A.
H.R. 1264, Commonsense Reporting Act of 2023 H.R. 2813, Self-Insurance Protection Act H.R. 2868, Association Health Plans Act S. 127, Pharmacy Benefit Manager Transparency Act of 2023 S. 142, Preserve Access to Affordable Generics and Biosimilars Act S. 148, Stop Significant and Time-wasting Abuse Limiting Legitimate Innovation of New Generics (Stop STALLING) Act S. 150, Affordable Prescriptions for Patients Act of 2023 S. 1067, Ensuring Timely Access to Generics Act of 2023 S. 1114, Expanding Access to Low-Cost Generics Act of 2023 S. 1214, Retaining Access and Restoring Exclusivity (RARE) Act S. 1339, Pharmacy Benefit Manager Reform Act Various issues relating to the employer-sponsored health care system, implementation of regulatory process, provider network adequacy, health savings account (HSAs), health reimbursement account (HRAs), employer mandate; Medicare Drug Price Negotiation Program: Initial Memorandum, Implementation of Sections 1191 - 1198 of the Social Security Act for Initial Price Applicability Year 2026, and Solicitation of Comments; implementation of the American Rescue Plan Act (P.L. 117-2); implementation of the Inflation Reduction Act (P.L. 117-169); balance or surprise billing and related issues; single-payer health care options; health reimbursement arrangements and other account-based group health plans; Health and Human Services international pricing index (IPI) model; mental health parity; drug pricing; COBRA subsidies; Federal Trade Commissions multilateral pharmaceutical merger taskforce; telehealth, including coverage of telehealth under High Deductible Health Plans (HDHPs) and expanding telehealth options for employees; impact of Pharmacy Benefit Managers Practices; FTC-2022-0015; petition to HHS to grant march-in rights for the patents on the drug Xtandi; ERISA preemption protections; artificial price caps on providing insulin; efforts to reform the World Health Organizations (WHO) engagement with private sector; continued U.S. membership to the World Health Organization (WHO); support for necessary market conditions to incentivize health sector investment from private sector; support for private sector involvement in health systems strengthening; greater harmonization of standards and investment in digital health internationally; role of private sector related pandemic prevention, preparedness and response; oversight issues related to the U.S. Food and Drug Administration
Preserve Access to Affordable Generics and Biosimilars Act
Client: CHAMBER OF COMMERCE OF THE U.S.A. · Firm: CHAMBER OF COMMERCE OF THE U.S.A.
S. 127, Pharmacy Benefit Manager Transparency Act of 2023 S. 142, Preserve Access to Affordable Generics and Biosimilars Act S. 148, Stop Significant and Time-wasting Abuse Limiting Legitimate Innovation of New Generics (Stop STALLING) Act S. 150, Affordable Prescriptions for Patients Act of 2023 Various issues relating to the employer-sponsored health care system, the "family glitch", implementation of regulatory process, provider network adequacy, health savings account (HSAs), health reimbursement account (HRAs), employer mandate; coronavirus pandemic; vaccine distribution, PPE, testing, medications and treatments, and vaccination incentives; digital health credentials; vaccine diplomacy; COVID-19 vaccine requirements, including a potential Emergency Temporary Standard from the Occupational Safety and Health Administration relating to employers with more than 100 employees; vaccine requirements for federal contractors; Executive Order 14042, Ensuring Adequate COVID Safety Protocols for Federal Contractors; implementation of the American Rescue Plan Act (P.L. 117-2); balance or surprise billing and related issues; single-payer health care options; health reimbursement arrangements and other account-based group health plans; Health and Human Services international pricing index (IPI) model; mental health parity; drug pricing; COBRA subsidies; Federal Trade Commissions multilateral pharmaceutical merger taskforce; telehealth, including coverage of telehealth under High Deductible Health Plans (HDHPs) and expanding telehealth options for employees; impact of Pharmacy Benefit Managers Practices; FTC-2022-0015; petition to HHS to grant march-in rights for the patents on the drug Xtandi; Centers for Medicare & Medicaid Services; Advance Notice of Methodological Changes for Calendar Year (CY) 2024 for Medicare Advantage (MA) Capitation Rates and Part C and Part D Payment Policies (February 1, 2023); comments on COVID-19 Telehealth Program Application Evaluation Metrics (WC Docket No. 20-89); efforts to reform the World Health Organizations (WHO) engagement with private sector; continued U.S. membership to the World Health Organization (WHO); support for necessary market conditions to incentivize health sector investment from private sector; support for private sector involvement in health systems strengthening; greater harmonization of standards and investment in digital health internationally; role of private sector related pandemic prevention, preparedness and response; request for input, United States Senate Committee on Health, Education, Labor, and Pensions; U.S. Healthcare Workforce Shortage RFI (March 2, 2023)
Preserve Access to Affordable Generics and Biosimilars Act
Client: CHAMBER OF COMMERCE OF THE U.S.A. · Firm: CHAMBER OF COMMERCE OF THE U.S.A.
H.R. 1264, Commonsense Reporting Act of 2023 H.R. 2813, Self-Insurance Protection Act H.R. 2868, Association Health Plans Act S. 127, Pharmacy Benefit Manager Transparency Act of 2023 S. 142, Preserve Access to Affordable Generics and Biosimilars Act S. 148, Stop Significant and Time-wasting Abuse Limiting Legitimate Innovation of New Generics (Stop STALLING) Act S. 150, Affordable Prescriptions for Patients Act of 2023 S. 1067, Ensuring Timely Access to Generics Act of 2023 S. 1114, Expanding Access to Low-Cost Generics Act of 2023 S. 1214, Retaining Access and Restoring Exclusivity (RARE) Act S. 1339, Pharmacy Benefit Manager Reform Act Various issues relating to the employer-sponsored health care system, implementation of regulatory process, provider network adequacy, health savings account (HSAs), health reimbursement account (HRAs), employer mandate; Medicare Drug Price Negotiation Program: Initial Memorandum, Implementation of Sections 1191 - 1198 of the Social Security Act for Initial Price Applicability Year 2026, and Solicitation of Comments; implementation of the American Rescue Plan Act (P.L. 117-2); implementation of the Inflation Reduction Act (P.L. 117-169); balance or surprise billing and related issues; single-payer health care options; health reimbursement arrangements and other account-based group health plans; Health and Human Services international pricing index (IPI) model; mental health parity; drug pricing; COBRA subsidies; Federal Trade Commissions multilateral pharmaceutical merger taskforce; telehealth, including coverage of telehealth under High Deductible Health Plans (HDHPs) and expanding telehealth options for employees; impact of Pharmacy Benefit Managers Practices; FTC-2022-0015; petition to HHS to grant march-in rights for the patents on the drug Xtandi; ERISA preemption protections; artificial price caps on providing insulin; efforts to reform the World Health Organizations (WHO) engagement with private sector; continued U.S. membership to the World Health Organization (WHO); support for necessary market conditions to incentivize health sector investment from private sector; support for private sector involvement in health systems strengthening; greater harmonization of standards and investment in digital health internationally; role of private sector related pandemic prevention, preparedness and response; oversight issues related to the U.S. Food and Drug Administration
Preserve Access to Affordable Generics and Biosimilars Act
Client: CHAMBER OF COMMERCE OF THE U.S.A. · Firm: CHAMBER OF COMMERCE OF THE U.S.A.
S. 127, Pharmacy Benefit Manager Transparency Act of 2023 S. 142, Preserve Access to Affordable Generics and Biosimilars Act S. 148, Stop Significant and Time-wasting Abuse Limiting Legitimate Innovation of New Generics (Stop STALLING) Act S. 150, Affordable Prescriptions for Patients Act of 2023 Various issues relating to the employer-sponsored health care system, the "family glitch", implementation of regulatory process, provider network adequacy, health savings account (HSAs), health reimbursement account (HRAs), employer mandate; coronavirus pandemic; vaccine distribution, PPE, testing, medications and treatments, and vaccination incentives; digital health credentials; vaccine diplomacy; COVID-19 vaccine requirements, including a potential Emergency Temporary Standard from the Occupational Safety and Health Administration relating to employers with more than 100 employees; vaccine requirements for federal contractors; Executive Order 14042, Ensuring Adequate COVID Safety Protocols for Federal Contractors; implementation of the American Rescue Plan Act (P.L. 117-2); balance or surprise billing and related issues; single-payer health care options; health reimbursement arrangements and other account-based group health plans; Health and Human Services international pricing index (IPI) model; mental health parity; drug pricing; COBRA subsidies; Federal Trade Commissions multilateral pharmaceutical merger taskforce; telehealth, including coverage of telehealth under High Deductible Health Plans (HDHPs) and expanding telehealth options for employees; impact of Pharmacy Benefit Managers Practices; FTC-2022-0015; petition to HHS to grant march-in rights for the patents on the drug Xtandi; Centers for Medicare & Medicaid Services; Advance Notice of Methodological Changes for Calendar Year (CY) 2024 for Medicare Advantage (MA) Capitation Rates and Part C and Part D Payment Policies (February 1, 2023); comments on COVID-19 Telehealth Program Application Evaluation Metrics (WC Docket No. 20-89); efforts to reform the World Health Organizations (WHO) engagement with private sector; continued U.S. membership to the World Health Organization (WHO); support for necessary market conditions to incentivize health sector investment from private sector; support for private sector involvement in health systems strengthening; greater harmonization of standards and investment in digital health internationally; role of private sector related pandemic prevention, preparedness and response; request for input, United States Senate Committee on Health, Education, Labor, and Pensions; U.S. Healthcare Workforce Shortage RFI (March 2, 2023)
Stop STALLING Act
Client: CHAMBER OF COMMERCE OF THE U.S.A. · Firm: CHAMBER OF COMMERCE OF THE U.S.A.
S. 127, Pharmacy Benefit Manager Transparency Act of 2023 S. 142, Preserve Access to Affordable Generics and Biosimilars Act S. 148, Stop Significant and Time-wasting Abuse Limiting Legitimate Innovation of New Generics (Stop STALLING) Act S. 150, Affordable Prescriptions for Patients Act of 2023 Various issues relating to the employer-sponsored health care system, the "family glitch", implementation of regulatory process, provider network adequacy, health savings account (HSAs), health reimbursement account (HRAs), employer mandate; coronavirus pandemic; vaccine distribution, PPE, testing, medications and treatments, and vaccination incentives; digital health credentials; vaccine diplomacy; COVID-19 vaccine requirements, including a potential Emergency Temporary Standard from the Occupational Safety and Health Administration relating to employers with more than 100 employees; vaccine requirements for federal contractors; Executive Order 14042, Ensuring Adequate COVID Safety Protocols for Federal Contractors; implementation of the American Rescue Plan Act (P.L. 117-2); balance or surprise billing and related issues; single-payer health care options; health reimbursement arrangements and other account-based group health plans; Health and Human Services international pricing index (IPI) model; mental health parity; drug pricing; COBRA subsidies; Federal Trade Commissions multilateral pharmaceutical merger taskforce; telehealth, including coverage of telehealth under High Deductible Health Plans (HDHPs) and expanding telehealth options for employees; impact of Pharmacy Benefit Managers Practices; FTC-2022-0015; petition to HHS to grant march-in rights for the patents on the drug Xtandi; Centers for Medicare & Medicaid Services; Advance Notice of Methodological Changes for Calendar Year (CY) 2024 for Medicare Advantage (MA) Capitation Rates and Part C and Part D Payment Policies (February 1, 2023); comments on COVID-19 Telehealth Program Application Evaluation Metrics (WC Docket No. 20-89); efforts to reform the World Health Organizations (WHO) engagement with private sector; continued U.S. membership to the World Health Organization (WHO); support for necessary market conditions to incentivize health sector investment from private sector; support for private sector involvement in health systems strengthening; greater harmonization of standards and investment in digital health internationally; role of private sector related pandemic prevention, preparedness and response; request for input, United States Senate Committee on Health, Education, Labor, and Pensions; U.S. Healthcare Workforce Shortage RFI (March 2, 2023)
Stop STALLING Act
Client: CHAMBER OF COMMERCE OF THE U.S.A. · Firm: CHAMBER OF COMMERCE OF THE U.S.A.
H.R. 1264, Commonsense Reporting Act of 2023 H.R. 2813, Self-Insurance Protection Act H.R. 2868, Association Health Plans Act S. 127, Pharmacy Benefit Manager Transparency Act of 2023 S. 142, Preserve Access to Affordable Generics and Biosimilars Act S. 148, Stop Significant and Time-wasting Abuse Limiting Legitimate Innovation of New Generics (Stop STALLING) Act S. 150, Affordable Prescriptions for Patients Act of 2023 S. 1067, Ensuring Timely Access to Generics Act of 2023 S. 1114, Expanding Access to Low-Cost Generics Act of 2023 S. 1214, Retaining Access and Restoring Exclusivity (RARE) Act S. 1339, Pharmacy Benefit Manager Reform Act Various issues relating to the employer-sponsored health care system, implementation of regulatory process, provider network adequacy, health savings account (HSAs), health reimbursement account (HRAs), employer mandate; Medicare Drug Price Negotiation Program: Initial Memorandum, Implementation of Sections 1191 - 1198 of the Social Security Act for Initial Price Applicability Year 2026, and Solicitation of Comments; implementation of the American Rescue Plan Act (P.L. 117-2); implementation of the Inflation Reduction Act (P.L. 117-169); balance or surprise billing and related issues; single-payer health care options; health reimbursement arrangements and other account-based group health plans; Health and Human Services international pricing index (IPI) model; mental health parity; drug pricing; COBRA subsidies; Federal Trade Commissions multilateral pharmaceutical merger taskforce; telehealth, including coverage of telehealth under High Deductible Health Plans (HDHPs) and expanding telehealth options for employees; impact of Pharmacy Benefit Managers Practices; FTC-2022-0015; petition to HHS to grant march-in rights for the patents on the drug Xtandi; ERISA preemption protections; artificial price caps on providing insulin; efforts to reform the World Health Organizations (WHO) engagement with private sector; continued U.S. membership to the World Health Organization (WHO); support for necessary market conditions to incentivize health sector investment from private sector; support for private sector involvement in health systems strengthening; greater harmonization of standards and investment in digital health internationally; role of private sector related pandemic prevention, preparedness and response; oversight issues related to the U.S. Food and Drug Administration
Stop STALLING Act
Client: CHAMBER OF COMMERCE OF THE U.S.A. · Firm: CHAMBER OF COMMERCE OF THE U.S.A.
S. 127, Pharmacy Benefit Manager Transparency Act of 2023 S. 142, Preserve Access to Affordable Generics and Biosimilars Act S. 148, Stop Significant and Time-wasting Abuse Limiting Legitimate Innovation of New Generics (Stop STALLING) Act S. 150, Affordable Prescriptions for Patients Act of 2023 Various issues relating to the employer-sponsored health care system, the "family glitch", implementation of regulatory process, provider network adequacy, health savings account (HSAs), health reimbursement account (HRAs), employer mandate; coronavirus pandemic; vaccine distribution, PPE, testing, medications and treatments, and vaccination incentives; digital health credentials; vaccine diplomacy; COVID-19 vaccine requirements, including a potential Emergency Temporary Standard from the Occupational Safety and Health Administration relating to employers with more than 100 employees; vaccine requirements for federal contractors; Executive Order 14042, Ensuring Adequate COVID Safety Protocols for Federal Contractors; implementation of the American Rescue Plan Act (P.L. 117-2); balance or surprise billing and related issues; single-payer health care options; health reimbursement arrangements and other account-based group health plans; Health and Human Services international pricing index (IPI) model; mental health parity; drug pricing; COBRA subsidies; Federal Trade Commissions multilateral pharmaceutical merger taskforce; telehealth, including coverage of telehealth under High Deductible Health Plans (HDHPs) and expanding telehealth options for employees; impact of Pharmacy Benefit Managers Practices; FTC-2022-0015; petition to HHS to grant march-in rights for the patents on the drug Xtandi; Centers for Medicare & Medicaid Services; Advance Notice of Methodological Changes for Calendar Year (CY) 2024 for Medicare Advantage (MA) Capitation Rates and Part C and Part D Payment Policies (February 1, 2023); comments on COVID-19 Telehealth Program Application Evaluation Metrics (WC Docket No. 20-89); efforts to reform the World Health Organizations (WHO) engagement with private sector; continued U.S. membership to the World Health Organization (WHO); support for necessary market conditions to incentivize health sector investment from private sector; support for private sector involvement in health systems strengthening; greater harmonization of standards and investment in digital health internationally; role of private sector related pandemic prevention, preparedness and response; request for input, United States Senate Committee on Health, Education, Labor, and Pensions; U.S. Healthcare Workforce Shortage RFI (March 2, 2023)
Affordable Prescriptions for Patients Act of 2023
Client: CHAMBER OF COMMERCE OF THE U.S.A. · Firm: CHAMBER OF COMMERCE OF THE U.S.A.
S. 127, Pharmacy Benefit Manager Transparency Act of 2023 S. 142, Preserve Access to Affordable Generics and Biosimilars Act S. 148, Stop Significant and Time-wasting Abuse Limiting Legitimate Innovation of New Generics (Stop STALLING) Act S. 150, Affordable Prescriptions for Patients Act of 2023 Various issues relating to the employer-sponsored health care system, the "family glitch", implementation of regulatory process, provider network adequacy, health savings account (HSAs), health reimbursement account (HRAs), employer mandate; coronavirus pandemic; vaccine distribution, PPE, testing, medications and treatments, and vaccination incentives; digital health credentials; vaccine diplomacy; COVID-19 vaccine requirements, including a potential Emergency Temporary Standard from the Occupational Safety and Health Administration relating to employers with more than 100 employees; vaccine requirements for federal contractors; Executive Order 14042, Ensuring Adequate COVID Safety Protocols for Federal Contractors; implementation of the American Rescue Plan Act (P.L. 117-2); balance or surprise billing and related issues; single-payer health care options; health reimbursement arrangements and other account-based group health plans; Health and Human Services international pricing index (IPI) model; mental health parity; drug pricing; COBRA subsidies; Federal Trade Commissions multilateral pharmaceutical merger taskforce; telehealth, including coverage of telehealth under High Deductible Health Plans (HDHPs) and expanding telehealth options for employees; impact of Pharmacy Benefit Managers Practices; FTC-2022-0015; petition to HHS to grant march-in rights for the patents on the drug Xtandi; Centers for Medicare & Medicaid Services; Advance Notice of Methodological Changes for Calendar Year (CY) 2024 for Medicare Advantage (MA) Capitation Rates and Part C and Part D Payment Policies (February 1, 2023); comments on COVID-19 Telehealth Program Application Evaluation Metrics (WC Docket No. 20-89); efforts to reform the World Health Organizations (WHO) engagement with private sector; continued U.S. membership to the World Health Organization (WHO); support for necessary market conditions to incentivize health sector investment from private sector; support for private sector involvement in health systems strengthening; greater harmonization of standards and investment in digital health internationally; role of private sector related pandemic prevention, preparedness and response; request for input, United States Senate Committee on Health, Education, Labor, and Pensions; U.S. Healthcare Workforce Shortage RFI (March 2, 2023)
Affordable Prescriptions for Patients Act of 2023
Client: CHAMBER OF COMMERCE OF THE U.S.A. · Firm: CHAMBER OF COMMERCE OF THE U.S.A.
S. 127, Pharmacy Benefit Manager Transparency Act of 2023 S. 142, Preserve Access to Affordable Generics and Biosimilars Act S. 148, Stop Significant and Time-wasting Abuse Limiting Legitimate Innovation of New Generics (Stop STALLING) Act S. 150, Affordable Prescriptions for Patients Act of 2023 Various issues relating to the employer-sponsored health care system, the "family glitch", implementation of regulatory process, provider network adequacy, health savings account (HSAs), health reimbursement account (HRAs), employer mandate; coronavirus pandemic; vaccine distribution, PPE, testing, medications and treatments, and vaccination incentives; digital health credentials; vaccine diplomacy; COVID-19 vaccine requirements, including a potential Emergency Temporary Standard from the Occupational Safety and Health Administration relating to employers with more than 100 employees; vaccine requirements for federal contractors; Executive Order 14042, Ensuring Adequate COVID Safety Protocols for Federal Contractors; implementation of the American Rescue Plan Act (P.L. 117-2); balance or surprise billing and related issues; single-payer health care options; health reimbursement arrangements and other account-based group health plans; Health and Human Services international pricing index (IPI) model; mental health parity; drug pricing; COBRA subsidies; Federal Trade Commissions multilateral pharmaceutical merger taskforce; telehealth, including coverage of telehealth under High Deductible Health Plans (HDHPs) and expanding telehealth options for employees; impact of Pharmacy Benefit Managers Practices; FTC-2022-0015; petition to HHS to grant march-in rights for the patents on the drug Xtandi; Centers for Medicare & Medicaid Services; Advance Notice of Methodological Changes for Calendar Year (CY) 2024 for Medicare Advantage (MA) Capitation Rates and Part C and Part D Payment Policies (February 1, 2023); comments on COVID-19 Telehealth Program Application Evaluation Metrics (WC Docket No. 20-89); efforts to reform the World Health Organizations (WHO) engagement with private sector; continued U.S. membership to the World Health Organization (WHO); support for necessary market conditions to incentivize health sector investment from private sector; support for private sector involvement in health systems strengthening; greater harmonization of standards and investment in digital health internationally; role of private sector related pandemic prevention, preparedness and response; request for input, United States Senate Committee on Health, Education, Labor, and Pensions; U.S. Healthcare Workforce Shortage RFI (March 2, 2023)
Affordable Prescriptions for Patients Act of 2023
Client: CHAMBER OF COMMERCE OF THE U.S.A. · Firm: CHAMBER OF COMMERCE OF THE U.S.A.
H.R. 1264, Commonsense Reporting Act of 2023 H.R. 2813, Self-Insurance Protection Act H.R. 2868, Association Health Plans Act S. 127, Pharmacy Benefit Manager Transparency Act of 2023 S. 142, Preserve Access to Affordable Generics and Biosimilars Act S. 148, Stop Significant and Time-wasting Abuse Limiting Legitimate Innovation of New Generics (Stop STALLING) Act S. 150, Affordable Prescriptions for Patients Act of 2023 S. 1067, Ensuring Timely Access to Generics Act of 2023 S. 1114, Expanding Access to Low-Cost Generics Act of 2023 S. 1214, Retaining Access and Restoring Exclusivity (RARE) Act S. 1339, Pharmacy Benefit Manager Reform Act Various issues relating to the employer-sponsored health care system, implementation of regulatory process, provider network adequacy, health savings account (HSAs), health reimbursement account (HRAs), employer mandate; Medicare Drug Price Negotiation Program: Initial Memorandum, Implementation of Sections 1191 - 1198 of the Social Security Act for Initial Price Applicability Year 2026, and Solicitation of Comments; implementation of the American Rescue Plan Act (P.L. 117-2); implementation of the Inflation Reduction Act (P.L. 117-169); balance or surprise billing and related issues; single-payer health care options; health reimbursement arrangements and other account-based group health plans; Health and Human Services international pricing index (IPI) model; mental health parity; drug pricing; COBRA subsidies; Federal Trade Commissions multilateral pharmaceutical merger taskforce; telehealth, including coverage of telehealth under High Deductible Health Plans (HDHPs) and expanding telehealth options for employees; impact of Pharmacy Benefit Managers Practices; FTC-2022-0015; petition to HHS to grant march-in rights for the patents on the drug Xtandi; ERISA preemption protections; artificial price caps on providing insulin; efforts to reform the World Health Organizations (WHO) engagement with private sector; continued U.S. membership to the World Health Organization (WHO); support for necessary market conditions to incentivize health sector investment from private sector; support for private sector involvement in health systems strengthening; greater harmonization of standards and investment in digital health internationally; role of private sector related pandemic prevention, preparedness and response; oversight issues related to the U.S. Food and Drug Administration
American Rescue Plan Act of 2021
Client: CHAMBER OF COMMERCE OF THE U.S.A. · Firm: CHAMBER OF COMMERCE OF THE U.S.A.
H.R. 3, Elijah E. Cummings Lower Drug Costs Now Act H.R. 1319, American Rescue Plan Act of 2021 H.R. 1976, Medicare for All Act of 2021 H.R. 2471, Consolidated Appropriations Act, 2022 H.R. 2873, Affordable Prescriptions for Patients Through Promoting Competition Act of 2021 H.R. 2884, Affordable Prescriptions for Patients Through Improvements to Patent Litigation Act H.R. 2891, Preserve Access to Affordable Generics and Biosimilars Act H.R. 3114, Longshore and Harbor Workers COVID-19 Compensation Act of 2021 H.R. 4502, Labor, Health and Human Services, Education, Agriculture, Rural Development, Energy and Water Development, Financial Services and General Government, Interior, Environment, Military Construction, Veterans Affairs, Transportation, and Housing and Urban Development Appropriations Act, 2022 H.R. 5981/S.1704, Telehealth Expansion Act of 2021 H.R. 8295, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2023 H.R. 8594/S. 4750, Restore Protections for Dialysis Patients Act S. 150, Ensuring Parity in Medicare Advantage for Audio-Only Telehealth Act S. 380, Health Savings Act of 2021 S. 1428, Preserve Access to Affordable Generics and Biosimilars Act S. 1435, Affordable Prescriptions for Patients Act of 2021 Implementation of the Transparency in Coverage Final Rule; Internal Revenue Service, Department of the Treasury; Employee Benefits Security Administration, Department of Labor; Centers for Medicare & Medicaid Services, Department of Health and Human Services (85 Fed. Reg. 72,158 - 72,310, November 12, 2020) Requirements Related to Surprise Billing; Internal Revenue Service; Employee Benefits Security Administration; Department of Health and Human Services (87 Fed. Reg. 52,618-52,655, August 26, 2022) Request for Information, Centers for Medicare & Medicaid Services; Medicare Program (87 Fed. Reg. 46,918-46,921, August 1, 2022) Notice of Proposed Rule, Employee Benefits Security Administration; Proposed Amendment to Prohibited Transaction Class Exemption 84-14 (the QPAM Exemption (87 Fed. Reg. 45,204-45,232, July 27, 2022) Affordability of Employer Coverage for Family Members of Employees (Family Glitch Regulation) (87 Fed. Reg. 20,354-20,364, April 7, 2022) Various issues relating to the employer-sponsored health care system, the "family glitch", implementation of regulatory process, provider network adequacy, health savings account (HSAs), health reimbursement account (HRAs), employer mandate; coronavirus pandemic; vaccine distribution, PPE, testing, medications and treatments, and vaccination incentives; digital health credentials; vaccine diplomacy; COVID-19 vaccine requirements, including a potential Emergency Temporary Standard from the Occupational Safety and Health Administration relating to employers with more than 100 employees; vaccine requirements for federal contractors; Executive Order 14042, Ensuring Adequate COVID Safety Protocols for Federal Contractors; implementation of the American Rescue Plan Act (P.L. 117-2); balance or surprise billing and related issues; single-payer health care options; health reimbursement arrangements and other account-based group health plans; Health and Human Services international pricing index (IPI) model; mental health parity; drug pricing; COBRA subsidies; Federal Trade Commissions multilateral pharmaceutical merger taskforce; telehealth, including coverage of telehealth under High Deductible Health Plans (HDHPs) and expanding telehealth options for employees; impact of Pharmacy Benefit Managers Practices; FTC-2022-0015; petition to HHS to grant march-in rights for the patents on the drug Xtandi; comments on COVID-19 Telehealth Program Application Evaluation Metrics (WC Docket No. 20-89); efforts to reform the World Health Organizations (WHO) engagement with private sector; continued U.S. membership to the World Health Organization (WHO); support for necessary market conditions to incentivize health sector investment from private sector; support for private sector involvement in health systems strengthening; greater harmonization of standards and investment in digital health internationally; role of private sector related pandemic prevention, preparedness and response
American Rescue Plan Act of 2021
Client: CHAMBER OF COMMERCE OF THE U.S.A. · Firm: CHAMBER OF COMMERCE OF THE U.S.A.
H.R. 3, Elijah E. Cummings Lower Drug Costs Now Act H.R. 1319, American Rescue Plan Act of 2021 H.R. 1976, Medicare for All Act of 2021 H.R. 2471, Consolidated Appropriations Act, 2022 H.R. 2873, Affordable Prescriptions for Patients Through Promoting Competition Act of 2021 H.R. 2884, Affordable Prescriptions for Patients Through Improvements to Patent Litigation Act H.R. 2891, Preserve Access to Affordable Generics and Biosimilars Act H.R. 3114, Longshore and Harbor Workers COVID-19 Compensation Act of 2021 H.R. 4502, Labor, Health and Human Services, Education, Agriculture, Rural Development, Energy and Water Development, Financial Services and General Government, Interior, Environment, Military Construction, Veterans Affairs, Transportation, and Housing and Urban Development Appropriations Act, 2022 S. 150, Ensuring Parity in Medicare Advantage for Audio-Only Telehealth Act S. 380, Health Savings Act of 2021 S. 1428, Preserve Access to Affordable Generics and Biosimilars Act S. 1435, Affordable Prescriptions for Patients Act of 2021 Implementation of the Transparency in Coverage Final Rule; Internal Revenue Service, Department of the Treasury; Employee Benefits Security Administration, Department of Labor; Centers for Medicare & Medicaid Services, Department of Health and Human Services (85 Fed. Reg. 72,158 - 72,310, November 12, 2020) Interim final rule, Most Favored Nation (MFN) Model (85 Fed. Reg. 76,180-76,259, November 27, 2020) Various issues relating to Patient Protection and Affordable Care Act (P.L. 111-148) and the Health Care and Education Affordability Reconciliation Act of 2010 (P.L. 111-152), including the employer-sponsored health care system, implementation of regulatory process, provider network adequacy, delivery system reform, health savings account (HSAs), health reimbursement account (HRAs), and flexible spending account (FSAs) changes, IPAB, employer mandate, reporting requirements for issuers and applicable large employers, premium stabilization programs, medical loss ratio, medical malpractice reform, exchanges, the impact on small business; coronavirus pandemic; vaccine distribution, PPE, testing, medications and treatments, and vaccination incentives; digital health credentials; vaccine diplomacy; COVID-19 vaccine requirements, including a potential Emergency Temporary Standard from the Occupational Safety and Health Administration relating to employers with more than 100 employees; vaccine requirements for federal contractors; Executive Order 14042, Ensuring Adequate COVID Safety Protocols for Federal Contractors; implementation of the American Rescue Plan Act (P.L. 117-2); balance or surprise billing and related issues; single-payer health care options; health reimbursement arrangements and other account-based group health plans; Health and Human Services international pricing index (IPI) model; mental health parity; drug pricing; COBRA subsidies; Federal Trade Commissions multilateral pharmaceutical merger taskforce; telehealth, including coverage of telehealth under High Deductible Health Plans (HDHPs) and expanding telehealth options for employees; petition to HHS to grant march-in rights for the patents on the drug Xtandi; comments on IRS Notice 2020-76; Transition Relief Related to Health Coverage Reporting Required by Sections 6055 and 6056 for 2020; comments on COVID-19 Telehealth Program Application Evaluation Metrics (WC Docket No. 20-89); efforts to reform the World Health Organizations (WHO) engagement with private sector; continued U.S. membership to the World Health Organization (WHO); support for necessary market conditions to incentivize health sector investment from private sector; support for private sector involvement in health system strengthening
American Rescue Plan Act of 2021
Client: CHAMBER OF COMMERCE OF THE U.S.A. · Firm: CHAMBER OF COMMERCE OF THE U.S.A.
H.R. 3, Elijah E. Cummings Lower Drug Costs Now Act H.R. 1319, American Rescue Plan Act of 2021 H.R. 1976, Medicare for All Act of 2021 H.R. 2471, Consolidated Appropriations Act, 2022 H.R. 2873, Affordable Prescriptions for Patients Through Promoting Competition Act of 2021 H.R. 2884, Affordable Prescriptions for Patients Through Improvements to Patent Litigation Act H.R. 2891, Preserve Access to Affordable Generics and Biosimilars Act H.R. 3114, Longshore and Harbor Workers COVID-19 Compensation Act of 2021 H.R. 4502, Labor, Health and Human Services, Education, Agriculture, Rural Development, Energy and Water Development, Financial Services and General Government, Interior, Environment, Military Construction, Veterans Affairs, Transportation, and Housing and Urban Development Appropriations Act, 2022 S. 150, Ensuring Parity in Medicare Advantage for Audio-Only Telehealth Act S. 380, Health Savings Act of 2021 S. 1428, Preserve Access to Affordable Generics and Biosimilars Act S. 1435, Affordable Prescriptions for Patients Act of 2021 Draft legislation titled Making appropriations for the Departments of Labor, Health and Human Services, and Education, and related agencies for the fiscal year ending September 30, 2023, and for other purposes Nomination of Robert Gordon to be Assistant Secretary for Financial Resources at the Department of Health and Human Services Implementation of the Transparency in Coverage Final Rule; Internal Revenue Service, Department of the Treasury; Employee Benefits Security Administration, Department of Labor; Centers for Medicare & Medicaid Services, Department of Health and Human Services (85 Fed. Reg. 72,158 - 72,310, November 12, 2020) Interim final rule, Most Favored Nation (MFN) Model (85 Fed. Reg. 76,180-76,259, November 27, 2020) Proposed rule regarding Affordability of Employer Coverage for Family Members of Employees (87 Fed. Reg. 20,354-20,364, April 7, 2022) Withdrawal of a Notice of Proposed Rulemaking, Internal Revenue Service; Affordability of Employer Coverage for Family Members of Employees (87 Fed. Reg. 20,354-20,364, April 7, 2022) Various issues relating to Patient Protection and Affordable Care Act (P.L. 111-148) and the Health Care and Education Affordability Reconciliation Act of 2010 (P.L. 111-152), including the employer-sponsored health care system, implementation of regulatory process, provider network adequacy, delivery system reform, health savings account (HSAs), health reimbursement account (HRAs), and flexible spending account (FSAs) changes, IPAB, employer mandate, reporting requirements for issuers and applicable large employers, premium stabilization programs, medical loss ratio, medical malpractice reform, exchanges, the impact on small business; coronavirus pandemic; vaccine distribution, PPE, testing, medications and treatments, and vaccination incentives; digital health credentials; vaccine diplomacy; COVID-19 vaccine requirements, including a potential Emergency Temporary Standard from the Occupational Safety and Health Administration relating to employers with more than 100 employees; vaccine requirements for federal contractors; Executive Order 14042, Ensuring Adequate COVID Safety Protocols for Federal Contractors; implementation of the American Rescue Plan Act (P.L. 117-2); balance or surprise billing and related issues; single-payer health care options; health reimbursement arrangements and other account-based group health plans; Health and Human Services international pricing index (IPI) model; mental health parity; drug pricing; COBRA subsidies; Federal Trade Commissions multilateral pharmaceutical merger taskforce; telehealth, including coverage of telehealth under High Deductible Health Plans (HDHPs) and expanding telehealth options for employees; impact of Pharmacy Benefit Managers Practices; FTC-2022-0015; petition to HHS to grant march-in rights for the patents on the drug Xtandi; efforts to reform the World Health Organizations (WHO) engagement with private sector; continued U.S. membership to the World Health Organization (WHO); support for necessary market conditions to incentivize health sector investment from private sector; support for private sector involvement in health system strengthening
American Rescue Plan Act of 2021
Client: CHAMBER OF COMMERCE OF THE U.S.A. · Firm: CHAMBER OF COMMERCE OF THE U.S.A.
H.R. 3, Elijah E. Cummings Lower Drug Costs Now Act H.R. 1319, American Rescue Plan Act of 2021 H.R. 1976, Medicare for All Act of 2021 H.R. 2471, Consolidated Appropriations Act, 2022 H.R. 2873, Affordable Prescriptions for Patients Through Promoting Competition Act of 2021 H.R. 2884, Affordable Prescriptions for Patients Through Improvements to Patent Litigation Act H.R. 2891, Preserve Access to Affordable Generics and Biosimilars Act H.R. 3114, Longshore and Harbor Workers COVID-19 Compensation Act of 2021 H.R. 4502, Labor, Health and Human Services, Education, Agriculture, Rural Development, Energy and Water Development, Financial Services and General Government, Interior, Environment, Military Construction, Veterans Affairs, Transportation, and Housing and Urban Development Appropriations Act, 2022 H.R. 8295, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2023 S. 150, Ensuring Parity in Medicare Advantage for Audio-Only Telehealth Act S. 380, Health Savings Act of 2021 S. 1428, Preserve Access to Affordable Generics and Biosimilars Act S. 1435, Affordable Prescriptions for Patients Act of 2021 Nomination of Robert Gordon to be Assistant Secretary for Financial Resources at the Department of Health and Human Services Implementation of the Transparency in Coverage Final Rule; Internal Revenue Service, Department of the Treasury; Employee Benefits Security Administration, Department of Labor; Centers for Medicare & Medicaid Services, Department of Health and Human Services (85 Fed. Reg. 72,158 - 72,310, November 12, 2020) Requirements Related to Surprise Billing; Internal Revenue Service; Employee Benefits Security Administration; Department of Health and Human Services (87 Fed. Reg. 52,618-52,655, August 26, 2022) Request for Information, Centers for Medicare & Medicaid Services; Medicare Program (87 Fed. Reg. 46,918-46,921, August 1, 2022) Affordability of Employer Coverage for Family Members of Employees (Family Glitch Regulation) (87 Fed. Reg. 20,354-20,364, April 7, 2022) Various issues relating to Patient Protection and Affordable Care Act (P.L. 111-148) and the Health Care and Education Affordability Reconciliation Act of 2010 (P.L. 111-152), including the employer-sponsored health care system, implementation of regulatory process, provider network adequacy, delivery system reform, health savings account (HSAs), health reimbursement account (HRAs), and flexible spending account (FSAs) changes, IPAB, employer mandate, reporting requirements for issuers and applicable large employers, premium stabilization programs, medical loss ratio, medical malpractice reform, exchanges, the impact on small business; coronavirus pandemic; vaccine distribution, PPE, testing, medications and treatments, and vaccination incentives; digital health credentials; vaccine diplomacy; COVID-19 vaccine requirements, including a potential Emergency Temporary Standard from the Occupational Safety and Health Administration relating to employers with more than 100 employees; vaccine requirements for federal contractors; Executive Order 14042, Ensuring Adequate COVID Safety Protocols for Federal Contractors; implementation of the American Rescue Plan Act (P.L. 117-2); balance or surprise billing and related issues; single-payer health care options; health reimbursement arrangements and other account-based group health plans; Health and Human Services international pricing index (IPI) model; mental health parity; drug pricing; COBRA subsidies; Federal Trade Commissions multilateral pharmaceutical merger taskforce; telehealth, including coverage of telehealth under High Deductible Health Plans (HDHPs) and expanding telehealth options for employees; impact of Pharmacy Benefit Managers Practices; FTC-2022-0015; petition to HHS to grant march-in rights for the patents on the drug Xtandi; petition to the Department of Labor Requesting a 60-Day Extension to Comment on Proposed Amendment(s) to Prohibited Transaction Class Exemption 84-14; comments on COVID-19 Telehealth Program Application Evaluation Metrics (WC Docket No. 20-89); efforts to reform the World Health Organizations (WHO) engagement with private sector; continued U.S. membership to the World Health Organization (WHO); support for necessary market conditions to incentivize health sector investment from private sector; support for private sector involvement in health system strengthening; greater harmonization of standards and investment in digital health internationally; role of private sector related pandemic prevention, preparedness and response
Medicare for All Act of 2021
Client: CHAMBER OF COMMERCE OF THE U.S.A. · Firm: CHAMBER OF COMMERCE OF THE U.S.A.
H.R. 3, Elijah E. Cummings Lower Drug Costs Now Act H.R. 1319, American Rescue Plan Act of 2021 H.R. 1976, Medicare for All Act of 2021 H.R. 2471, Consolidated Appropriations Act, 2022 H.R. 2873, Affordable Prescriptions for Patients Through Promoting Competition Act of 2021 H.R. 2884, Affordable Prescriptions for Patients Through Improvements to Patent Litigation Act H.R. 2891, Preserve Access to Affordable Generics and Biosimilars Act H.R. 3114, Longshore and Harbor Workers COVID-19 Compensation Act of 2021 H.R. 4502, Labor, Health and Human Services, Education, Agriculture, Rural Development, Energy and Water Development, Financial Services and General Government, Interior, Environment, Military Construction, Veterans Affairs, Transportation, and Housing and Urban Development Appropriations Act, 2022 H.R. 8295, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2023 S. 150, Ensuring Parity in Medicare Advantage for Audio-Only Telehealth Act S. 380, Health Savings Act of 2021 S. 1428, Preserve Access to Affordable Generics and Biosimilars Act S. 1435, Affordable Prescriptions for Patients Act of 2021 Nomination of Robert Gordon to be Assistant Secretary for Financial Resources at the Department of Health and Human Services Implementation of the Transparency in Coverage Final Rule; Internal Revenue Service, Department of the Treasury; Employee Benefits Security Administration, Department of Labor; Centers for Medicare & Medicaid Services, Department of Health and Human Services (85 Fed. Reg. 72,158 - 72,310, November 12, 2020) Requirements Related to Surprise Billing; Internal Revenue Service; Employee Benefits Security Administration; Department of Health and Human Services (87 Fed. Reg. 52,618-52,655, August 26, 2022) Request for Information, Centers for Medicare & Medicaid Services; Medicare Program (87 Fed. Reg. 46,918-46,921, August 1, 2022) Affordability of Employer Coverage for Family Members of Employees (Family Glitch Regulation) (87 Fed. Reg. 20,354-20,364, April 7, 2022) Various issues relating to Patient Protection and Affordable Care Act (P.L. 111-148) and the Health Care and Education Affordability Reconciliation Act of 2010 (P.L. 111-152), including the employer-sponsored health care system, implementation of regulatory process, provider network adequacy, delivery system reform, health savings account (HSAs), health reimbursement account (HRAs), and flexible spending account (FSAs) changes, IPAB, employer mandate, reporting requirements for issuers and applicable large employers, premium stabilization programs, medical loss ratio, medical malpractice reform, exchanges, the impact on small business; coronavirus pandemic; vaccine distribution, PPE, testing, medications and treatments, and vaccination incentives; digital health credentials; vaccine diplomacy; COVID-19 vaccine requirements, including a potential Emergency Temporary Standard from the Occupational Safety and Health Administration relating to employers with more than 100 employees; vaccine requirements for federal contractors; Executive Order 14042, Ensuring Adequate COVID Safety Protocols for Federal Contractors; implementation of the American Rescue Plan Act (P.L. 117-2); balance or surprise billing and related issues; single-payer health care options; health reimbursement arrangements and other account-based group health plans; Health and Human Services international pricing index (IPI) model; mental health parity; drug pricing; COBRA subsidies; Federal Trade Commissions multilateral pharmaceutical merger taskforce; telehealth, including coverage of telehealth under High Deductible Health Plans (HDHPs) and expanding telehealth options for employees; impact of Pharmacy Benefit Managers Practices; FTC-2022-0015; petition to HHS to grant march-in rights for the patents on the drug Xtandi; petition to the Department of Labor Requesting a 60-Day Extension to Comment on Proposed Amendment(s) to Prohibited Transaction Class Exemption 84-14; comments on COVID-19 Telehealth Program Application Evaluation Metrics (WC Docket No. 20-89); efforts to reform the World Health Organizations (WHO) engagement with private sector; continued U.S. membership to the World Health Organization (WHO); support for necessary market conditions to incentivize health sector investment from private sector; support for private sector involvement in health system strengthening; greater harmonization of standards and investment in digital health internationally; role of private sector related pandemic prevention, preparedness and response
Medicare for All Act of 2021
Client: CHAMBER OF COMMERCE OF THE U.S.A. · Firm: CHAMBER OF COMMERCE OF THE U.S.A.
H.R. 3, Elijah E. Cummings Lower Drug Costs Now Act H.R. 1319, American Rescue Plan Act of 2021 H.R. 1976, Medicare for All Act of 2021 H.R. 2471, Consolidated Appropriations Act, 2022 H.R. 2873, Affordable Prescriptions for Patients Through Promoting Competition Act of 2021 H.R. 2884, Affordable Prescriptions for Patients Through Improvements to Patent Litigation Act H.R. 2891, Preserve Access to Affordable Generics and Biosimilars Act H.R. 3114, Longshore and Harbor Workers COVID-19 Compensation Act of 2021 H.R. 4502, Labor, Health and Human Services, Education, Agriculture, Rural Development, Energy and Water Development, Financial Services and General Government, Interior, Environment, Military Construction, Veterans Affairs, Transportation, and Housing and Urban Development Appropriations Act, 2022 S. 150, Ensuring Parity in Medicare Advantage for Audio-Only Telehealth Act S. 380, Health Savings Act of 2021 S. 1428, Preserve Access to Affordable Generics and Biosimilars Act S. 1435, Affordable Prescriptions for Patients Act of 2021 Draft legislation titled Making appropriations for the Departments of Labor, Health and Human Services, and Education, and related agencies for the fiscal year ending September 30, 2023, and for other purposes Nomination of Robert Gordon to be Assistant Secretary for Financial Resources at the Department of Health and Human Services Implementation of the Transparency in Coverage Final Rule; Internal Revenue Service, Department of the Treasury; Employee Benefits Security Administration, Department of Labor; Centers for Medicare & Medicaid Services, Department of Health and Human Services (85 Fed. Reg. 72,158 - 72,310, November 12, 2020) Interim final rule, Most Favored Nation (MFN) Model (85 Fed. Reg. 76,180-76,259, November 27, 2020) Proposed rule regarding Affordability of Employer Coverage for Family Members of Employees (87 Fed. Reg. 20,354-20,364, April 7, 2022) Withdrawal of a Notice of Proposed Rulemaking, Internal Revenue Service; Affordability of Employer Coverage for Family Members of Employees (87 Fed. Reg. 20,354-20,364, April 7, 2022) Various issues relating to Patient Protection and Affordable Care Act (P.L. 111-148) and the Health Care and Education Affordability Reconciliation Act of 2010 (P.L. 111-152), including the employer-sponsored health care system, implementation of regulatory process, provider network adequacy, delivery system reform, health savings account (HSAs), health reimbursement account (HRAs), and flexible spending account (FSAs) changes, IPAB, employer mandate, reporting requirements for issuers and applicable large employers, premium stabilization programs, medical loss ratio, medical malpractice reform, exchanges, the impact on small business; coronavirus pandemic; vaccine distribution, PPE, testing, medications and treatments, and vaccination incentives; digital health credentials; vaccine diplomacy; COVID-19 vaccine requirements, including a potential Emergency Temporary Standard from the Occupational Safety and Health Administration relating to employers with more than 100 employees; vaccine requirements for federal contractors; Executive Order 14042, Ensuring Adequate COVID Safety Protocols for Federal Contractors; implementation of the American Rescue Plan Act (P.L. 117-2); balance or surprise billing and related issues; single-payer health care options; health reimbursement arrangements and other account-based group health plans; Health and Human Services international pricing index (IPI) model; mental health parity; drug pricing; COBRA subsidies; Federal Trade Commissions multilateral pharmaceutical merger taskforce; telehealth, including coverage of telehealth under High Deductible Health Plans (HDHPs) and expanding telehealth options for employees; impact of Pharmacy Benefit Managers Practices; FTC-2022-0015; petition to HHS to grant march-in rights for the patents on the drug Xtandi; efforts to reform the World Health Organizations (WHO) engagement with private sector; continued U.S. membership to the World Health Organization (WHO); support for necessary market conditions to incentivize health sector investment from private sector; support for private sector involvement in health system strengthening
Medicare for All Act of 2021
Client: CHAMBER OF COMMERCE OF THE U.S.A. · Firm: CHAMBER OF COMMERCE OF THE U.S.A.
H.R. 3, Elijah E. Cummings Lower Drug Costs Now Act H.R. 1319, American Rescue Plan Act of 2021 H.R. 1976, Medicare for All Act of 2021 H.R. 2471, Consolidated Appropriations Act, 2022 H.R. 2873, Affordable Prescriptions for Patients Through Promoting Competition Act of 2021 H.R. 2884, Affordable Prescriptions for Patients Through Improvements to Patent Litigation Act H.R. 2891, Preserve Access to Affordable Generics and Biosimilars Act H.R. 3114, Longshore and Harbor Workers COVID-19 Compensation Act of 2021 H.R. 4502, Labor, Health and Human Services, Education, Agriculture, Rural Development, Energy and Water Development, Financial Services and General Government, Interior, Environment, Military Construction, Veterans Affairs, Transportation, and Housing and Urban Development Appropriations Act, 2022 H.R. 5981/S.1704, Telehealth Expansion Act of 2021 H.R. 8295, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2023 H.R. 8594/S. 4750, Restore Protections for Dialysis Patients Act S. 150, Ensuring Parity in Medicare Advantage for Audio-Only Telehealth Act S. 380, Health Savings Act of 2021 S. 1428, Preserve Access to Affordable Generics and Biosimilars Act S. 1435, Affordable Prescriptions for Patients Act of 2021 Implementation of the Transparency in Coverage Final Rule; Internal Revenue Service, Department of the Treasury; Employee Benefits Security Administration, Department of Labor; Centers for Medicare & Medicaid Services, Department of Health and Human Services (85 Fed. Reg. 72,158 - 72,310, November 12, 2020) Requirements Related to Surprise Billing; Internal Revenue Service; Employee Benefits Security Administration; Department of Health and Human Services (87 Fed. Reg. 52,618-52,655, August 26, 2022) Request for Information, Centers for Medicare & Medicaid Services; Medicare Program (87 Fed. Reg. 46,918-46,921, August 1, 2022) Notice of Proposed Rule, Employee Benefits Security Administration; Proposed Amendment to Prohibited Transaction Class Exemption 84-14 (the QPAM Exemption (87 Fed. Reg. 45,204-45,232, July 27, 2022) Affordability of Employer Coverage for Family Members of Employees (Family Glitch Regulation) (87 Fed. Reg. 20,354-20,364, April 7, 2022) Various issues relating to the employer-sponsored health care system, the "family glitch", implementation of regulatory process, provider network adequacy, health savings account (HSAs), health reimbursement account (HRAs), employer mandate; coronavirus pandemic; vaccine distribution, PPE, testing, medications and treatments, and vaccination incentives; digital health credentials; vaccine diplomacy; COVID-19 vaccine requirements, including a potential Emergency Temporary Standard from the Occupational Safety and Health Administration relating to employers with more than 100 employees; vaccine requirements for federal contractors; Executive Order 14042, Ensuring Adequate COVID Safety Protocols for Federal Contractors; implementation of the American Rescue Plan Act (P.L. 117-2); balance or surprise billing and related issues; single-payer health care options; health reimbursement arrangements and other account-based group health plans; Health and Human Services international pricing index (IPI) model; mental health parity; drug pricing; COBRA subsidies; Federal Trade Commissions multilateral pharmaceutical merger taskforce; telehealth, including coverage of telehealth under High Deductible Health Plans (HDHPs) and expanding telehealth options for employees; impact of Pharmacy Benefit Managers Practices; FTC-2022-0015; petition to HHS to grant march-in rights for the patents on the drug Xtandi; comments on COVID-19 Telehealth Program Application Evaluation Metrics (WC Docket No. 20-89); efforts to reform the World Health Organizations (WHO) engagement with private sector; continued U.S. membership to the World Health Organization (WHO); support for necessary market conditions to incentivize health sector investment from private sector; support for private sector involvement in health systems strengthening; greater harmonization of standards and investment in digital health internationally; role of private sector related pandemic prevention, preparedness and response
Medicare for All Act of 2021
Client: CHAMBER OF COMMERCE OF THE U.S.A. · Firm: CHAMBER OF COMMERCE OF THE U.S.A.
H.R. 3, Elijah E. Cummings Lower Drug Costs Now Act H.R. 1319, American Rescue Plan Act of 2021 H.R. 1976, Medicare for All Act of 2021 H.R. 2471, Consolidated Appropriations Act, 2022 H.R. 2873, Affordable Prescriptions for Patients Through Promoting Competition Act of 2021 H.R. 2884, Affordable Prescriptions for Patients Through Improvements to Patent Litigation Act H.R. 2891, Preserve Access to Affordable Generics and Biosimilars Act H.R. 3114, Longshore and Harbor Workers COVID-19 Compensation Act of 2021 H.R. 4502, Labor, Health and Human Services, Education, Agriculture, Rural Development, Energy and Water Development, Financial Services and General Government, Interior, Environment, Military Construction, Veterans Affairs, Transportation, and Housing and Urban Development Appropriations Act, 2022 S. 150, Ensuring Parity in Medicare Advantage for Audio-Only Telehealth Act S. 380, Health Savings Act of 2021 S. 1428, Preserve Access to Affordable Generics and Biosimilars Act S. 1435, Affordable Prescriptions for Patients Act of 2021 Implementation of the Transparency in Coverage Final Rule; Internal Revenue Service, Department of the Treasury; Employee Benefits Security Administration, Department of Labor; Centers for Medicare & Medicaid Services, Department of Health and Human Services (85 Fed. Reg. 72,158 - 72,310, November 12, 2020) Interim final rule, Most Favored Nation (MFN) Model (85 Fed. Reg. 76,180-76,259, November 27, 2020) Various issues relating to Patient Protection and Affordable Care Act (P.L. 111-148) and the Health Care and Education Affordability Reconciliation Act of 2010 (P.L. 111-152), including the employer-sponsored health care system, implementation of regulatory process, provider network adequacy, delivery system reform, health savings account (HSAs), health reimbursement account (HRAs), and flexible spending account (FSAs) changes, IPAB, employer mandate, reporting requirements for issuers and applicable large employers, premium stabilization programs, medical loss ratio, medical malpractice reform, exchanges, the impact on small business; coronavirus pandemic; vaccine distribution, PPE, testing, medications and treatments, and vaccination incentives; digital health credentials; vaccine diplomacy; COVID-19 vaccine requirements, including a potential Emergency Temporary Standard from the Occupational Safety and Health Administration relating to employers with more than 100 employees; vaccine requirements for federal contractors; Executive Order 14042, Ensuring Adequate COVID Safety Protocols for Federal Contractors; implementation of the American Rescue Plan Act (P.L. 117-2); balance or surprise billing and related issues; single-payer health care options; health reimbursement arrangements and other account-based group health plans; Health and Human Services international pricing index (IPI) model; mental health parity; drug pricing; COBRA subsidies; Federal Trade Commissions multilateral pharmaceutical merger taskforce; telehealth, including coverage of telehealth under High Deductible Health Plans (HDHPs) and expanding telehealth options for employees; petition to HHS to grant march-in rights for the patents on the drug Xtandi; comments on IRS Notice 2020-76; Transition Relief Related to Health Coverage Reporting Required by Sections 6055 and 6056 for 2020; comments on COVID-19 Telehealth Program Application Evaluation Metrics (WC Docket No. 20-89); efforts to reform the World Health Organizations (WHO) engagement with private sector; continued U.S. membership to the World Health Organization (WHO); support for necessary market conditions to incentivize health sector investment from private sector; support for private sector involvement in health system strengthening
Consolidated Appropriations Act, 2022
Client: CHAMBER OF COMMERCE OF THE U.S.A. · Firm: CHAMBER OF COMMERCE OF THE U.S.A.
H.R. 3, Elijah E. Cummings Lower Drug Costs Now Act H.R. 1319, American Rescue Plan Act of 2021 H.R. 1976, Medicare for All Act of 2021 H.R. 2471, Consolidated Appropriations Act, 2022 H.R. 2873, Affordable Prescriptions for Patients Through Promoting Competition Act of 2021 H.R. 2884, Affordable Prescriptions for Patients Through Improvements to Patent Litigation Act H.R. 2891, Preserve Access to Affordable Generics and Biosimilars Act H.R. 3114, Longshore and Harbor Workers COVID-19 Compensation Act of 2021 H.R. 4502, Labor, Health and Human Services, Education, Agriculture, Rural Development, Energy and Water Development, Financial Services and General Government, Interior, Environment, Military Construction, Veterans Affairs, Transportation, and Housing and Urban Development Appropriations Act, 2022 H.R. 5981/S.1704, Telehealth Expansion Act of 2021 H.R. 8295, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2023 H.R. 8594/S. 4750, Restore Protections for Dialysis Patients Act S. 150, Ensuring Parity in Medicare Advantage for Audio-Only Telehealth Act S. 380, Health Savings Act of 2021 S. 1428, Preserve Access to Affordable Generics and Biosimilars Act S. 1435, Affordable Prescriptions for Patients Act of 2021 Implementation of the Transparency in Coverage Final Rule; Internal Revenue Service, Department of the Treasury; Employee Benefits Security Administration, Department of Labor; Centers for Medicare & Medicaid Services, Department of Health and Human Services (85 Fed. Reg. 72,158 - 72,310, November 12, 2020) Requirements Related to Surprise Billing; Internal Revenue Service; Employee Benefits Security Administration; Department of Health and Human Services (87 Fed. Reg. 52,618-52,655, August 26, 2022) Request for Information, Centers for Medicare & Medicaid Services; Medicare Program (87 Fed. Reg. 46,918-46,921, August 1, 2022) Notice of Proposed Rule, Employee Benefits Security Administration; Proposed Amendment to Prohibited Transaction Class Exemption 84-14 (the QPAM Exemption (87 Fed. Reg. 45,204-45,232, July 27, 2022) Affordability of Employer Coverage for Family Members of Employees (Family Glitch Regulation) (87 Fed. Reg. 20,354-20,364, April 7, 2022) Various issues relating to the employer-sponsored health care system, the "family glitch", implementation of regulatory process, provider network adequacy, health savings account (HSAs), health reimbursement account (HRAs), employer mandate; coronavirus pandemic; vaccine distribution, PPE, testing, medications and treatments, and vaccination incentives; digital health credentials; vaccine diplomacy; COVID-19 vaccine requirements, including a potential Emergency Temporary Standard from the Occupational Safety and Health Administration relating to employers with more than 100 employees; vaccine requirements for federal contractors; Executive Order 14042, Ensuring Adequate COVID Safety Protocols for Federal Contractors; implementation of the American Rescue Plan Act (P.L. 117-2); balance or surprise billing and related issues; single-payer health care options; health reimbursement arrangements and other account-based group health plans; Health and Human Services international pricing index (IPI) model; mental health parity; drug pricing; COBRA subsidies; Federal Trade Commissions multilateral pharmaceutical merger taskforce; telehealth, including coverage of telehealth under High Deductible Health Plans (HDHPs) and expanding telehealth options for employees; impact of Pharmacy Benefit Managers Practices; FTC-2022-0015; petition to HHS to grant march-in rights for the patents on the drug Xtandi; comments on COVID-19 Telehealth Program Application Evaluation Metrics (WC Docket No. 20-89); efforts to reform the World Health Organizations (WHO) engagement with private sector; continued U.S. membership to the World Health Organization (WHO); support for necessary market conditions to incentivize health sector investment from private sector; support for private sector involvement in health systems strengthening; greater harmonization of standards and investment in digital health internationally; role of private sector related pandemic prevention, preparedness and response
Filing targets: Agriculture, Dept of (USDA), Army, Dept of (Corps of Engineers), Bureau of Citizenship & Immigration Services (BCIS), Bureau of Industry and Security (BIS), Bureau of Reclamation, Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), Consumer Financial Protection Bureau (CFPB), Council on Environmental Quality (CEQ), Defense, Dept of (DOD), Education, Dept of, Energy, Dept of, Environmental Protection Agency (EPA), Equal Employment Opportunity Commission (EEOC), Executive Office of the President (EOP), Federal Aviation Administration (FAA), Federal Communications Commission (FCC), Federal Deposit Insurance Corporation (FDIC), Federal Emergency Management Agency (FEMA), Federal Energy Regulatory Commission (FERC), Federal Highway Administration (FHA), Federal Maritime Commission, Federal Reserve System, Federal Trade Commission (FTC), Food & Drug Administration (FDA), General Services Administration (GSA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Homeland Security, Dept of (DHS), Interior, Dept of (DOI), Internal Revenue Service (IRS), Intl Trade Administration (ITA), Justice, Dept of (DOJ), Labor, Dept of (DOL), Natl Aeronautics & Space Administration (NASA), Natl Economic Council (NEC), Natl Highway Traffic Safety Administration (NHTSA), Natl Institute of Standards & Technology (NIST), Natl Labor Relations Board (NLRB), Natl Oceanic & Atmospheric Administration (NOAA), Natl Security Council (NSC), Natl Telecommunications & Information Administration (NTIA), Occupational Safety & Health Administration (OSHA), Office of Management & Budget (OMB), Office of Science & Technology Policy (OSTP), Office of the Comptroller of the Currency (OCC), Patent & Trademark Office (PTO), Pension Benefit Guaranty Corporation (PBGC), SENATE, Securities & Exchange Commission (SEC), Small Business Administration (SBA), State, Dept of (DOS), Transportation, Dept of (DOT), Treasury, Dept of, U.S. Copyright Office, U.S. Customs & Border Protection, U.S. Fish & Wildlife Service (USFWS), U.S. Trade & Development Agency (USTDA), U.S. Trade Representative (USTR), White House Office
CHAMBER OF COMMERCE OF THE U.S.A. via CHAMBER OF COMMERCE OF THE U.S.A.
2026 · second_quarter · Q2
H.R. 2528/S. 1847, Association Health Plans Act H.R. 5463, Choice Arrangement Act of 2025 H.R. 8324, Great American Healthcare Plan, including provisions related to expansion of Health Savings Accounts (HSAs) S. 2875, Custom Health Option and Individual Care Expense (CHOICE) Act Various issues relating to the employer-sponsored health care system, implementation of regulatory process, provider network adequacy, health savings account (HSAs), health reimbursement account (HRAs), association health plans (AHPs), cost sharing reduction payments (CSRs), individual health reimbursement arrangements (ICHRAs), employer mandates; implementation of the One Big Beautiful Bill Act, (P.L. 119-21); health reimbursement arrangements and other account-based group health plans; mental health parity; telehealth, including coverage of telehealth under High-Deductible Health Plans (HDHPs) and expanding telehealth options for employees; legislative proposals to tax employer-provided health care coverage; artificial price caps on providing insulin; Executive Order 14297, Delivering Most‑Favored‑Nation Prescription Drug Pricing to American Patients; ERISA preemption protections including information on constructive changes/modifications to ERISA; TRUMP AMERICA AI Act and AI proposals impacting health care; Food and Drug Administration (FDA) and Department of Health and Human Services (HHS) pending rulemaking to rescind the "adequate provision" standard for direct-to-consumer (DTC) prescription drug advertisements, RIN number: 0910-AJ14; efforts to reform the World Health Organizations (WHO) engagement with private sector; continued U.S. membership to the World Health Organization (WHO); support for necessary market conditions to incentivize health sector investment, grow markets, sustain business operations, and improve access to health commodities globally; promote greater harmonization of standards and investment in digital health; health-related policy issues in the G20/G7 forums and other multilateral forums; support for continued and reformed U.S. foreign assistance, including in global health
Filing targets: Agriculture, Dept of (USDA), Army, Dept of (Corps of Engineers), Bureau of Citizenship & Immigration Services (BCIS), Bureau of Industry and Security (BIS), Bureau of Reclamation, Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), Commodity Futures Trading Commission (CFTC), Consumer Financial Protection Bureau (CFPB), Council on Environmental Quality (CEQ), Defense, Dept of (DOD), Education, Dept of, Energy, Dept of, Environmental Protection Agency (EPA), Equal Employment Opportunity Commission (EEOC), Executive Office of the President (EOP), Federal Aviation Administration (FAA), Federal Communications Commission (FCC), Federal Deposit Insurance Corporation (FDIC), Federal Emergency Management Agency (FEMA), Federal Energy Regulatory Commission (FERC), Federal Highway Administration (FHA), Federal Maritime Commission, Federal Reserve System, Federal Trade Commission (FTC), Food & Drug Administration (FDA), General Services Administration (GSA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Homeland Security, Dept of (DHS), Interior, Dept of (DOI), Internal Revenue Service (IRS), Justice, Dept of (DOJ), Labor, Dept of (DOL), Natl Aeronautics & Space Administration (NASA), Natl Economic Council (NEC), Natl Highway Traffic Safety Administration (NHTSA), Natl Institute of Standards & Technology (NIST), Natl Labor Relations Board (NLRB), Natl Oceanic & Atmospheric Administration (NOAA), Natl Science Foundation (NSF), Natl Security Council (NSC), Natl Telecommunications & Information Administration (NTIA), Occupational Safety & Health Administration (OSHA), Office of Management & Budget (OMB), Office of Science & Technology Policy (OSTP), Office of the Comptroller of the Currency (OCC), Patent & Trademark Office (PTO), Pension Benefit Guaranty Corporation (PBGC), SENATE, Securities & Exchange Commission (SEC), Small Business Administration (SBA), State, Dept of (DOS), Transportation, Dept of (DOT), Treasury, Dept of, U.S. Copyright Office, U.S. Customs & Border Protection, U.S. Fish & Wildlife Service (USFWS), U.S. Trade & Development Agency (USTDA), U.S. Trade Representative (USTR), White House Office
CHAMBER OF COMMERCE OF THE U.S.A. via CHAMBER OF COMMERCE OF THE U.S.A.
2026 · first_quarter · 1A
H.R. 1650/S. 763, Telehealth Expansion Act of 2025 H.R. 2528/S. 1847, Association Health Plans Act H.R. 6703, Lower Health Care Premiums for All Americans Act, including PBM transparency provisions Various issues relating to the employer-sponsored health care system, implementation of regulatory process, provider network adequacy, health savings account (HSAs), health reimbursement account (HRAs), association health plans (AHPs), cost sharing reduction payments (CSRs), individual health reimbursement arrangements (ICHRAs), employer mandates; implementation of the One Big Beautiful Bill Act, (P.L. 119-21); health reimbursement arrangements and other account-based group health plans; mental health parity; Federal Trade Commissions multilateral pharmaceutical merger taskforce; telehealth, including coverage of telehealth under High-Deductible Health Plans (HDHPs) and expanding telehealth options for employees; impact of Pharmacy Benefit Managers Practices; FTC-2022-0015; petition to HHS to grant march-in rights for the patents on the drug Xtandi; legislative proposals to tax employer-provided health care coverage; artificial price caps on providing insulin; Executive Order 14297, Delivering Most‑Favored‑Nation Prescription Drug Pricing to American Patients; ERISA preemption protections including information on constructive changes/modifications to ERISA; TRUMP AMERICA AI Act and AI proposals impacting health care; efforts to reform the World Health Organizations (WHO) engagement with private sector; continued U.S. membership to the WHO; support for necessary market conditions to incentivize health sector investment, grow markets, sustain business operations, and improve access to health commodities globally; promote greater harmonization of standards and investment in digital health; health-related policy issues in the G20/G7 forums and other multilateral forums; support for continued and reformed U.S. foreign assistance, including in global health
Filing targets: Agriculture, Dept of (USDA), Army, Dept of (Corps of Engineers), Bureau of Citizenship & Immigration Services (BCIS), Bureau of Industry and Security (BIS), Bureau of Reclamation, Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), Commodity Futures Trading Commission (CFTC), Consumer Financial Protection Bureau (CFPB), Council on Environmental Quality (CEQ), Defense, Dept of (DOD), Education, Dept of, Energy, Dept of, Environmental Protection Agency (EPA), Equal Employment Opportunity Commission (EEOC), Executive Office of the President (EOP), Federal Aviation Administration (FAA), Federal Communications Commission (FCC), Federal Deposit Insurance Corporation (FDIC), Federal Emergency Management Agency (FEMA), Federal Energy Regulatory Commission (FERC), Federal Highway Administration (FHA), Federal Maritime Commission, Federal Reserve System, Federal Trade Commission (FTC), General Services Administration (GSA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Homeland Security, Dept of (DHS), Housing & Urban Development, Dept of (HUD), Interior, Dept of (DOI), Internal Revenue Service (IRS), Intl Trade Administration (ITA), Justice, Dept of (DOJ), Labor, Dept of (DOL), Natl Aeronautics & Space Administration (NASA), Natl Economic Council (NEC), Natl Highway Traffic Safety Administration (NHTSA), Natl Institute of Standards & Technology (NIST), Natl Labor Relations Board (NLRB), Natl Oceanic & Atmospheric Administration (NOAA), Natl Science Foundation (NSF), Natl Security Council (NSC), Natl Telecommunications & Information Administration (NTIA), Occupational Safety & Health Administration (OSHA), Office of Management & Budget (OMB), Office of Science & Technology Policy (OSTP), Office of the Comptroller of the Currency (OCC), Patent & Trademark Office (PTO), Pension Benefit Guaranty Corporation (PBGC), SENATE, Securities & Exchange Commission (SEC), Small Business Administration (SBA), State, Dept of (DOS), Transportation, Dept of (DOT), Treasury, Dept of, U.S. Copyright Office, U.S. Customs & Border Protection, U.S. Fish & Wildlife Service (USFWS), U.S. Trade & Development Agency (USTDA), U.S. Trade Representative (USTR), White House Office
CHAMBER OF COMMERCE OF THE U.S.A. via CHAMBER OF COMMERCE OF THE U.S.A.
2026 · first_quarter · Q1
H.R. 1650/S. 763, Telehealth Expansion Act of 2025 H.R. 2528/S. 1847, Association Health Plans Act H.R. 6703, Lower Health Care Premiums for All Americans Act, including PBM transparency provisions Various issues relating to the employer-sponsored health care system, implementation of regulatory process, provider network adequacy, health savings account (HSAs), health reimbursement account (HRAs), association health plans (AHPs), cost sharing reduction payments (CSRs), individual health reimbursement arrangements (ICHRAs), employer mandates; implementation of the One Big Beautiful Bill Act, (P.L. 119-21); health reimbursement arrangements and other account-based group health plans; mental health parity; Federal Trade Commissions multilateral pharmaceutical merger taskforce; telehealth, including coverage of telehealth under High-Deductible Health Plans (HDHPs) and expanding telehealth options for employees; impact of Pharmacy Benefit Managers Practices; FTC-2022-0015; petition to HHS to grant march-in rights for the patents on the drug Xtandi; legislative proposals to tax employer-provided health care coverage; artificial price caps on providing insulin; Executive Order 14297, Delivering Most‑Favored‑Nation Prescription Drug Pricing to American Patients; ERISA preemption protections including information on constructive changes/modifications to ERISA; TRUMP AMERICA AI Act and AI proposals impacting health care; efforts to reform the World Health Organizations (WHO) engagement with private sector; continued U.S. membership to the WHO; support for necessary market conditions to incentivize health sector investment, grow markets, sustain business operations, and improve access to health commodities globally; promote greater harmonization of standards and investment in digital health; health-related policy issues in the G20/G7 forums and other multilateral forums; support for continued and reformed U.S. foreign assistance, including in global health
Filing targets: Agriculture, Dept of (USDA), Army, Dept of (Corps of Engineers), Bureau of Citizenship & Immigration Services (BCIS), Bureau of Industry and Security (BIS), Bureau of Reclamation, Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), Commodity Futures Trading Commission (CFTC), Consumer Financial Protection Bureau (CFPB), Council on Environmental Quality (CEQ), Defense, Dept of (DOD), Education, Dept of, Energy, Dept of, Environmental Protection Agency (EPA), Equal Employment Opportunity Commission (EEOC), Executive Office of the President (EOP), Federal Aviation Administration (FAA), Federal Communications Commission (FCC), Federal Deposit Insurance Corporation (FDIC), Federal Emergency Management Agency (FEMA), Federal Energy Regulatory Commission (FERC), Federal Highway Administration (FHA), Federal Maritime Commission, Federal Reserve System, Federal Trade Commission (FTC), General Services Administration (GSA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Homeland Security, Dept of (DHS), Housing & Urban Development, Dept of (HUD), Interior, Dept of (DOI), Internal Revenue Service (IRS), Intl Trade Administration (ITA), Justice, Dept of (DOJ), Labor, Dept of (DOL), Natl Aeronautics & Space Administration (NASA), Natl Economic Council (NEC), Natl Highway Traffic Safety Administration (NHTSA), Natl Institute of Standards & Technology (NIST), Natl Labor Relations Board (NLRB), Natl Oceanic & Atmospheric Administration (NOAA), Natl Science Foundation (NSF), Natl Security Council (NSC), Natl Telecommunications & Information Administration (NTIA), Occupational Safety & Health Administration (OSHA), Office of Management & Budget (OMB), Office of Science & Technology Policy (OSTP), Office of the Comptroller of the Currency (OCC), Patent & Trademark Office (PTO), Pension Benefit Guaranty Corporation (PBGC), SENATE, Securities & Exchange Commission (SEC), Small Business Administration (SBA), State, Dept of (DOS), Transportation, Dept of (DOT), Treasury, Dept of, U.S. Copyright Office, U.S. Customs & Border Protection, U.S. Fish & Wildlife Service (USFWS), U.S. Trade & Development Agency (USTDA), U.S. Trade Representative (USTR), White House Office
CHAMBER OF COMMERCE OF THE U.S.A. via CHAMBER OF COMMERCE OF THE U.S.A.
2025 · fourth_quarter · Q4
H.R. 661, MIRACLE Medical Technology Act of 2025 H.R. 1650/S. 763, Telehealth Expansion Act of 2025 H.R. 2213/S. 998, Medical Supply Chain Resiliency Act H.R. 2270, Empowering Employer Child and Elder Care Solutions Act H.R. 2528/S. 1847, Association Health Plans Act H.R. 6703, Lower Health Care Premiums for All Americans Act, including provisions excluding PBM transparency reform S. 2828, Child Care Modernization Act of 2025 Various issues relating to the employer-sponsored health care system, implementation of regulatory process, provider network adequacy, health savings account (HSAs), health reimbursement account (HRAs), association health plans (AHPs), cost sharing reduction payments (CSRs), individual health reimbursement arrangements (ICHRAs), employer mandates; implementation of the Inflation Reduction Act (P.L. 117-169); implementation of the One Big Beautiful Bill Act, (P.L. 119-21); balance or surprise billing and related issues; single-payer health care options; Affordable Care Act tax credits; health reimbursement arrangements and other account-based group health plans; Health and Human Services international pricing index (IPI) model; mental health parity; COBRA subsidies; Federal Trade Commissions multilateral pharmaceutical merger taskforce; telehealth, including coverage of telehealth under High-Deductible Health Plans (HDHPs) and expanding telehealth options for employees; impact of Pharmacy Benefit Managers Practices; FTC-2022-0015; petition to HHS to grant march-in rights for the patents on the drug Xtandi; legislative proposals to tax employer-provided health care coverage; artificial price caps on providing insulin; Reasonable Price Clause in reauthorization draft of the Pandemic and All Hazards Preparedness Act (PAHPA, P.L. 109-417); ERISA preemption protections including information on constructive changes/modifications to ERISA; expansion of the list of preventive care benefits that may be provided by a high-deductible health plan (HDHP); efforts to reform the World Health Organizations (WHO) engagement with private sector; continued U.S. membership to the World Health Organization (WHO); support for necessary market conditions to incentivize health sector investment from private sector; support for private sector involvement in health systems strengthening; promote greater harmonization of standards and investment in digital health; health-related policy issues in the G20/G7 forums and other multilateral forums; support for improving access to health products and technologies globally, including via regulatory alignment, addressing trade barriers, strengthening the global supply chain, pooled procurement mechanisms, and raising awareness on potential pitfalls of local manufacturing; combatting anti-microbial resistance infectious diseases, and non-communicable diseases; support for continued and reformed U.S. foreign assistance, including in global health
Filing targets: Agriculture, Dept of (USDA), Army, Dept of (Corps of Engineers), Bureau of Citizenship & Immigration Services (BCIS), Bureau of Industry and Security (BIS), Bureau of Reclamation, Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), Commodity Futures Trading Commission (CFTC), Consumer Financial Protection Bureau (CFPB), Council on Environmental Quality (CEQ), Defense, Dept of (DOD), Director of National Intelligence (ODNI), Education, Dept of, Energy, Dept of, Environmental Protection Agency (EPA), Equal Employment Opportunity Commission (EEOC), Executive Office of the President (EOP), Federal Aviation Administration (FAA), Federal Communications Commission (FCC), Federal Deposit Insurance Corporation (FDIC), Federal Emergency Management Agency (FEMA), Federal Energy Regulatory Commission (FERC), Federal Highway Administration (FHA), Federal Maritime Commission, Federal Reserve System, Federal Trade Commission (FTC), General Services Administration (GSA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Homeland Security, Dept of (DHS), Interior, Dept of (DOI), Internal Revenue Service (IRS), Justice, Dept of (DOJ), Labor, Dept of (DOL), Natl Aeronautics & Space Administration (NASA), Natl Economic Council (NEC), Natl Highway Traffic Safety Administration (NHTSA), Natl Institute of Standards & Technology (NIST), Natl Labor Relations Board (NLRB), Natl Oceanic & Atmospheric Administration (NOAA), Natl Science Foundation (NSF), Natl Security Council (NSC), Natl Telecommunications & Information Administration (NTIA), Occupational Safety & Health Administration (OSHA), Office of Management & Budget (OMB), Office of Science & Technology Policy (OSTP), Office of the Comptroller of the Currency (OCC), Patent & Trademark Office (PTO), Pension Benefit Guaranty Corporation (PBGC), SENATE, Securities & Exchange Commission (SEC), Small Business Administration (SBA), State, Dept of (DOS), Transportation, Dept of (DOT), Treasury, Dept of, U.S. Coast Guard (USCG), U.S. Copyright Office, U.S. Customs & Border Protection, U.S. Fish & Wildlife Service (USFWS), U.S. Trade & Development Agency (USTDA), U.S. Trade Representative (USTR), White House Office
CHAMBER OF COMMERCE OF THE U.S.A. via CHAMBER OF COMMERCE OF THE U.S.A.
2025 · third_quarter · Q3
H.R. 1, One Big Beautiful Bill Act H.R. 661, MIRACLE Medical Technology Act of 2025 H.R. 919, Chronic Disease Flexible Coverage Act H.R. 1650/S. 763, Telehealth Expansion Act of 2025 H.R. 2028/S. 1847, the Association Health Plans Act H.R. 2213/S. 998, Medical Supply Chain Resiliency Act H.R. 2270, Empowering Employer Child and Elder Care Solutions Act H.R. 2528/S. 1847, Association Health Plans Act H.R. 2571, Self-Insurance Protection Act S. 763, Telehealth Expansion Act of 2025 S. 1096, Preserve Access to Affordable Generics and Biosimilars Act Final Rule, Mental Health Parity and Addiction Equity Act (89 Fed. Reg. 77,586-77,751, September 23, 2024) Request for Information, Ultra Processed Foods (90 Fed. Reg. 35,305-35,309, July 25, 2025) Request for Information, NIH Artificial Intelligence Strategy (Response to NIH RFI NOT-OD-25-117), July 15, 2025 Request for Information, Ensuring Lawful Regulation and Unleashing Innovation to Make America Healthy Again (90 Fed. Reg. 20,478-20,481, July 14, 2025) Various issues relating to the employer-sponsored health care system, implementation of regulatory process, provider network adequacy, health savings account (HSAs), health reimbursement account (HRAs), employer mandate; implementation of the Inflation Reduction Act (P.L. 117-169); implementation of the One Big Beautiful Bill Act, (P.L. 119-21); balance or surprise billing and related issues; single-payer health care options; Affordable Care Act tax credit expiration; health reimbursement arrangements and other account-based group health plans; Health and Human Services international pricing index (IPI) model; mental health parity; COBRA subsidies; Federal Trade Commissions multilateral pharmaceutical merger taskforce; telehealth, including coverage of telehealth under High-Deductible Health Plans (HDHPs) and expanding telehealth options for employees; impact of Pharmacy Benefit Managers Practices; FTC-2022-0015; petition to HHS to grant march-in rights for the patents on the drug Xtandi; legislative proposals to tax employer-provided health care coverage; artificial price caps on providing insulin; Reasonable Price Clause in reauthorization draft of the Pandemic and All Hazards Preparedness Act (PAHPA, P.L. 109-417); ERISA preemption protections including information on constructive changes/modifications to ERISA; expansion of the list of preventive care benefits that may be provided by a high-deductible health plan (HDHP); efforts to reform the World Health Organizations (WHO) engagement with private sector; continued U.S. membership to the World Health Organization (WHO); support for necessary market conditions to incentivize health sector investment from private sector; support for private sector involvement in health systems strengthening; promote greater harmonization of standards and investment in digital health; health-related policy issues in the G20/G7 forums and other multilateral forums; support for improving access to health products and technologies globally, including via regulatory alignment, addressing trade barriers, strengthening the global supply chain, and raising awareness on potential pitfalls of local manufacturing; combatting anti-microbial resistance infectious diseases, and non-communicable diseases; support for continued and reformed U.S. foreign assistance, including in global health
CHAMBER OF COMMERCE OF THE U.S.A. via CHAMBER OF COMMERCE OF THE U.S.A.
2025 · second_quarter · Q2
H.R. 1, One Big Beautiful Bill Act H.R. 661, MIRACLE Medical Technology Act of 2025 H.R. 919, Chronic Disease Flexible Coverage Act H.R. 1650/S. 763, Telehealth Expansion Act of 2025 H.R. 2213/S. 998, Medical Supply Chain Resiliency Act H.R. 2270, Empowering Employer Child and Elder Care Solutions Act H.R. 2528, Association Health Plans Act H.R. 2571, Self-Insurance Protection Act S. 1096, Preserve Access to Affordable Generics and Biosimilars Act S. 763, Telehealth Expansion Act of 2025 Potential legislation similar to H.R. 9029, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2025 Final Rule, Mental Health Parity and Addiction Equity Act (89 Fed. Reg. 77,586-77,751, September 23, 2024) Advance Notice of Methodological Changes for Calendar Year (CY) 2025 for Medicare Advantage (MA) Capitation Rates and Part C and Part D Payment Policies, U.S. Centers for Medicare & Medicaid Services, U.S. Department of Health and Human Services (2025 Advance Notice, January 31, 2024); Various issues relating to the employer-sponsored health care system, implementation of regulatory process, provider network adequacy, health savings account (HSAs), health reimbursement account (HRAs), employer mandate; implementation of the American Rescue Plan Act (P.L. 117-2); implementation of the Inflation Reduction Act (P.L. 117-169); balance or surprise billing and related issues; single-payer health care options; health reimbursement arrangements and other account-based group health plans; Health and Human Services international pricing index (IPI) model; mental health parity; drug pricing; COBRA subsidies; Federal Trade Commissions multilateral pharmaceutical merger taskforce; telehealth, including coverage of telehealth under High-Deductible Health Plans (HDHPs) and expanding telehealth options for employees; impact of Pharmacy Benefit Managers Practices; FTC-2022-0015; petition to HHS to grant march-in rights for the patents on the drug Xtandi; legislative proposals to tax employer-provided health care coverage; artificial price caps on providing insulin; Reasonable Price Clause in reauthorization draft of the Pandemic and All Hazards Preparedness Act (PAHPA, P.L. 109-417); ERISA preemption protections including information on constructive changes/modifications to ERISA; expansion of the list of preventive care benefits that may be provided by a high-deductible health plan (HDHP); efforts to reform the World Health Organizations (WHO) engagement with private sector; continued U.S. membership to the World Health Organization (WHO); support for necessary market conditions to incentivize health sector investment from private sector; support for private sector involvement in health systems strengthening; promote greater harmonization of standards and investment in digital health; health-related policy issues in the G20/G7 forums and other multilateral forums; support for improving access to health products and technologies globally, including via regulatory alignment, addressing trade barriers, strengthening the global supply chain, and raising awareness on potential pitfalls of local manufacturing; combatting anti-microbial resistance; support for continued and reformed U.S. foreign assistance, including in global health
CHAMBER OF COMMERCE OF THE U.S.A. via CHAMBER OF COMMERCE OF THE U.S.A.
2025 · first_quarter · Q1
H.R. 661, MIRACLE Medical Technology Act of 2025 H.R. 1650/S. 763, Telehealth Expansion Act of 2025 Potential legislation similar to H.R. 1843/S. 1001, Telehealth Expansion Act of 2023 Potential legislation similar to H.R. 2868, Association Health Plans Act Potential legislation similar to H.R. 3800, Chronic Disease Flexible Coverage Act Potential legislation similar to H.R. 4307/S. 2115, Medical Supply Chain Resiliency Act Potential legislation similar to H.R. 6363, Further Continuing Appropriations and Other Extensions Act of 2024, and issues pertaining to H.R. 1843/S. 1001, The Telehealth Expansion Act of 2023 Potential legislation similar to H.R. 6860, Restore Protections for Dialysis Patients Act Potential legislation similar to H.R. 9029, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2025 Potential legislation similar to S. 142, Preserve Access to Affordable Generics and Biosimilars Act Potential legislation similar to S. 150, Affordable Prescriptions for Patients Act of 2023 Potential legislation similar to S. 1067, Ensuring Timely Access to Generics Act of 2023 Potential legislation similar to S. 1114, Expanding Access to Low-Cost Generics Act of 2023 Potential legislation similar to S. 2624, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2024 Potential legislation similar to S. 2780, The Medication Affordability and Patent Integrity Act Final Rule, Mental Health Parity and Addiction Equity Act (89 Fed. Reg. 77,586-77,751, September 23, 2024) Various issues relating to the employer-sponsored health care system, implementation of regulatory process, provider network adequacy, health savings account (HSAs), health reimbursement account (HRAs), employer mandate; implementation of the American Rescue Plan Act (P.L. 117-2); implementation of the Inflation Reduction Act (P.L. 117-169); balance or surprise billing and related issues; single-payer health care options; health reimbursement arrangements and other account-based group health plans; Health and Human Services international pricing index (IPI) model; mental health parity; drug pricing; COBRA subsidies; Federal Trade Commissions multilateral pharmaceutical merger taskforce; telehealth, including coverage of telehealth under High Deductible Health Plans (HDHPs) and expanding telehealth options for employees; impact of Pharmacy Benefit Managers Practices; FTC-2022-0015; petition to HHS to grant march-in rights for the patents on the drug Xtandi; legislative proposals to tax employer-provided health care coverage; artificial price caps on providing insulin; Reasonable Price Clause in reauthorization draft of the Pandemic and All Hazards Preparedness Act (PAHPA, P.L. 109-417); ERISA preemption protections including information on constructive changes/modifications to ERISA; efforts to reform the World Health Organizations (WHO) engagement with private sector; continued U.S. membership to the World Health Organization (WHO); support for necessary market conditions to incentivize health sector investment from private sector; support for private sector involvement in health systems strengthening; promote greater harmonization of standards and investment in digital health; health-related policy issues in the G20/G7 forums and other multilateral forums; support for improving access to health products and technologies globally, including via regulatory alignment, addressing trade barriers, strengthening the global supply chain, and raising awareness on potential pitfalls of local manufacturing; combatting anti-microbial resistance; support for continued and reformed U.S. foreign assistance, including in global health; Advance Notice of Methodological Changes for Calendar Year (CY) 2025 for Medicare Advantage (MA) Capitation Rates and Part C and Part D Payment Policies, U.S. Centers for Medicare & Medicaid Services, U.S. Department of Health and Human Services (2025 Advance Notice, January 31, 2024)
CHAMBER OF COMMERCE OF THE U.S.A. via CHAMBER OF COMMERCE OF THE U.S.A.
2023 · second_quarter · Q2
H.R. 1264, Commonsense Reporting Act of 2023 H.R. 2813, Self-Insurance Protection Act H.R. 2868, Association Health Plans Act S. 127, Pharmacy Benefit Manager Transparency Act of 2023 S. 142, Preserve Access to Affordable Generics and Biosimilars Act S. 148, Stop Significant and Time-wasting Abuse Limiting Legitimate Innovation of New Generics (Stop STALLING) Act S. 150, Affordable Prescriptions for Patients Act of 2023 S. 1067, Ensuring Timely Access to Generics Act of 2023 S. 1114, Expanding Access to Low-Cost Generics Act of 2023 S. 1214, Retaining Access and Restoring Exclusivity (RARE) Act S. 1339, Pharmacy Benefit Manager Reform Act Various issues relating to the employer-sponsored health care system, implementation of regulatory process, provider network adequacy, health savings account (HSAs), health reimbursement account (HRAs), employer mandate; Medicare Drug Price Negotiation Program: Initial Memorandum, Implementation of Sections 1191 - 1198 of the Social Security Act for Initial Price Applicability Year 2026, and Solicitation of Comments; implementation of the American Rescue Plan Act (P.L. 117-2); implementation of the Inflation Reduction Act (P.L. 117-169); balance or surprise billing and related issues; single-payer health care options; health reimbursement arrangements and other account-based group health plans; Health and Human Services international pricing index (IPI) model; mental health parity; drug pricing; COBRA subsidies; Federal Trade Commissions multilateral pharmaceutical merger taskforce; telehealth, including coverage of telehealth under High Deductible Health Plans (HDHPs) and expanding telehealth options for employees; impact of Pharmacy Benefit Managers Practices; FTC-2022-0015; petition to HHS to grant march-in rights for the patents on the drug Xtandi; ERISA preemption protections; artificial price caps on providing insulin; efforts to reform the World Health Organizations (WHO) engagement with private sector; continued U.S. membership to the World Health Organization (WHO); support for necessary market conditions to incentivize health sector investment from private sector; support for private sector involvement in health systems strengthening; greater harmonization of standards and investment in digital health internationally; role of private sector related pandemic prevention, preparedness and response; oversight issues related to the U.S. Food and Drug Administration
CHAMBER OF COMMERCE OF THE U.S.A. via CHAMBER OF COMMERCE OF THE U.S.A.
2023 · first_quarter · 1A
S. 127, Pharmacy Benefit Manager Transparency Act of 2023 S. 142, Preserve Access to Affordable Generics and Biosimilars Act S. 148, Stop Significant and Time-wasting Abuse Limiting Legitimate Innovation of New Generics (Stop STALLING) Act S. 150, Affordable Prescriptions for Patients Act of 2023 Various issues relating to the employer-sponsored health care system, the "family glitch", implementation of regulatory process, provider network adequacy, health savings account (HSAs), health reimbursement account (HRAs), employer mandate; coronavirus pandemic; vaccine distribution, PPE, testing, medications and treatments, and vaccination incentives; digital health credentials; vaccine diplomacy; COVID-19 vaccine requirements, including a potential Emergency Temporary Standard from the Occupational Safety and Health Administration relating to employers with more than 100 employees; vaccine requirements for federal contractors; Executive Order 14042, Ensuring Adequate COVID Safety Protocols for Federal Contractors; implementation of the American Rescue Plan Act (P.L. 117-2); balance or surprise billing and related issues; single-payer health care options; health reimbursement arrangements and other account-based group health plans; Health and Human Services international pricing index (IPI) model; mental health parity; drug pricing; COBRA subsidies; Federal Trade Commissions multilateral pharmaceutical merger taskforce; telehealth, including coverage of telehealth under High Deductible Health Plans (HDHPs) and expanding telehealth options for employees; impact of Pharmacy Benefit Managers Practices; FTC-2022-0015; petition to HHS to grant march-in rights for the patents on the drug Xtandi; Centers for Medicare & Medicaid Services; Advance Notice of Methodological Changes for Calendar Year (CY) 2024 for Medicare Advantage (MA) Capitation Rates and Part C and Part D Payment Policies (February 1, 2023); comments on COVID-19 Telehealth Program Application Evaluation Metrics (WC Docket No. 20-89); efforts to reform the World Health Organizations (WHO) engagement with private sector; continued U.S. membership to the World Health Organization (WHO); support for necessary market conditions to incentivize health sector investment from private sector; support for private sector involvement in health systems strengthening; greater harmonization of standards and investment in digital health internationally; role of private sector related pandemic prevention, preparedness and response; request for input, United States Senate Committee on Health, Education, Labor, and Pensions; U.S. Healthcare Workforce Shortage RFI (March 2, 2023)
CHAMBER OF COMMERCE OF THE U.S.A. via CHAMBER OF COMMERCE OF THE U.S.A.
2023 · first_quarter · Q1
S. 127, Pharmacy Benefit Manager Transparency Act of 2023 S. 142, Preserve Access to Affordable Generics and Biosimilars Act S. 148, Stop Significant and Time-wasting Abuse Limiting Legitimate Innovation of New Generics (Stop STALLING) Act S. 150, Affordable Prescriptions for Patients Act of 2023 Various issues relating to the employer-sponsored health care system, the "family glitch", implementation of regulatory process, provider network adequacy, health savings account (HSAs), health reimbursement account (HRAs), employer mandate; coronavirus pandemic; vaccine distribution, PPE, testing, medications and treatments, and vaccination incentives; digital health credentials; vaccine diplomacy; COVID-19 vaccine requirements, including a potential Emergency Temporary Standard from the Occupational Safety and Health Administration relating to employers with more than 100 employees; vaccine requirements for federal contractors; Executive Order 14042, Ensuring Adequate COVID Safety Protocols for Federal Contractors; implementation of the American Rescue Plan Act (P.L. 117-2); balance or surprise billing and related issues; single-payer health care options; health reimbursement arrangements and other account-based group health plans; Health and Human Services international pricing index (IPI) model; mental health parity; drug pricing; COBRA subsidies; Federal Trade Commissions multilateral pharmaceutical merger taskforce; telehealth, including coverage of telehealth under High Deductible Health Plans (HDHPs) and expanding telehealth options for employees; impact of Pharmacy Benefit Managers Practices; FTC-2022-0015; petition to HHS to grant march-in rights for the patents on the drug Xtandi; Centers for Medicare & Medicaid Services; Advance Notice of Methodological Changes for Calendar Year (CY) 2024 for Medicare Advantage (MA) Capitation Rates and Part C and Part D Payment Policies (February 1, 2023); comments on COVID-19 Telehealth Program Application Evaluation Metrics (WC Docket No. 20-89); efforts to reform the World Health Organizations (WHO) engagement with private sector; continued U.S. membership to the World Health Organization (WHO); support for necessary market conditions to incentivize health sector investment from private sector; support for private sector involvement in health systems strengthening; greater harmonization of standards and investment in digital health internationally; role of private sector related pandemic prevention, preparedness and response; request for input, United States Senate Committee on Health, Education, Labor, and Pensions; U.S. Healthcare Workforce Shortage RFI (March 2, 2023)
CHAMBER OF COMMERCE OF THE U.S.A. via CHAMBER OF COMMERCE OF THE U.S.A.
2022 · fourth_quarter · Q4
H.R. 3, Elijah E. Cummings Lower Drug Costs Now Act H.R. 1319, American Rescue Plan Act of 2021 H.R. 1976, Medicare for All Act of 2021 H.R. 2471, Consolidated Appropriations Act, 2022 H.R. 2873, Affordable Prescriptions for Patients Through Promoting Competition Act of 2021 H.R. 2884, Affordable Prescriptions for Patients Through Improvements to Patent Litigation Act H.R. 2891, Preserve Access to Affordable Generics and Biosimilars Act H.R. 3114, Longshore and Harbor Workers COVID-19 Compensation Act of 2021 H.R. 4502, Labor, Health and Human Services, Education, Agriculture, Rural Development, Energy and Water Development, Financial Services and General Government, Interior, Environment, Military Construction, Veterans Affairs, Transportation, and Housing and Urban Development Appropriations Act, 2022 H.R. 5981/S.1704, Telehealth Expansion Act of 2021 H.R. 8295, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2023 H.R. 8594/S. 4750, Restore Protections for Dialysis Patients Act S. 150, Ensuring Parity in Medicare Advantage for Audio-Only Telehealth Act S. 380, Health Savings Act of 2021 S. 1428, Preserve Access to Affordable Generics and Biosimilars Act S. 1435, Affordable Prescriptions for Patients Act of 2021 Implementation of the Transparency in Coverage Final Rule; Internal Revenue Service, Department of the Treasury; Employee Benefits Security Administration, Department of Labor; Centers for Medicare & Medicaid Services, Department of Health and Human Services (85 Fed. Reg. 72,158 - 72,310, November 12, 2020) Requirements Related to Surprise Billing; Internal Revenue Service; Employee Benefits Security Administration; Department of Health and Human Services (87 Fed. Reg. 52,618-52,655, August 26, 2022) Request for Information, Centers for Medicare & Medicaid Services; Medicare Program (87 Fed. Reg. 46,918-46,921, August 1, 2022) Notice of Proposed Rule, Employee Benefits Security Administration; Proposed Amendment to Prohibited Transaction Class Exemption 84-14 (the QPAM Exemption (87 Fed. Reg. 45,204-45,232, July 27, 2022) Affordability of Employer Coverage for Family Members of Employees (Family Glitch Regulation) (87 Fed. Reg. 20,354-20,364, April 7, 2022) Various issues relating to the employer-sponsored health care system, the "family glitch", implementation of regulatory process, provider network adequacy, health savings account (HSAs), health reimbursement account (HRAs), employer mandate; coronavirus pandemic; vaccine distribution, PPE, testing, medications and treatments, and vaccination incentives; digital health credentials; vaccine diplomacy; COVID-19 vaccine requirements, including a potential Emergency Temporary Standard from the Occupational Safety and Health Administration relating to employers with more than 100 employees; vaccine requirements for federal contractors; Executive Order 14042, Ensuring Adequate COVID Safety Protocols for Federal Contractors; implementation of the American Rescue Plan Act (P.L. 117-2); balance or surprise billing and related issues; single-payer health care options; health reimbursement arrangements and other account-based group health plans; Health and Human Services international pricing index (IPI) model; mental health parity; drug pricing; COBRA subsidies; Federal Trade Commissions multilateral pharmaceutical merger taskforce; telehealth, including coverage of telehealth under High Deductible Health Plans (HDHPs) and expanding telehealth options for employees; impact of Pharmacy Benefit Managers Practices; FTC-2022-0015; petition to HHS to grant march-in rights for the patents on the drug Xtandi; comments on COVID-19 Telehealth Program Application Evaluation Metrics (WC Docket No. 20-89); efforts to reform the World Health Organizations (WHO) engagement with private sector; continued U.S. membership to the World Health Organization (WHO); support for necessary market conditions to incentivize health sector investment from private sector; support for private sector involvement in health systems strengthening; greater harmonization of standards and investment in digital health internationally; role of private sector related pandemic prevention, preparedness and response
CHAMBER OF COMMERCE OF THE U.S.A. via CHAMBER OF COMMERCE OF THE U.S.A.
2022 · third_quarter · Q3
H.R. 3, Elijah E. Cummings Lower Drug Costs Now Act H.R. 1319, American Rescue Plan Act of 2021 H.R. 1976, Medicare for All Act of 2021 H.R. 2471, Consolidated Appropriations Act, 2022 H.R. 2873, Affordable Prescriptions for Patients Through Promoting Competition Act of 2021 H.R. 2884, Affordable Prescriptions for Patients Through Improvements to Patent Litigation Act H.R. 2891, Preserve Access to Affordable Generics and Biosimilars Act H.R. 3114, Longshore and Harbor Workers COVID-19 Compensation Act of 2021 H.R. 4502, Labor, Health and Human Services, Education, Agriculture, Rural Development, Energy and Water Development, Financial Services and General Government, Interior, Environment, Military Construction, Veterans Affairs, Transportation, and Housing and Urban Development Appropriations Act, 2022 H.R. 8295, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2023 S. 150, Ensuring Parity in Medicare Advantage for Audio-Only Telehealth Act S. 380, Health Savings Act of 2021 S. 1428, Preserve Access to Affordable Generics and Biosimilars Act S. 1435, Affordable Prescriptions for Patients Act of 2021 Nomination of Robert Gordon to be Assistant Secretary for Financial Resources at the Department of Health and Human Services Implementation of the Transparency in Coverage Final Rule; Internal Revenue Service, Department of the Treasury; Employee Benefits Security Administration, Department of Labor; Centers for Medicare & Medicaid Services, Department of Health and Human Services (85 Fed. Reg. 72,158 - 72,310, November 12, 2020) Requirements Related to Surprise Billing; Internal Revenue Service; Employee Benefits Security Administration; Department of Health and Human Services (87 Fed. Reg. 52,618-52,655, August 26, 2022) Request for Information, Centers for Medicare & Medicaid Services; Medicare Program (87 Fed. Reg. 46,918-46,921, August 1, 2022) Affordability of Employer Coverage for Family Members of Employees (Family Glitch Regulation) (87 Fed. Reg. 20,354-20,364, April 7, 2022) Various issues relating to Patient Protection and Affordable Care Act (P.L. 111-148) and the Health Care and Education Affordability Reconciliation Act of 2010 (P.L. 111-152), including the employer-sponsored health care system, implementation of regulatory process, provider network adequacy, delivery system reform, health savings account (HSAs), health reimbursement account (HRAs), and flexible spending account (FSAs) changes, IPAB, employer mandate, reporting requirements for issuers and applicable large employers, premium stabilization programs, medical loss ratio, medical malpractice reform, exchanges, the impact on small business; coronavirus pandemic; vaccine distribution, PPE, testing, medications and treatments, and vaccination incentives; digital health credentials; vaccine diplomacy; COVID-19 vaccine requirements, including a potential Emergency Temporary Standard from the Occupational Safety and Health Administration relating to employers with more than 100 employees; vaccine requirements for federal contractors; Executive Order 14042, Ensuring Adequate COVID Safety Protocols for Federal Contractors; implementation of the American Rescue Plan Act (P.L. 117-2); balance or surprise billing and related issues; single-payer health care options; health reimbursement arrangements and other account-based group health plans; Health and Human Services international pricing index (IPI) model; mental health parity; drug pricing; COBRA subsidies; Federal Trade Commissions multilateral pharmaceutical merger taskforce; telehealth, including coverage of telehealth under High Deductible Health Plans (HDHPs) and expanding telehealth options for employees; impact of Pharmacy Benefit Managers Practices; FTC-2022-0015; petition to HHS to grant march-in rights for the patents on the drug Xtandi; petition to the Department of Labor Requesting a 60-Day Extension to Comment on Proposed Amendment(s) to Prohibited Transaction Class Exemption 84-14; comments on COVID-19 Telehealth Program Application Evaluation Metrics (WC Docket No. 20-89); efforts to reform the World Health Organizations (WHO) engagement with private sector; continued U.S. membership to the World Health Organization (WHO); support for necessary market conditions to incentivize health sector investment from private sector; support for private sector involvement in health system strengthening; greater harmonization of standards and investment in digital health internationally; role of private sector related pandemic prevention, preparedness and response
CHAMBER OF COMMERCE OF THE U.S.A. via CHAMBER OF COMMERCE OF THE U.S.A.
2022 · second_quarter · Q2
H.R. 3, Elijah E. Cummings Lower Drug Costs Now Act H.R. 1319, American Rescue Plan Act of 2021 H.R. 1976, Medicare for All Act of 2021 H.R. 2471, Consolidated Appropriations Act, 2022 H.R. 2873, Affordable Prescriptions for Patients Through Promoting Competition Act of 2021 H.R. 2884, Affordable Prescriptions for Patients Through Improvements to Patent Litigation Act H.R. 2891, Preserve Access to Affordable Generics and Biosimilars Act H.R. 3114, Longshore and Harbor Workers COVID-19 Compensation Act of 2021 H.R. 4502, Labor, Health and Human Services, Education, Agriculture, Rural Development, Energy and Water Development, Financial Services and General Government, Interior, Environment, Military Construction, Veterans Affairs, Transportation, and Housing and Urban Development Appropriations Act, 2022 S. 150, Ensuring Parity in Medicare Advantage for Audio-Only Telehealth Act S. 380, Health Savings Act of 2021 S. 1428, Preserve Access to Affordable Generics and Biosimilars Act S. 1435, Affordable Prescriptions for Patients Act of 2021 Draft legislation titled Making appropriations for the Departments of Labor, Health and Human Services, and Education, and related agencies for the fiscal year ending September 30, 2023, and for other purposes Nomination of Robert Gordon to be Assistant Secretary for Financial Resources at the Department of Health and Human Services Implementation of the Transparency in Coverage Final Rule; Internal Revenue Service, Department of the Treasury; Employee Benefits Security Administration, Department of Labor; Centers for Medicare & Medicaid Services, Department of Health and Human Services (85 Fed. Reg. 72,158 - 72,310, November 12, 2020) Interim final rule, Most Favored Nation (MFN) Model (85 Fed. Reg. 76,180-76,259, November 27, 2020) Proposed rule regarding Affordability of Employer Coverage for Family Members of Employees (87 Fed. Reg. 20,354-20,364, April 7, 2022) Withdrawal of a Notice of Proposed Rulemaking, Internal Revenue Service; Affordability of Employer Coverage for Family Members of Employees (87 Fed. Reg. 20,354-20,364, April 7, 2022) Various issues relating to Patient Protection and Affordable Care Act (P.L. 111-148) and the Health Care and Education Affordability Reconciliation Act of 2010 (P.L. 111-152), including the employer-sponsored health care system, implementation of regulatory process, provider network adequacy, delivery system reform, health savings account (HSAs), health reimbursement account (HRAs), and flexible spending account (FSAs) changes, IPAB, employer mandate, reporting requirements for issuers and applicable large employers, premium stabilization programs, medical loss ratio, medical malpractice reform, exchanges, the impact on small business; coronavirus pandemic; vaccine distribution, PPE, testing, medications and treatments, and vaccination incentives; digital health credentials; vaccine diplomacy; COVID-19 vaccine requirements, including a potential Emergency Temporary Standard from the Occupational Safety and Health Administration relating to employers with more than 100 employees; vaccine requirements for federal contractors; Executive Order 14042, Ensuring Adequate COVID Safety Protocols for Federal Contractors; implementation of the American Rescue Plan Act (P.L. 117-2); balance or surprise billing and related issues; single-payer health care options; health reimbursement arrangements and other account-based group health plans; Health and Human Services international pricing index (IPI) model; mental health parity; drug pricing; COBRA subsidies; Federal Trade Commissions multilateral pharmaceutical merger taskforce; telehealth, including coverage of telehealth under High Deductible Health Plans (HDHPs) and expanding telehealth options for employees; impact of Pharmacy Benefit Managers Practices; FTC-2022-0015; petition to HHS to grant march-in rights for the patents on the drug Xtandi; efforts to reform the World Health Organizations (WHO) engagement with private sector; continued U.S. membership to the World Health Organization (WHO); support for necessary market conditions to incentivize health sector investment from private sector; support for private sector involvement in health system strengthening
CHAMBER OF COMMERCE OF THE U.S.A. via CHAMBER OF COMMERCE OF THE U.S.A.
2022 · first_quarter · Q1
H.R. 3, Elijah E. Cummings Lower Drug Costs Now Act H.R. 1319, American Rescue Plan Act of 2021 H.R. 1976, Medicare for All Act of 2021 H.R. 2471, Consolidated Appropriations Act, 2022 H.R. 2873, Affordable Prescriptions for Patients Through Promoting Competition Act of 2021 H.R. 2884, Affordable Prescriptions for Patients Through Improvements to Patent Litigation Act H.R. 2891, Preserve Access to Affordable Generics and Biosimilars Act H.R. 3114, Longshore and Harbor Workers COVID-19 Compensation Act of 2021 H.R. 4502, Labor, Health and Human Services, Education, Agriculture, Rural Development, Energy and Water Development, Financial Services and General Government, Interior, Environment, Military Construction, Veterans Affairs, Transportation, and Housing and Urban Development Appropriations Act, 2022 S. 150, Ensuring Parity in Medicare Advantage for Audio-Only Telehealth Act S. 380, Health Savings Act of 2021 S. 1428, Preserve Access to Affordable Generics and Biosimilars Act S. 1435, Affordable Prescriptions for Patients Act of 2021 Implementation of the Transparency in Coverage Final Rule; Internal Revenue Service, Department of the Treasury; Employee Benefits Security Administration, Department of Labor; Centers for Medicare & Medicaid Services, Department of Health and Human Services (85 Fed. Reg. 72,158 - 72,310, November 12, 2020) Interim final rule, Most Favored Nation (MFN) Model (85 Fed. Reg. 76,180-76,259, November 27, 2020) Various issues relating to Patient Protection and Affordable Care Act (P.L. 111-148) and the Health Care and Education Affordability Reconciliation Act of 2010 (P.L. 111-152), including the employer-sponsored health care system, implementation of regulatory process, provider network adequacy, delivery system reform, health savings account (HSAs), health reimbursement account (HRAs), and flexible spending account (FSAs) changes, IPAB, employer mandate, reporting requirements for issuers and applicable large employers, premium stabilization programs, medical loss ratio, medical malpractice reform, exchanges, the impact on small business; coronavirus pandemic; vaccine distribution, PPE, testing, medications and treatments, and vaccination incentives; digital health credentials; vaccine diplomacy; COVID-19 vaccine requirements, including a potential Emergency Temporary Standard from the Occupational Safety and Health Administration relating to employers with more than 100 employees; vaccine requirements for federal contractors; Executive Order 14042, Ensuring Adequate COVID Safety Protocols for Federal Contractors; implementation of the American Rescue Plan Act (P.L. 117-2); balance or surprise billing and related issues; single-payer health care options; health reimbursement arrangements and other account-based group health plans; Health and Human Services international pricing index (IPI) model; mental health parity; drug pricing; COBRA subsidies; Federal Trade Commissions multilateral pharmaceutical merger taskforce; telehealth, including coverage of telehealth under High Deductible Health Plans (HDHPs) and expanding telehealth options for employees; petition to HHS to grant march-in rights for the patents on the drug Xtandi; comments on IRS Notice 2020-76; Transition Relief Related to Health Coverage Reporting Required by Sections 6055 and 6056 for 2020; comments on COVID-19 Telehealth Program Application Evaluation Metrics (WC Docket No. 20-89); efforts to reform the World Health Organizations (WHO) engagement with private sector; continued U.S. membership to the World Health Organization (WHO); support for necessary market conditions to incentivize health sector investment from private sector; support for private sector involvement in health system strengthening
Filing targets: Agriculture, Dept of (USDA), Alcohol & Tobacco Tax & Trade Bureau (TTB), Army, Dept of (Corps of Engineers), Bureau of Citizenship & Immigration Services (BCIS), Bureau of Industry and Security (BIS), Bureau of Reclamation, Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), Commodity Futures Trading Commission (CFTC), Consumer Financial Protection Bureau (CFPB), Council on Environmental Quality (CEQ), Defense, Dept of (DOD), Director of National Intelligence (ODNI), Education, Dept of, Energy, Dept of, Environmental Protection Agency (EPA), Equal Employment Opportunity Commission (EEOC), Executive Office of the President (EOP), Federal Aviation Administration (FAA), Federal Communications Commission (FCC), Federal Deposit Insurance Corporation (FDIC), Federal Emergency Management Agency (FEMA), Federal Energy Regulatory Commission (FERC), Federal Highway Administration (FHA), Federal Maritime Commission, Federal Reserve System, Federal Trade Commission (FTC), General Services Administration (GSA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Homeland Security, Dept of (DHS), Interior, Dept of (DOI), Internal Revenue Service (IRS), Justice, Dept of (DOJ), Labor, Dept of (DOL), Natl Aeronautics & Space Administration (NASA), Natl Economic Council (NEC), Natl Highway Traffic Safety Administration (NHTSA), Natl Institute of Standards & Technology (NIST), Natl Labor Relations Board (NLRB), Natl Oceanic & Atmospheric Administration (NOAA), Natl Science Foundation (NSF), Natl Security Council (NSC), Natl Telecommunications & Information Administration (NTIA), Occupational Safety & Health Administration (OSHA), Office of Management & Budget (OMB), Office of Science & Technology Policy (OSTP), Office of the Comptroller of the Currency (OCC), Patent & Trademark Office (PTO), Pension Benefit Guaranty Corporation (PBGC), SENATE, Securities & Exchange Commission (SEC), Small Business Administration (SBA), State, Dept of (DOS), Transportation, Dept of (DOT), Treasury, Dept of, U.S. Agency for International Development (USAID), U.S. Coast Guard (USCG), U.S. Copyright Office, U.S. Customs & Border Protection, U.S. Fish & Wildlife Service (USFWS), U.S. Trade & Development Agency (USTDA), U.S. Trade Representative (USTR), White House Office
Filing targets: Agriculture, Dept of (USDA), Alcohol & Tobacco Tax & Trade Bureau (TTB), Army, Dept of (Corps of Engineers), Bureau of Citizenship & Immigration Services (BCIS), Bureau of Industry and Security (BIS), Bureau of Reclamation, Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), Commodity Futures Trading Commission (CFTC), Consumer Financial Protection Bureau (CFPB), Council on Environmental Quality (CEQ), Defense, Dept of (DOD), Director of National Intelligence (ODNI), Education, Dept of, Energy, Dept of, Environmental Protection Agency (EPA), Equal Employment Opportunity Commission (EEOC), Executive Office of the President (EOP), Federal Aviation Administration (FAA), Federal Communications Commission (FCC), Federal Deposit Insurance Corporation (FDIC), Federal Emergency Management Agency (FEMA), Federal Energy Regulatory Commission (FERC), Federal Highway Administration (FHA), Federal Maritime Commission, Federal Reserve System, Federal Trade Commission (FTC), General Services Administration (GSA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Homeland Security, Dept of (DHS), Interior, Dept of (DOI), Internal Revenue Service (IRS), Justice, Dept of (DOJ), Labor, Dept of (DOL), Natl Aeronautics & Space Administration (NASA), Natl Economic Council (NEC), Natl Highway Traffic Safety Administration (NHTSA), Natl Institute of Standards & Technology (NIST), Natl Labor Relations Board (NLRB), Natl Oceanic & Atmospheric Administration (NOAA), Natl Science Foundation (NSF), Natl Security Council (NSC), Natl Telecommunications & Information Administration (NTIA), Occupational Safety & Health Administration (OSHA), Office of Management & Budget (OMB), Office of Science & Technology Policy (OSTP), Office of the Comptroller of the Currency (OCC), Patent & Trademark Office (PTO), Pension Benefit Guaranty Corporation (PBGC), SENATE, Securities & Exchange Commission (SEC), Small Business Administration (SBA), State, Dept of (DOS), Transportation, Dept of (DOT), Treasury, Dept of, U.S. Agency for International Development (USAID), U.S. Coast Guard (USCG), U.S. Copyright Office, U.S. Customs & Border Protection, U.S. Fish & Wildlife Service (USFWS), U.S. Trade & Development Agency (USTDA), U.S. Trade Representative (USTR), White House Office
Filing targets: Agriculture, Dept of (USDA), Alcohol & Tobacco Tax & Trade Bureau (TTB), Army, Dept of (Corps of Engineers), Bureau of Citizenship & Immigration Services (BCIS), Bureau of Industry and Security (BIS), Bureau of Reclamation, Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), Commodity Futures Trading Commission (CFTC), Consumer Financial Protection Bureau (CFPB), Council on Environmental Quality (CEQ), Defense, Dept of (DOD), Education, Dept of, Energy, Dept of, Environmental Protection Agency (EPA), Equal Employment Opportunity Commission (EEOC), Executive Office of the President (EOP), Federal Aviation Administration (FAA), Federal Communications Commission (FCC), Federal Deposit Insurance Corporation (FDIC), Federal Emergency Management Agency (FEMA), Federal Energy Regulatory Commission (FERC), Federal Highway Administration (FHA), Federal Reserve System, Federal Trade Commission (FTC), General Services Administration (GSA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Homeland Security, Dept of (DHS), Interior, Dept of (DOI), Internal Revenue Service (IRS), Justice, Dept of (DOJ), Labor, Dept of (DOL), Natl Aeronautics & Space Administration (NASA), Natl Economic Council (NEC), Natl Highway Traffic Safety Administration (NHTSA), Natl Institute of Standards & Technology (NIST), Natl Labor Relations Board (NLRB), Natl Oceanic & Atmospheric Administration (NOAA), Natl Science Foundation (NSF), Natl Security Council (NSC), Natl Telecommunications & Information Administration (NTIA), Occupational Safety & Health Administration (OSHA), Office of Management & Budget (OMB), Office of Science & Technology Policy (OSTP), Office of the Comptroller of the Currency (OCC), Patent & Trademark Office (PTO), Pension Benefit Guaranty Corporation (PBGC), SENATE, Securities & Exchange Commission (SEC), Small Business Administration (SBA), State, Dept of (DOS), Transportation, Dept of (DOT), Treasury, Dept of, U.S. Agency for International Development (USAID), U.S. Coast Guard (USCG), U.S. Copyright Office, U.S. Customs & Border Protection, U.S. Fish & Wildlife Service (USFWS), U.S. Trade & Development Agency (USTDA), U.S. Trade Representative (USTR), White House Office
Filing targets: Agriculture, Dept of (USDA), Army, Dept of (Corps of Engineers), Bureau of Alcohol Tobacco Firearms & Explosives, Bureau of Citizenship & Immigration Services (BCIS), Bureau of Industry and Security (BIS), Bureau of Reclamation, Commerce, Dept of (DOC), Commodity Futures Trading Commission (CFTC), Consumer Financial Protection Bureau (CFPB), Council on Environmental Quality (CEQ), Defense, Dept of (DOD), Education, Dept of, Energy, Dept of, Environmental Protection Agency (EPA), Equal Employment Opportunity Commission (EEOC), Executive Office of the President (EOP), Federal Aviation Administration (FAA), Federal Communications Commission (FCC), Federal Deposit Insurance Corporation (FDIC), Federal Emergency Management Agency (FEMA), Federal Energy Regulatory Commission (FERC), Federal Highway Administration (FHA), Federal Motor Carrier Safety Administration, Federal Reserve System, Federal Trade Commission (FTC), General Services Administration (GSA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Homeland Security, Dept of (DHS), Interior, Dept of (DOI), Internal Revenue Service (IRS), Intl Trade Administration (ITA), Justice, Dept of (DOJ), Labor, Dept of (DOL), Natl Aeronautics & Space Administration (NASA), Natl Economic Council (NEC), Natl Highway Traffic Safety Administration (NHTSA), Natl Institute of Standards & Technology (NIST), Natl Labor Relations Board (NLRB), Natl Oceanic & Atmospheric Administration (NOAA), Natl Science Foundation (NSF), Natl Security Council (NSC), Natl Telecommunications & Information Administration (NTIA), Occupational Safety & Health Administration (OSHA), Office of Management & Budget (OMB), Office of Science & Technology Policy (OSTP), Office of the Comptroller of the Currency (OCC), Patent & Trademark Office (PTO), Pension Benefit Guaranty Corporation (PBGC), SENATE, Securities & Exchange Commission (SEC), Small Business Administration (SBA), State, Dept of (DOS), Transportation, Dept of (DOT), Treasury, Dept of, U.S. Agency for International Development (USAID), U.S. Copyright Office, U.S. Customs & Border Protection, U.S. Fish & Wildlife Service (USFWS), U.S. Trade & Development Agency (USTDA), U.S. Trade Representative (USTR), Veterans Affairs, Dept of (VA), White House Office
Filing targets: Agriculture, Dept of (USDA), Army, Dept of (Corps of Engineers), Bureau of Citizenship & Immigration Services (BCIS), Bureau of Industry and Security (BIS), Bureau of Reclamation, Commerce, Dept of (DOC), Commodity Futures Trading Commission (CFTC), Consumer Financial Protection Bureau (CFPB), Council on Environmental Quality (CEQ), Defense, Dept of (DOD), Education, Dept of, Energy, Dept of, Environmental Protection Agency (EPA), Equal Employment Opportunity Commission (EEOC), Executive Office of the President (EOP), Federal Aviation Administration (FAA), Federal Communications Commission (FCC), Federal Deposit Insurance Corporation (FDIC), Federal Emergency Management Agency (FEMA), Federal Energy Regulatory Commission (FERC), Federal Highway Administration (FHA), Federal Reserve System, Federal Trade Commission (FTC), General Services Administration (GSA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Homeland Security, Dept of (DHS), Interior, Dept of (DOI), Internal Revenue Service (IRS), Intl Trade Administration (ITA), Justice, Dept of (DOJ), Labor, Dept of (DOL), Natl Aeronautics & Space Administration (NASA), Natl Economic Council (NEC), Natl Highway Traffic Safety Administration (NHTSA), Natl Institute of Standards & Technology (NIST), Natl Labor Relations Board (NLRB), Natl Oceanic & Atmospheric Administration (NOAA), Natl Science Foundation (NSF), Natl Security Council (NSC), Natl Telecommunications & Information Administration (NTIA), Occupational Safety & Health Administration (OSHA), Office of Management & Budget (OMB), Office of Science & Technology Policy (OSTP), Office of the Comptroller of the Currency (OCC), Patent & Trademark Office (PTO), Pension Benefit Guaranty Corporation (PBGC), SENATE, Securities & Exchange Commission (SEC), Small Business Administration (SBA), State, Dept of (DOS), Transportation, Dept of (DOT), Treasury, Dept of, U.S. Agency for International Development (USAID), U.S. Copyright Office, U.S. Customs & Border Protection, U.S. Fish & Wildlife Service (USFWS), U.S. Trade & Development Agency (USTDA), U.S. Trade Representative (USTR), Veterans Affairs, Dept of (VA), White House Office
Filing targets: Agriculture, Dept of (USDA), Army, Dept of (Corps of Engineers), Bureau of Citizenship & Immigration Services (BCIS), Bureau of Industry and Security (BIS), Bureau of Reclamation, Commerce, Dept of (DOC), Commodity Futures Trading Commission (CFTC), Consumer Financial Protection Bureau (CFPB), Council on Environmental Quality (CEQ), Defense, Dept of (DOD), Education, Dept of, Energy, Dept of, Environmental Protection Agency (EPA), Equal Employment Opportunity Commission (EEOC), Executive Office of the President (EOP), Federal Aviation Administration (FAA), Federal Communications Commission (FCC), Federal Deposit Insurance Corporation (FDIC), Federal Emergency Management Agency (FEMA), Federal Energy Regulatory Commission (FERC), Federal Highway Administration (FHA), Federal Reserve System, Federal Trade Commission (FTC), General Services Administration (GSA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Homeland Security, Dept of (DHS), Interior, Dept of (DOI), Internal Revenue Service (IRS), Intl Trade Administration (ITA), Justice, Dept of (DOJ), Labor, Dept of (DOL), Natl Aeronautics & Space Administration (NASA), Natl Economic Council (NEC), Natl Highway Traffic Safety Administration (NHTSA), Natl Institute of Standards & Technology (NIST), Natl Labor Relations Board (NLRB), Natl Oceanic & Atmospheric Administration (NOAA), Natl Science Foundation (NSF), Natl Security Council (NSC), Natl Telecommunications & Information Administration (NTIA), Occupational Safety & Health Administration (OSHA), Office of Management & Budget (OMB), Office of Science & Technology Policy (OSTP), Office of the Comptroller of the Currency (OCC), Patent & Trademark Office (PTO), Pension Benefit Guaranty Corporation (PBGC), SENATE, Securities & Exchange Commission (SEC), Small Business Administration (SBA), State, Dept of (DOS), Transportation, Dept of (DOT), Treasury, Dept of, U.S. Agency for International Development (USAID), U.S. Copyright Office, U.S. Customs & Border Protection, U.S. Fish & Wildlife Service (USFWS), U.S. Trade & Development Agency (USTDA), U.S. Trade Representative (USTR), Veterans Affairs, Dept of (VA), White House Office
Filing targets: Agriculture, Dept of (USDA), Army, Dept of (Corps of Engineers), Bureau of Citizenship & Immigration Services (BCIS), Bureau of Industry and Security (BIS), Bureau of Reclamation, Central Intelligence Agency (CIA), Commerce, Dept of (DOC), Commodity Futures Trading Commission (CFTC), Consumer Financial Protection Bureau (CFPB), Council on Environmental Quality (CEQ), Defense, Dept of (DOD), Education, Dept of, Energy, Dept of, Environmental Protection Agency (EPA), Equal Employment Opportunity Commission (EEOC), Executive Office of the President (EOP), Federal Aviation Administration (FAA), Federal Bureau of Investigation (FBI), Federal Communications Commission (FCC), Federal Deposit Insurance Corporation (FDIC), Federal Emergency Management Agency (FEMA), Federal Energy Regulatory Commission (FERC), Federal Highway Administration (FHA), Federal Reserve System, Federal Trade Commission (FTC), General Services Administration (GSA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Homeland Security, Dept of (DHS), Interior, Dept of (DOI), Internal Revenue Service (IRS), Intl Trade Administration (ITA), Justice, Dept of (DOJ), Labor, Dept of (DOL), Natl Aeronautics & Space Administration (NASA), Natl Economic Council (NEC), Natl Highway Traffic Safety Administration (NHTSA), Natl Institute of Standards & Technology (NIST), Natl Labor Relations Board (NLRB), Natl Oceanic & Atmospheric Administration (NOAA), Natl Science Foundation (NSF), Natl Security Agency (NSA), Natl Security Council (NSC), Natl Telecommunications & Information Administration (NTIA), Occupational Safety & Health Administration (OSHA), Office of Management & Budget (OMB), Office of Science & Technology Policy (OSTP), Office of the Comptroller of the Currency (OCC), Patent & Trademark Office (PTO), Pension Benefit Guaranty Corporation (PBGC), SENATE, Securities & Exchange Commission (SEC), Small Business Administration (SBA), State, Dept of (DOS), Transportation, Dept of (DOT), Treasury, Dept of, U.S. Agency for International Development (USAID), U.S. Copyright Office, U.S. Customs & Border Protection, U.S. Fish & Wildlife Service (USFWS), U.S. Trade & Development Agency (USTDA), U.S. Trade Representative (USTR), Veterans Affairs, Dept of (VA), White House Office
Filing targets: Agriculture, Dept of (USDA), Army, Dept of (Corps of Engineers), Bureau of Citizenship & Immigration Services (BCIS), Bureau of Industry and Security (BIS), Central Intelligence Agency (CIA), Commerce, Dept of (DOC), Commodity Futures Trading Commission (CFTC), Consumer Financial Protection Bureau (CFPB), Council on Environmental Quality (CEQ), Defense, Dept of (DOD), Education, Dept of, Energy, Dept of, Environmental Protection Agency (EPA), Equal Employment Opportunity Commission (EEOC), Executive Office of the President (EOP), Federal Aviation Administration (FAA), Federal Bureau of Investigation (FBI), Federal Communications Commission (FCC), Federal Deposit Insurance Corporation (FDIC), Federal Emergency Management Agency (FEMA), Federal Energy Regulatory Commission (FERC), Federal Reserve System, Federal Trade Commission (FTC), General Services Administration (GSA), Government Accountability Office (GAO), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Homeland Security, Dept of (DHS), Interior, Dept of (DOI), Internal Revenue Service (IRS), Intl Trade Administration (ITA), Justice, Dept of (DOJ), Labor, Dept of (DOL), Natl Aeronautics & Space Administration (NASA), Natl Economic Council (NEC), Natl Highway Traffic Safety Administration (NHTSA), Natl Institute of Standards & Technology (NIST), Natl Labor Relations Board (NLRB), Natl Oceanic & Atmospheric Administration (NOAA), Natl Science Foundation (NSF), Natl Security Agency (NSA), Natl Security Council (NSC), Natl Telecommunications & Information Administration (NTIA), Occupational Safety & Health Administration (OSHA), Office of Management & Budget (OMB), Office of Science & Technology Policy (OSTP), Office of the Comptroller of the Currency (OCC), Patent & Trademark Office (PTO), Pension Benefit Guaranty Corporation (PBGC), SENATE, Securities & Exchange Commission (SEC), Small Business Administration (SBA), State, Dept of (DOS), Transportation, Dept of (DOT), Treasury, Dept of, U.S. Copyright Office, U.S. Customs & Border Protection, U.S. Fish & Wildlife Service (USFWS), U.S. Trade Representative (USTR), White House Office
Filing targets: Agriculture, Dept of (USDA), Army, Dept of (Corps of Engineers), Bureau of Citizenship & Immigration Services (BCIS), Bureau of Industry and Security (BIS), Bureau of Reclamation, Central Intelligence Agency (CIA), Commerce, Dept of (DOC), Commodity Futures Trading Commission (CFTC), Consumer Financial Protection Bureau (CFPB), Council on Environmental Quality (CEQ), Defense, Dept of (DOD), Education, Dept of, Energy, Dept of, Environmental Protection Agency (EPA), Equal Employment Opportunity Commission (EEOC), Executive Office of the President (EOP), Federal Aviation Administration (FAA), Federal Bureau of Investigation (FBI), Federal Communications Commission (FCC), Federal Deposit Insurance Corporation (FDIC), Federal Emergency Management Agency (FEMA), Federal Energy Regulatory Commission (FERC), Federal Reserve System, Federal Trade Commission (FTC), General Services Administration (GSA), Government Accountability Office (GAO), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Homeland Security, Dept of (DHS), Interior, Dept of (DOI), Internal Revenue Service (IRS), Intl Trade Administration (ITA), Justice, Dept of (DOJ), Labor, Dept of (DOL), Natl Aeronautics & Space Administration (NASA), Natl Economic Council (NEC), Natl Highway Traffic Safety Administration (NHTSA), Natl Institute of Standards & Technology (NIST), Natl Labor Relations Board (NLRB), Natl Oceanic & Atmospheric Administration (NOAA), Natl Science Foundation (NSF), Natl Security Agency (NSA), Natl Security Council (NSC), Natl Telecommunications & Information Administration (NTIA), Occupational Safety & Health Administration (OSHA), Office of Management & Budget (OMB), Office of Science & Technology Policy (OSTP), Office of the Comptroller of the Currency (OCC), Patent & Trademark Office (PTO), Pension Benefit Guaranty Corporation (PBGC), SENATE, Securities & Exchange Commission (SEC), Small Business Administration (SBA), State, Dept of (DOS), Transportation, Dept of (DOT), Treasury, Dept of, U.S. Copyright Office, U.S. Customs & Border Protection, U.S. Fish & Wildlife Service (USFWS), U.S. Trade Representative (USTR), White House Office
Filing targets: Agriculture, Dept of (USDA), Army, Dept of (Corps of Engineers), Bureau of Citizenship & Immigration Services (BCIS), Bureau of Industry and Security (BIS), Bureau of Reclamation, Central Intelligence Agency (CIA), Commerce, Dept of (DOC), Commodity Futures Trading Commission (CFTC), Consumer Financial Protection Bureau (CFPB), Council on Environmental Quality (CEQ), Defense, Dept of (DOD), Education, Dept of, Energy, Dept of, Environmental Protection Agency (EPA), Equal Employment Opportunity Commission (EEOC), Executive Office of the President (EOP), Federal Aviation Administration (FAA), Federal Bureau of Investigation (FBI), Federal Communications Commission (FCC), Federal Deposit Insurance Corporation (FDIC), Federal Emergency Management Agency (FEMA), Federal Energy Regulatory Commission (FERC), Federal Reserve System, Federal Trade Commission (FTC), General Services Administration (GSA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Homeland Security, Dept of (DHS), Interior, Dept of (DOI), Internal Revenue Service (IRS), Intl Trade Administration (ITA), Justice, Dept of (DOJ), Labor, Dept of (DOL), Natl Aeronautics & Space Administration (NASA), Natl Economic Council (NEC), Natl Highway Traffic Safety Administration (NHTSA), Natl Institute of Standards & Technology (NIST), Natl Labor Relations Board (NLRB), Natl Oceanic & Atmospheric Administration (NOAA), Natl Science Foundation (NSF), Natl Security Agency (NSA), Natl Security Council (NSC), Natl Telecommunications & Information Administration (NTIA), Occupational Safety & Health Administration (OSHA), Office of Management & Budget (OMB), Office of Science & Technology Policy (OSTP), Office of the Comptroller of the Currency (OCC), Patent & Trademark Office (PTO), Pension Benefit Guaranty Corporation (PBGC), SENATE, Securities & Exchange Commission (SEC), Small Business Administration (SBA), State, Dept of (DOS), Transportation, Dept of (DOT), Treasury, Dept of, U.S. Copyright Office, U.S. Customs & Border Protection, U.S. Fish & Wildlife Service (USFWS), U.S. Trade Representative (USTR), White House Office